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Abstract 
 
PART I 
 
To evaluate the role of MMP-13, a catabolic enzyme, in osteoarthritis (OA) pathogenesis, 
we utilized a case-control study design to analyze cartilage samples obtained from 48 OA 
patients and 30 healthy controls. We found that MMP-13 expression was significantly 
increased in OA-affected cartilage compared to healthy cartilage. A CpG site in the 
promoter of MMP-13 was also significantly demethylated in osteoarthritic cartilage but 
was not correlated with the gene expression. The results suggest a potential role for 
MMP-13 in OA pathogenesis. 
 
PART II 
Founder populations, such as Newfoundland & Labrador (NL), often have higher 
prevalences of genetic disease, making them ideal for disease gene mapping. Mean 
frequencies of common disease-associated alleles from over 140 diseases were evaluated 
in the NL population. The mean risk allele frequencies of coronary heart disease, celiac 
disease and bladder cancer were elevated in NL when compared to an out-bred 
population. The elevated disease allele frequencies were in concert with the high 
prevalence of the diseases in NL. This novel approach to studying disease risk in a 
population may provide new insights into genetic risk of complex conditions and could be 
used to inform health policy. 
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1 PART I: GENE EXPRESSION AND METHYLATION IN THE 
PROMOTER OF MATRIX METALLOPROTEINASE-13 AND 
OSTEOARTHRITIS 
 
  
 2 
1.1 CHAPTER 1: Introduction 
 
1.1.1 Osteoarthritis 
 
1.1.1.1 Definition 
Osteoarthritis (OA) is described as a chronic disorder of the muscoskeletal system. 
It most commonly affects joints of the knee, hip, hand, foot and spine. Characteristics of 
OA include the degradation of cartilage, synovial inflammation, subchondral bone 
remodelling, osteophyte (bone spur) growth, degeneration of ligaments and hypertrophy 
of the affected joint (Poole, 2012). These processes result in inflammation, significant 
pain, deformation and a progressive loss of joint function (Arthritis Alliance of Canada, 
2011).  
 
1.1.1.2 Diagnosis  
OA is diagnosed by physical examination in conjunction with radiographic 
evidence by X-Ray or magnetic resonance imaging (MRI). Several scoring systems exist 
for assessment of radiographic OA; one of the most commonly used is the Kellgren-
Lawrence scale (K-L grade) developed in 1957. It uses five grades (0 – 4) to assess OA 
severity based primarily on joint space narrowing (JSN) and osteophyte growth. A grade 
of 2 or more is classified as radiographic OA (Table 1) (Kellgren & Lawrence, 1957).  
Table 1.1 The Kellgren-Lawrence System for Classification of Osteoarthritis 
Grade 0 No radiographic features of osteoarthritis 
Grade 1 Doubtful narrowing of joint space, possible osteophytic growth 
Grade 2 Possible joint space narrowing and definite osteophyte  
Grade 3 Definite narrowing of joint space, multiple moderate 
osteophytes and minor sclerosis and possible deformity of bone 
contour 
Grade 4 Marked joint space narrowing, large osteophytes, severe 
sclerosis and definite deformity of bone contour 
 
Another commonly used scoring system is the Osteoarthritis Research Society 
International (OARSI) atlas, which uses semi-quantitative scoring to establish a grade 
from 0 to 3. Osteophyte growth and JSN are evaluated separately and then combined for a 
 3 
final grade (R. D. Altman, Hochberg, Murphy, Wolfe, & Lequesne, 1995; R. D. Altman 
& Gold, 2007; Culvenor, Engen, Oiestad, Engebretsen, & Risberg, 2014). To reach the 
cut-off, one of three separate criteria must be met, either a JSN grade of 2 or higher, sum 
osteophyte growth of grade 2 or higher, or JSN grade 1 combined with osteophyte grade 
1, and includes lateral and medial tibiofemoral compartments separately (R. D. Altman et 
al., 1995; R. D. Altman & Gold, 2007; Culvenor et al., 2014). The OARSI atlas method 
of evaluating JSN and osteophyte growth separately provides more flexibility than the K-
L grade in the diagnosis of radiographic OA. 
Laboratory tests are often ordered to support a diagnosis of OA or eliminate other 
alternatives. Tests for C–reactive protein (CRP) or erythrocyte sedimentation rate (ESR) 
are among those often used, although they are only effective as indicators of 
inflammation and are not site or disease specific (S. Singh, Kumar, & Sharma, 2014). The 
American College of Rheumatology (ACR) developed criteria for diagnosing OA that 
includes clinical and laboratory features to identify symptomatic OA patients (R. Altman 
et al., 1991). An example of the criteria used to diagnose hip OA is as follows. 
Classification of a patient with hip OA includes pain with 1) internal hip rotation of ≥ 
15°, hip morning stiffness for ≤ 60 minutes, and greater than 50 years of age, or 2) 
internal hip rotation of < 15° and ESR of ≤ 45 mm/hour or hip flexion of ≤ 115 °. When 
radiographic evidence is included with clinical evidence, pain with at least 2 of the 3 
following criteria: osteophytes, JSN, and ESR < 20 mm/hour, a doctor can establish a 
diagnosis. 
The Western Ontario and McMaster university osteoarthritis index (WOMAC 
scores) can also be used to assess pain, disability and joint stiffness for knee OA (see 
appendix). Histological grading systems have also been developed to assess the pathology 
of the articular surface. The OA Histological Histochemical Grading System (HHGS) 
introduced by Mankin et al. in 1971, and the Osteoarthritis Cartilage Histopathology 
(OACH) scoring system established in 1998, are commonly used. The Mankin score uses 
a sum of four categories; surface structure, cells, safranin-O staining and tidemark 
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integrity to give a scale range between 0 and 14 (Pearson, Kurien, Shu, & Scammell, 
2011), while OACH is a product of grade and stage, giving a scale of 0 to 24 (Pritzker et 
al., 2006). 
 
1.1.1.3  Epidemiology of Osteoarthritis 
OA is the most common form of arthritis. According to the World Health 
Organization (WHO), OA affects approximately 9.6% of men and 18% of women 
globally (World Health Organization, 2011). Currently, more than 4.6 million Canadians 
age 15 years and older have symptoms of arthritis (The Arthritis Society, February 2015). 
While in 2010, the prevalence for OA in Canadian men was 10.6% and 15.5% for 
women, and 13.0% overall (Arthritis Alliance of Canada, 2011). By 2030 OA is 
estimated to be the greatest cause of disability worldwide (Thomas, Peat, & Croft, 2014) 
and by 2035, one-in-four Canadians is expected to be living with arthritis (Arthritis 
Alliance of Canada, 2011). The economic burden for direct and indirect health-care costs 
related to arthritis in Canada is predicted to reach $233.5 billion in a five year period from 
2010 to 2015 (The Arthritis Society, February 2015), while the United States reaches 
128$ billion each year (Yelin et al., 2007). Over 80% of hip replacement surgeries and 
90% of knee replacement surgeries performed in Canada are attributed to OA (The 
Arthritis Society, February 2015). This represents a significant economic burden, with 
disability due to OA rivalling that of cardiovascular disease (Guccione et al., 1994). 
Individuals diagnosed with arthritis are also more likely to have other chronic health 
conditions such as diabetes, high blood pressure, heart disease, cancer, or suffer from a 
stroke or poor mental health (Arthritis Community Research and Evaluation Unit 
(ACREU), 2013a; The Arthritis Society, February 2015).  
In Newfoundland and Labrador, approximately 95,000 individuals aged 15 years 
or older report having arthritis, this accounts for 22% of the population (Arthritis 
Community Research and Evaluation Unit (ACREU), 2013b), higher than the national 
average at 16 % (Public Health Agency of Canada, 2011). This number is expected to 
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increase from 95,000 to 127,000 by 2036 (Arthritis Community Research and Evaluation 
Unit (ACREU), 2013b). OA can significantly reduce mobility, 38% of Newfoundlanders 
report arthritis pain preventing activities, in contrast to only 12% from people with other 
chronic conditions (individuals aged 45 years and older) (Arthritis Community Research 
and Evaluation Unit (ACREU), 2013b). The aging population, both in Newfoundland and 
Canada-wide means these numbers will continue to rise in the coming years, representing 
a significant increasing socioeconomic burden to society. 
 
1.1.1.4 Aetiology of Osteoarthritis 
The primary risk factor for developing OA is aging. As evidenced in a cohort 
study by Jordan et al., the presence of radiographic knee OA rose almost 25% between 
age groups of 55-64 to 75 + and symptoms of knee OA increased by 15 % between these 
groups (Jordan et al., 2009). Other risk factors include prior injury, abnormal 
biomechanics, sex and obesity. Women are more likely to develop OA than men, 20% of 
women and 13% of men in Canada reported having OA in 2013 (Arthritis Community 
Research and Evaluation Unit (ACREU), 2013a). However, even when OA patients are 
excluded, women are at an increased risk of either cartilage loss or defects than men, 
indicating gender differences in overall cartilage health before the onset of disease 
(Hanna et al., 2009). Obese individuals are also up to four times more likely to develop 
knee OA than they are to develop type-2 diabetes or hypertension (Arthritis Research UK, 
2011), although the relationship between obesity and risk of OA in other joints is not 
clear (Grazio & Balen, 2009). Furthermore, although obesity is a risk factor for knee OA, 
it does not seem to affect its progression (Niu et al., 2009). Despite these known factors 
affecting its aetiology, the prevalence of OA exceeds what would be expected due to 
increasing obesity rates or an aging population (Losina, Thornhill, Rome, Wright, & 
Katz, 2012).  
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While OA was once considered a necessary condition of aging, it is now 
understood that not everyone will develop arthritis. Some individuals live into their 
nineties with no evidence of OA. Over a period of many years, the effect of mechanical 
loading can have a “wear-and-tear” effect on cartilage, as aging progresses this erosion 
may or may not develop into OA. Considering the prevailing view for many years (that 
OA was an inevitable consequence of aging) not a lot of research had been done 
previously to elucidate the pathogenesis of OA and currently it is still not well 
understood. Some confusion remains around the initiating factors, mechanisms of 
progression and the general aetiology of the disease. Multiple tissues and processes have 
been implicated. As the development of OA is now considered to be a “whole-joint” 
phenomenon, where bone, cartilage, synovium and ligaments are considered together as a 
whole organ and all contribute to OA (Hugle, Geurts, Nuesch, Muller-Gerbl, & 
Valderrabano, 2012). Furthermore, most individuals only seek medical advice during the 
advanced stages of the disease when significant pain or reduced mobility affects daily 
activities. This creates some difficulty in determining the mechanisms contributing to 
OA. More research is necessary to determine these contributing factors and tissues, and 
how they interact in OA pathology. 
 
1.1.1.5 Management 
Treatment options for OA are limited. Initiation of a self-management plan 
including healthy eating, physical activity and joint-protection exercises is suggested 
upon diagnosis and throughout disease progression. Analgesic agents such as 
acetaminophen or non-steroidal anti-inflammatory drugs (NSAIDs) are used to relieve 
pain. Viscosupplementation can also be effective; it is a procedure where hyaluronic acid 
is injected into the synovial fluid of the affected joint (used mostly for knee OA). Features 
of OA include lower levels of hyaluronic acid in the synovial fluid making the fluid 
unable to protect the joints effectively (Legre-Boyer, 2015). The injection of hyaluron is 
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used to increase joint fluid volume and lubrication in mild to moderate knee OA (Legre-
Boyer, 2015). Following other management strategies, a total joint replacement surgery is 
typically an eventual requirement for severe OA. However, this surgery is limited mainly 
to hip and knee replacements. OA in other joints such as the hands or spine cannot be 
treated effectively with surgery. Unfortunately, as of yet, there are no disease–modifying  
medications approved to treat OA, even though the incidence of OA is 400-fold higher 
than rheumatoid arthritis, another common form of arthritis (Sacks, Luo, & Helmick, 
2010). Other over-the-counter medicines include oral chondroitin, although the effect is 
contradictory (J. A. Singh, Noorbaloochi, MacDonald, & Maxwell, 2015). The lack of 
treatment options for OA is largely due to the limited knowledge regarding its’ aetiology, 
the complexity and variable phenotype of the disease.  
 
1.1.1.6 Genetics 
OA is a multifactorial, complex disease influenced by age, genetics and the 
environment. It has a strong genetic component (Blanco & Rego-Perez, 2014) with 
heredity ranging from 40% to 65% depending on the affected joint site (Kraus et al., 
2007; Spector, Cicuttini, Baker, Loughlin, & Hart, 1996). Heritability is considered 
higher for hand and hip OA than it is for knee (Kraus et al., 2007; Spector et al., 1996). 
Familial aggregation studies have estimated the sibling recurrence risk at approximately 5 
in the UK (Valdes & Spector, 2011). Genes implicated in OA include those regulating 
endochondral ossification, embryonic development and postnatal skeletal maintenance 
(Reynard & Loughlin, 2013). Endochondral ossification is tightly controlled by 
interactions with a number of hormones such thyroid hormones, and growth factors 
(TGF-β , BMPs, GDF5) parathyroid-hormone-related-protein (PTHrP), transcription 
factors, RUNX2 and ECM components secreted by chondrocytes, such as matrix 
metalloproteinases (MMPs) (Mackie, Tatarczuch, & Mirams, 2011). Furthermore, human 
monogenic skeletal disorders often display mutations in GDF5, RUNX2, PTHLH and 
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TP63 (Reynard & Loughlin, 2013). These genes, involved in muscoskeletal processes 
such as joint development, chondrocyte and osteoblast differentiation, are also implicated 
in OA susceptibility.  
To date, genome-wide association studies have identified 22 variants reaching 
genome-wide significance (p < 5 x 10 -8)  (Burdett et al., 2015)  
(http://www.ebi.ac.uk/gwas/search?query=osteoarthritis#association). SNPs associated 
with the growth differentiation factor 5 (GDF5) gene have shown strong, reproducible 
associations with OA in multiple studies (Miyamoto et al., 2007; Valdes et al., 2011). 
GDF5, also known as bone morphogenic protein 14, is a member of the transforming 
growth factor (TGF-β) superfamily, previously implicated in a multitude of other 
skeletal disorders in humans (Cornelis, Luyten, & Lories, 2011). Variants in DVWA 
(encoding protein with regions corresponding to the von Willebrand factor type A 
domain) have been associated with knee OA in Japanese and Chinese cohorts (Miyamoto 
et al., 2008). Human leucocyte antigen (HLA) class II/III has been associated with 
susceptibility to knee OA in some Japanese and European populations, supporting an 
immunologic mechanism implicated in the pathogenesis of OA (Nakajima et al., 2010). 
Furthermore, a SNP located in the MCF2L gene (MCF.2 cell line derived transforming 
sequence-like), has been implicated in skeletal and pain-related outcomes of OA (Day-
Williams et al., 2011). Other OA-associated variants are linked to the genes ASTN2 
(astrotactin 2), FILIP1/SENP6 (filamin A interacting protein 1/ sentrin specific peptidase 
6), KLHDC5/PTHLH (kelch domain containing 5/ parathyroid hormone-like hormone), 
CHST11 (carbohydrate sulfotransferase 11), TP63 (tumour protein p63), FTO (fat mass 
and obesity associated), NCOA3 and DOT1L (Panoutsopoulou & Zeggini, 2013). The 
COL12A1 gene has also been associated with OA in European population (arcOGEN 
Consortium et al., 2012).  
However, these variants and associated genes cannot explain the full susceptibility to 
the disease, accounting for less than 10% of the genetic factor (Tsezou, 2014). 
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Additionally, a study by Panoutsopoulou et al. found that the effect of the FTO variant on 
OA is due to its effect on body mass index, and no direct association between OA 
susceptibility and FTO was found (Panoutsopoulou et al., 2014). The presence of multiple 
low penetrance polymorphisms in the general population could explain this discrepancy. 
Other possible causes for missing heritability include rare variants of strong effect, gene-
environment interactions and structural variations, such as copy number variants 
(CNV’s), among others (Manolio et al., 2009a) (see part II, page 54 for more in-depth 
information on missing heritability). Alternatively, the unexplained heritable component 
could be due to epigenetic alterations. 
Selection of a good candidate gene involves assessing the association between alleles 
of a gene that may be involved in the disease (a candidate gene) and the disease itself  
(Kwon & Goate, 2000). Candidate gene studies are generally better suited for detecting 
genes underlying complex or common diseases where the risk associated with any given 
candidate gene is small (Collins, Guyer, & Charkravarti, 1997). This study uses a similar 
approach. The underlying disease pathology is used as a basis for research on the matrix 
metalloproteinase 13 gene, which is involved in cartilage degradation. However, 
associations with different alleles are not tested through segregation. Instead, the 
mechanism of association between OA and MMP-13 is evaluated through epigenetics. 
 
1.1.1.7 Introduction to Matrix Metalloproteinases  
Matrix metalloproteinases (MMPs) are endopeptidases that belong to the 
metzincin superfamily of proteases. They are initially synthesized in latent form and 
secreted as proenzymes that require extracellular activation. Their structures share 
common features including a pro–peptide domain, catalytic domain and C–terminal 
domain. The catalytic domains are specific to the substrate and depend on zinc ions as a 
co-factor. The collagenases, MMP-1, MMP-8 and MMP-13 are named because they 
specifically cleave a single locus in all three collagen chains at a point three-quarters of 
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the length from the N-terminus. Generally, while all MMPs act to degrade ECM proteins 
they can also process bioactive molecules such as cytokines and chemokines (Van Lint & 
Libert, 2007). In mammals, the only proteinases that degrade triple helical collagens at 
neutral pH are from the MMP family (Billinghurst et al., 1997). Normal cartilage ECM is 
in a perpetual state of synthesis and degradation, balancing a state of dynamic 
equilibrium. MMPs are important because they facilitate ECM turnover and breakdown in 
physiology and pathology (Murphy et al., 2002) and have been found to influence the 
progression of numerous inflammatory processes (Van Lint & Libert, 2007). Substrates 
of MMP-13 (also called collagenase 3) include collagen I-IV, IX, X, XIV and gelatin. 
Specifically, the gene degrades the resistant triple-helical fibrillar type II collagen 
(Knauper, Lopez-Otin, Smith, Knight, & Murphy, 1996). In studying OA, type II 
collagen is particularly important because it gives tensile strength to cartilage and is the 
most abundant (of only two) cartilage ECM macromolecules. The other abundant protein, 
aggrecan, resists compression (Eyre, 2002). Therefore, MMP-13’s preference for cleaving 
type II collagen makes it of interest in studying OA pathology.  
Murine models of injury-induced OA can be created using surgical destabilization 
of the medial meniscus (DMM) (Bateman et al., 2013; Glasson, Blanchet, & Morris, 
2007) and these models show increased MMP-13 mRNA expression in osteoarthritic 
joints when compared to sham-operated controls. However the altered expression does 
not persist over time (Bateman et al., 2013; Leahy et al., 2015; Loeser et al., 2013). In 
contrast, using near-infrared fluorescence, a murine model of knee OA showed enhanced 
MMP activity and the total emitted fluorescence intensity increased over the course of 
OA progression (Leahy et al., 2015). 
In humans, aged cartilage has been shown to exhibit increased expression of 
MMP-3 and MMP-13 (Wu et al., 2002), and MMP-2 and MMP-13 proteins have been 
detected in synovial fluid (Ryu et al., 2012). Also increased in synovial fluid of OA 
patients is interleukin-1 (IL-1), a major cytokine involved in arthritic inflammation as 
well as cartilage destruction (Ahmad et al., 2007). IL-1 not only represses healthy 
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chondrocyte ECM genes but it also stimulates MMP activity (Ahmad et al., 2007). 
However, synovial fluid alone does not accurately reflect protein activities such as MMPs 
when using it for OA comparisons due to the “whole-joint” model of OA disease (Poole, 
2012) and the potential tissue-specific nature of proteins. Leahy et al. speculate that 
overall MMP activity may sensitively reflect metabolic changes occurring as OA 
develops, although the dynamics of the net MMP activity is not clear (Leahy et al., 2015). 
However, the increased levels of MMPs during aging could enhance cartilage matrix 
degeneration (Dejica et al., 2012). Of the MMPs, MMP-13 appears to be one of the most 
actively involved in joint damage (Leahy et al., 2015). Rego-Perez et al. reported that 
people in Spain with a mitochondrial haplotype H have higher serum levels of MMP-13 
whereas haplotype J is associated with a lower risk of OA (Rego-Perez et al., 2011). In 
contrast, another study found MMP proteins and mRNA analysis did not indicate a 
change in MMP levels during the course of OA progression (Bateman et al., 2013; Loeser 
et al., 2013). To date, none of the 22 OA-associated variants identified through GWAS 
correspond to the MMP-13 gene and while there is strong evidence to support a role for 
MMPs, specifically MMP-13 in OA pathogenesis, the mechanism remains controversial.  
 
1.1.2 Epigenetics 
 
1.1.2.1 Introduction to Epigenetics 
Epigenetics is defined as stable, mitotically heritable changes that alter gene 
expression in response to environmental cues (both external and internal), without 
affecting the underlying DNA sequence. These changes are “heritable”, meaning they can 
persist following cell division and often between generations (Jablonka & Raz, 2009). In 
mammalian germ cells, which give rise to gametes, the epigenome is reset before 
reprogramming into a totipotent state (Feng, Jacobsen, & Reik, 2010). Thus, a person’s 
epigenome is established before birth and changes continuously in response to 
environmental stimuli as he/she ages. Precise control of gene expression is necessary for 
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maintaining proper development, differentiation, growth and supporting homeostasis. 
Epigenetic mechanisms are necessary regulators of gene expression and establish stable, 
long-term expression patterns passed on through cell division (Gibney & Nolan, 2010). 
Epigenetic mechanisms include DNA methylation, posttranscriptional histone 
modification and noncoding RNAs (such as micro RNAs), among others. Processes such 
as development (Kiefer, 2007) and aging (Brunet & Berger, 2014) are now considered to 
be under significant epigenetic control, as well as almost every biological processes in 
between (Delcuve, Rastegar, & Davie, 2009). Not only are epigenetics involved in 
healthy growth and development, they are important mechanisms that respond to, and 
may even control, certain disease processes (Delcuve et al., 2009). There is strong 
evidence that epigenetics, specifically DNA methylation, plays a crucial role in many 
complex, multi-factorial conditions such as cancer and arthritis (Delcuve et al., 2009). 
 
1.1.2.2 DNA Methylation 
DNA methylation is a reversible, covalent modification of the 5’– carbon of a 
cytosine residue to form 5–methyl cytosine (5mC). The methyl group (CH3) is transferred 
from a methyl donor S-adenosyl methionine (SAM) to the cytosine residue in cytosine-
phosphate-guanine dinucleotides. In mammals, the methylation of cytosine is restricted to 
residues located 5’ to a guanosine, known as a CpG site. Areas of the genome where CpG 
sites occur frequently are known as CpG islands (Vrtacnik, Marc, & Ostanek, 2014). 
These islands are often found in promoter regions of genes where CpG density tends to be 
high, and when methylation occurs in these areas it usually results in gene silencing 
(Blanco & Rego-Perez, 2014). On the other hand, methylation can facilitate protein 
binding when it occurs in gene bodies, leading to increased gene expression (Hellman & 
Chess, 2007). Thus, the process of methylation can increase or decrease gene expression 
depending on environmental cues such as aging or during disease pathology. Ageing and 
age-related diseases often exhibit genome-wide hypomethylation, but promoter-specific 
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hypermethylation, resulting in inappropriate silencing and a loss of gene expression 
regulation (Blanco & Rego-Perez, 2014; A. A. Johnson et al., 2012). The repressed state 
can be passed on to future cells due to the heritable nature of methylation during mitosis. 
A limitation to studying methylation is that only some of the CpGs present in the human 
genome are involved in gene transcription and therefore, it is necessary to experimentally 
confirm the role of individual CpG sites (Vrtacnik et al., 2014). 
 
1.1.2.3 Chondrocytes 
Cartilage is the firm, flexible connective tissue that protects the articulating 
surfaces of bones. It is susceptible to degeneration. Knee cartilage can thin naturally due 
to aging, particularly on the femur (Hudelmaier et al., 2001) and patellae (Ding, Cicuttini, 
Scott, Cooley, & Jones, 2005). Chondrocytes are the only cell type found in healthy 
cartilage and as such they are of particular interest in studying OA. Chondrocytes are 
essential to maintaining healthy cartilage homeostasis. They produce extracellular matrix 
proteins, integral for structure and biochemical support to the cartilage tissue. Normal 
adult articular chondrocytes do not typically undergo apoptosis or cell division (Aigner et 
al., 2001). They are vulnerable to the effects of aging, for example through telomere 
shortening, and aged chondrocytes collected from older adults are prone to cell death 
when exposed to reactive oxygen species (ROS), which increase naturally in cartilage as 
aging occurs (Carlo & Loeser, 2003; J. A. Martin & Buckwalter, 2003). Chondrocyte 
development is mainly regulated by anabolic growth factors (Fortier, Barker, Strauss, 
McCarrel, & Cole, 2011). For example, aged chondrocytes become less responsive to 
growth factors such as bone morphogenic protein-7 (BMP-7) (Chubinskaya et al., 2002) 
and transforming growth-factor β (TGF-β) (Davidson, Scharstuhl, Vitters, van der 
Kraan, & van den Berg, 2005). TGF-β  also stimulates articular chondrocyte 
proteoglycan synthesis in young mice, but the ability is diminished in older ones (van 
Beuningen, van der Kraan, Arntz, & van den Berg, 1994). Providing evidence that the 
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aging process could alter the epigenetic landscape in cartilage, resulting in decreased 
synthesis of healthy maintenance proteins.   
 
1.1.2.4 Epigenetics in Osteoarthritis 
Several rheumatic diseases have been linked to aberrant epigenetic regulation 
causing either gene silencing or increased expression. Epigenetics and the aetiology of 
systemic lupus erythematosus have been well established (Jeffries & Sawalha, 2011) and 
epigenetic abnormalities are thought to play a key role in pathogenicity of rheumatoid 
arthritis (Bottini & Firestein, 2013; Liu et al., 2013). Epigenetic profiles are often disease 
specific, for example osteoporotic and osteoarthritic bone tissue samples display 
hypomethylation in members of the tumour necrosis (TNF) superfamily that are unique to 
the underlying pathology (Delgado-Calle et al., 2012) and chondrocytes from OA patients 
have distinct methylation profiles when compared to healthy controls (Rushton et al., 
2014). Epigenomic landscapes can also be tissue or joint-specific. It has been noted that 
the majority of tissue-specific methylation correlating with transcriptional suppression of 
genes occurs in regions of low-density CpGs close to CpG islands such as in promoter 
regions (Barter, Bui, & Young, 2012). Rushton et al. found that epigenomic profiles of 
hip and knee OA segregate into clusters, and that a proportion of differentially methylated 
loci did not overlap between the two joints, indicating different genes or pathways 
involved in the disease (Rushton et al., 2014). Also, epigenetic profiles from hip OA 
alone can segregate into distinct clusters, indicating potential disease heterogeneity 
(Rushton et al., 2014). However, most genes were involved in anabolic/catabolic 
pathways of cartilage homeostasis such as the TGF- β family and other genes involved 
in the degradation of the extra cellular matrix (ECM) including matrix metalloproteinases 
(MMPs) (Rushton et al., 2014). There is even evidence to suggest a correlation between 
methylation of CpG sites and histologic severity of OA (Jeffries et al., 2014). In sum, 
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evidence suggests that OA not only has a distinct epigenetic profile but that it is also 
tissue and possibly even joint-specific.  
Cartilage and bone homeostasis is an important factor in OA pathology and can 
also be influenced by epigenetics. Genome-wide methylation profiling reveals samples 
taken from bone tissue of osteoarthritic patients have differences in methylation of genes 
involved in cell-matrix interactions during skeletal development (Vrtacnik et al., 2014). 
DNA methylation has been shown to regulate multiple genes involved in bone 
remodelling and homeostasis (Vrtacnik et al., 2014). One essential method of maintaining 
bone homeostasis, that has also been shown to affect OA pathogenesis, is the mechanical 
stimulation of joints (Arnsdorf, Tummala, Castillo, Zhang, & Jacobs, 2010). The process 
increases expression of osteopontin (an extracellular structural protein in bone) by 
reducing DNA methylation in the promoter region (Arnsdorf et al., 2010). Thereby 
providing evidence that knee and hip articular cartilage can have distinct cellular 
phenotypes due to differing epigenomic influences and that gene expression can also be 
influenced by joint-specific mechanical signals, through epigenetic regulation. 
OA has a distinct methylation profile from that found in other rheumatic diseases. 
Other epigenetic modifications are most likely distinct as well, such as histone 
modifications or microRNAs. Regardless, studying DNA methylation holds promise for 
elucidation of complex disease mechanisms with the potential to discover novel gene 
associations, biomarkers and develop medications. In fact, the field of oncology has 
already begun using DNA methylation in clinical applications. For example, as 
biomarkers that can potentially predict recurrence risk in lung cancer (Harada et al., 2015) 
and renal cell cancer (Luo et al., 2015). Furthermore, DNA methyltransferase (DNMT) 
inhibitors such as zebularine have been approved by the FDA to treat breast cancer 
(Pouliot, Labrie, Diorio, & Durocher, 2015). This makes the use of epigenetics for 
diagnostics or treatments of osteoarthritis a tangible goal.  
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1.1.2.5 MMP-13 and Epigenetics 
MMP-13’s unique ability to cleave type II collagen, the most abundant protein in 
healthy cartilage makes it important for OA studies. The emergence of epigenetics has 
brought new methods for studying the relationship between genetics and environment in 
complex diseases. A study by da Silva and colleagues found that OA cartilage exhibited 
increased expression of MMPs including MMP-13 and that it correlated with reduced 
DNA methylation (da Silva, Yamada, Clarke, & Roach, 2009). However, it is difficult to 
draw conclusions from this study based on the fact that cartilage from only one control 
was used and most samples were compared to secondary OA patients. An article by 
Cheung et al. also identified hypomethylated CpG sites in the promoter region of MMP-
13 in OA chondrocytes. However, no gene expression analysis or correlation was done 
(Cheung, Hashimoto, Yamada, & Roach, 2009). There is further evidence that a 
hypomethylated region within the promoter of MMP-13 could lead to increased gene 
expression. Bui et al. found a CpG site located at –104 relative to the TSS within the 
promoter region of MMP-13 to be hypomethylated in OA chondrocytes where they also 
found increased MMP-13 expression (Bui et al., 2012). They also found that the 
transcriptional binding factor cAMP-response-element binding protein (CREB) interacts 
with the promoter at site –104. This interaction relies on the methylation status and 
affects binding affinity (Bui et al., 2012). MMP-13’s transcription may be regulated by 
CREB, indicating other factors involved in its regulation. Therefore, some studies suggest 
an association between reduced methylation of certain CpG sites within the promoter of 
MMP-13 and increased gene expression (Tsezou, 2014). Whether or not there is a 
correlation between the gene expression and methylation status is still under debate.  
Mechanisms of methylation are well known, such as the addition of a methyl 
group from SAM to a CpG dinucleotide. Just recently, a pathway of demethylation has 
been described. Ten eleven translocation protein (TET) has been identified as an enzyme 
that converts 5-methyl-cytosine to 5-hydroxymethyl-cytosine (5hmC), a de-methylation 
pathway (Taylor, Smeriglio, Dhulipala, Rath, & Bhutani, 2014). Taylor et al. also 
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identified an increase in TET expression in OA chondrocytes as well as an enrichment of 
5hmC in the promoter region of OA-related genes MMP-1, MMP-3 and MMP-13. 
Leading to an increase in the metalloproteinases expression in OA, supporting the 
hypothesis that up-regulation of MMPs in OA can occur via a de-methylation pathway 
(Taylor et al., 2014). In addition, chondrocytes treated with the DNA methyltransferase 
inhibitor Aza resulted in specific demethylation of sites within the MMP-13 promoter, 
concomitant with increased gene expression (Bui et al., 2012). The effect of methylation 
on gene expression is not certain. Alternative theories of regulatory methods exist. Other 
possible mechanisms of MMP-13 regulation include microRNAs such as miR-140, which 
has been shown in vitro to directly mediate MMP-13 expression in articular chondrocytes 
(Liang et al., 2012). Additional studies have shown other microRNAs capable of 
regulating MMP-13 expression in human OA chondrocytes as well (Akhtar et al., 2010). 
It is important to determine the mechanisms of regulation in genes associated with OA 
such as MMP-13, to better understand the pathogenesis of disease. Studying these 
mechanisms, including DNA methylation of genes gives us the ability to examine more 
closely how environmental cues alter gene expression contributing to an OA phenotype. 
 
1.1.3 Summary of Current Hypothesis 
 
While the mechanisms of development and progression of OA remain unclear, 
several theories exist and the development of OA is likely due to a combination of several 
factors. For example, mitochondrial dysfunction and oxidative stress (Blanco, Rego, & 
Ruiz-Romero, 2011) may play a role, as well as an abnormal increase in advance 
glycation reaction (or non-enzymatic glycosylation) end products (AGEs) (Huang et al., 
2011). A delicate balance between catabolic and anabolic processes most likely exists in 
joints and perturbations to the balance can encourage the development or progression of 
OA (Henrotin, Kurz, & Aigner, 2005). In fact, an age driven decline in anabolic activity 
could tip the balance and result in up-regulation of catabolic genes that drive OA 
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susceptibility (van der Kraan, 2014). Several lines of evidence support this theory. With 
OA progression, the disproportionate increase in catabolic activity results in further 
destruction of the cartilage matrix and aberrant cartilage homeostasis (Li, Wei, Zhou, & 
Wei, 2013). Epigenetics are most likely involved in the phenotypic modulation that 
causes healthy articular chondrocytes in anabolic homeostasis to become “altered” 
destructive chondrocytes, over-expressing cartilage-degrading proteases, cytokines and 
other inflammatory mediators which can alter a healthy homeostasis towards catabolism 
and matrix degradation (Blanco & Rego-Perez, 2014; Roach et al., 2005). The catabolic 
activities occurring during cartilage degradation are regulated by pro-inflammatory 
cytokines (for example IL-1) and mediators such as the matrix metalloproteinases 
(MMPs) and disintegrin and metalloproteinase and thrombospondin motifs (ADAMTS) 
(Sun, 2010). These pro-inflammatory cytokines and matrix metalloproteinases can be up-
regulated during times of joint stress, for example in the presence of increased ROS levels 
(Nelson & Melendez, 2004). ROS also activate ERK/ MAP kinase, suppressing the 
expression of type II collagen and chondrocyte aggrecan (Goodwin et al., 2010). The 
association between ERK/MAP kinase and TGF-β pathways influencing MMPs is well 
established in cancer research. In a cancer study, TGF-β was shown to activate the ERK 
pathway and affect expression of MMP-9 leading to glioblastoma progression (W. Chen 
et al., 2015). Also, genistein, a candidate chemopreventative drug in clinical trials, has 
been shown to block prostate cancer cell invasion by preventing TGF-β from activating 
MAP kinase, a pathway that regulates matrix metalloproteinase activity and cell invasion 
(Xu & Bergan, 2006).  
Van der Kraan and colleagues hypothesize that changes in the TGF-β signalling 
pathway, driven by age, can trigger chondrocytes to a destructive phenotype thereby 
promoting the degradation of cartilage and the surrounding matrix (van der Kraan, 2014). 
MMP-13 can be up regulated by TGF-β, and has been observed to localize to deep tissue 
in arthritic cartilage (Moldovan, Pelletier, Hambor, Cloutier, & Martel-Pelletier, 1997). 
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IL-1 and TGF-β were both found to increase the number of chondrocytes producing 
MMP-13 (Moldovan et al., 1997). SMAD-3 is an intracellular mediator of TGF- β 
signalling and has been shown to regulate matrix mineralization and chondrocyte 
proliferation. SMAD3 can also regulate cartilage homeostasis by inducing type II collagen 
and MMP-13 expression (C. G. Chen, Thuillier, Chin, & Alliston, 2012). In articular 
cartilage, TGF- β  signalling through a SMAD-3 dependent mechanism maintains 
homeostasis by preventing improper expression of RUNX2-inducible genes such as 
MMP-13 (Reynard & Loughlin, 2013). Interestingly, a TGF-β1 gene polymorphism has 
also been shown to interact with obesity in influencing the risk of OA in large joints 
(Muthuri et al., 2013).  
In summary, in an aged individual, joint stress could lead to increased reactive 
oxygen species in the joints that can up-regulate catabolic pathways such as TGF-β and 
ERK/ MAP kinase causing an up-regulation of matrix metalloproteinases such as MMP-
13 and concomitant suppression of healthy anabolic type II collagen expressed by 
chondrocytes, shifting homeostasis to a destructive phenotype.   
MMP-13, a catabolic enzyme essential for cartilage homeostasis, is suspected to 
be up regulated by epigenetic means in OA cartilage. While previous studies have looked 
into this question, the mechanisms by which it occurs remains unclear.  
I hypothesize that the promoter region of MMP-13 is hypomethylated in OA 
cartilage when compared to healthy cartilage, and that this aberrant methylation 
up-regulates the MMP-13 gene, thereby stimulating cartilage degradation.  
 
1.1.4 Objectives 
 
The overall objective of this study is to compare the role of MMP-13 in OA 
patients versus healthy controls. This will indicate whether epigenetic phenomena, 
specifically gene methylation, regulate the expression of MMP-13 and modulate the effect 
it has on the pathogenesis of OA. 
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Specific objectives: 
1. Assess the level of MMP-13 expression to determine if there is a 
difference between osteoarthritic cartilage and healthy cartilage. 
2. Determine the methylation level at several CpG sites within the MMP-
13 promoter region. 
3. Use statistical methods to determine if a significant correlation exists 
between methylation status and MMP-13 mRNA levels. 
4. Identify and adjust for potential confounders such as age, sex and body 
mass index (BMI).  
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1.2 CHAPTER 2. Materials and Methods 
 
1.2.1 Study Participant Recruitment 
 
Study participants are part of the ongoing Newfoundland Osteoarthritis Study 
(NFOAS). NFOAS is a hospital-based case-control study, aimed at identifying novel 
biochemical, genetic and epigenetic factors for OA (Zhai et al., 2013; Zhang et al., 2014; 
Zhang et al., 2015). Recruitment began in November 2011, with the goal of obtaining 
1000 individuals with OA and 1000 healthy controls. Patients were recruited from 
individuals undergoing total knee or hip joint replacement due to primary OA at St. 
Clare’s Mercy Hospital and Health Sciences Centre General Hospital in St. John’s, 
Newfoundland Labrador, Canada between November 2011 and December 2013.  Healthy 
controls with no evidence of OA undergoing emergency hemiarthroplasty due to hip 
fracture were recruited from the same hospitals. Knee or hip OA was confirmed by 
pathology reports on the removed cartilage and orthopaedic surgeon’s assessment based 
on the American College of Rheumatology criteria (R. Altman et al., 1991). Consent was 
obtained along with a medical health questionnaire and Western Ontario and McMaster 
Universities Osteoarthritis index (WOMAC) questionnaire, used to assess pain, stiffness, 
and physical function in patients with hip and/or knee OA (see appendix B-E for consent 
form, health questionnaire and WOMAC).  
Demographic information obtained by the health questionnaires included sex, age, 
height, weight, relevant medical history and medications, and was verified where 
necessary by research staff using hospital admission and medical records. BMI was also 
calculated by weight (kilograms) / height (metres2) (for sample calculation see appendix 
A).  
 
1.2.2 Ethical Considerations 
 
Ethical approval was obtained from Health Research Ethics Authority (HREA) of 
Newfoundland and Labrador. All study participants were entered into a password-
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protected database and given study ID, DNA ID and RNA ID numbers to obscure 
identity. All files, including consent forms, questionnaires and WOMAC assessments 
were kept in a locked file cabinet. Informed consent was obtained while study participants 
were in hospital for joint replacement surgery. Participants either filled out the consent 
forms and questionnaires while in the hospital with help from a research team member 
when necessary or took the forms home to be completed at their leisure and mailed back 
upon completion. 
 
1.2.3 Cartilage Preparation 
 
Up to 5 cartilage samples, weighing on average 200 mg per sample, were retained 
during knee or hip replacement surgery from patients and controls. Cartilage was 
procured from the tibial plateau during knee replacements or from the femoral head 
during hip replacement. Cartilage samples were flash frozen within thirty minutes of 
surgery and stored in liquid nitrogen (LN2) at -140 °C.  
 
1.2.4 RNA/DNA Extraction from Cartilage 
 
RNA and DNA extraction was performed on the same cartilage sample to avoid 
sampling bias. RNA and DNA were extracted as follows, a frozen cartilage sample of 
approximately 200 mg was transferred to a homogenizing cylinder with 1 mL TRIzol 
reagent and 200 uL guanidine thiocyanate, then ground in a cryogenic freezer mill (Spex 
CertiPrep 6770; Spex, Metuchen, NJ, USA) with the following protocol; initial pre-cool 
of ten minutes followed by two rounds of two minutes of grinding followed by a ten 
minute cool-down between grinding cycles. After grinding, the sample was transferred to 
a 50 mL tube until thawed. 200 µL chloroform was added and mixed gently then 
transferred to a 2 mL tube and mixed vigorously for thirty seconds then centrifuged for 15 
minutes at 11,500 g at – 4 °C. Following centrifugation, the mixture separates into a 
lower red organic phase, an interphase and a colourless, upper aqueous phase. RNA 
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remains exclusively in the upper aqueous phase while DNA remains in the lower and 
interphase. RNA was removed and placed in a new 2 mL tube then purified using RNeasy 
Lipid Tissue Mini Kit according to the Manufacturer’s protocol from (74804, Qiagen, 
Venlo, Netherlands). DNA extraction protocol was adapted from TRIzol and Qiagen 
protocols as follows. After removal of upper RNA phase, DNA remaining in lower and 
interphase was treated with 0.3 mL’s 100% ethanol (per 1 mL TRIzol reagent used for 
initial homogenization). Samples were mixed by vortex and stored at 15-30 °C for 3 
minutes followed by centrifugation at 8,000 g for 5 minutes at 4 °C. The supernatant was 
discarded and an additional wash was completed using the same conditions. Following 
the second wash and removal of supernatant, 900 uL ATL buffer and 120 uL proteinase K 
was added and samples were mixed thoroughly by vortex then incubated in a 56 °C water 
bath overnight. The following morning, samples were centrifuged and the supernatant 
was pipetted into a new 2 mL tube. One volume of phenol:chloroform:isoamyl alcohol  
(25:24:1, Invitrogen, 15593049, Waltham, Massachusetts, USA) was added to the sample 
and shaken thoroughly for approximately 20 seconds. The sample was then centrifuged at 
16,000 g for five minutes at room temperature (22 °C). The lower organic phase was 
carefully removed and discarded and the sample was centrifuged for another five minutes 
at 16,000 g at room temperature. The upper phase containing DNA was carefully 
transferred to a new 1.5 mL tube. One volume of chloroform:isoamyl alcohol (24:1) 
(Sigma-Aldrich, St. Louis, MO, USA) was added to the sample, capped and shaken 
thoroughly for 20 seconds. The sample was centrifuged at room temperature for five 
minutes at 16,000 g. The bottom organic phase was carefully removed and sample was 
centrifuged again at 16,000 g for 3 minutes. The sample separated into two layers with an 
upper aqueous phase that was carefully transferred to a new 2 mL tube. 3 volumes of 100 
% ethanol were added and mixed by inversion. Samples were then placed in a – 80 °C 
freezer for at least 30 minutes to precipitate the DNA. Following precipitation, the sample 
was centrifuged at 20,000 g for 30 minutes at room temperature. The supernatant was 
then discarded, leaving a small DNA pellet. The pellet was rinsed with 70% ethanol and 
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centrifuged again for 15 minutes followed by removal of supernatant (discarded). Pellet 
was washed 3 more times following the same procedure. Following removal of 
supernatant after the last wash, DNA pellet was left to dry for ten minutes then dissolved 
in 50 uL Tris-EDTA (TE) buffer. DNA concentration, A260/280 and A260/230 ratio 
were measured on NanoDrop 1000 Spectrophotometer and software v 3.6 
(ThermoFisher).  DNA was further purified when necessary using DNeasy Blood & 
Tissue Handbook according to the manufacturer’s protocol (69504, Qiagen, Venlo, 
Netherlands).  
 
1.2.5 MMP-13 Promoter Methylation Analysis 
 
Methylation analysis was completed using the Sequenom MassARRAY 
EpiTYPER protocol. The Sequenom MassARRAY is used for quantitative analysis of 
DNA methylation by mass spectrometry, displaying methylated and non-methylated 
DNA as distinct signals. Amplicon primers were designed using Epidesigner website 
(http://www.epidesigner.com/). Two different sets of primers were designed due to 
complications that arose and to cover more CpG sites. Originally a sequence of 600 base 
pairs from the promoter region was utilized to generate a primer pair covering 4 CpG 
sites starting at 230 base pairs upstream and ending approximately 40 base pairs upstream 
of the first exon (see Table 1.2).  
Table 1.2 1st Primer Pair Sequence: Target 224 – Reverse Primer 
Primer 
Left: aggaagagagTTTTTATAGGTTTGTAATGGTGAGTT 
 
Right: 
cagtaatacgactcactatagggagaaggctCCCACAATATCCATAAATATACTAAAACC 
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Table 1.3 Description of CpG sites analyzed with primer pair # 1 
CpG Name CpG Unit Position Sequence CpGs Base Mass 
(kDA) 
CpG_Unit_1 CpG_Unit_1 156 *taaac 1 1945.244 
CpG_Unit_2 CpG_Unit_1 151 *c 1 653.417 
CpG_Unit_3 CpG_Unit_2 131 *aaaaaaaaaaaa
aaaaatc 
1 6554.181 
CpG_Unit_4 CpG_Unit_3 41 *tttattttac 1 3441.214 
Position refers to number of base pairs from forward primer, not position from TSS. 
CpG sites 1 and 2 are located so close together that the signals overlap, therefore 
CpG sites 1 and 2 are described as unit 1 as they are indistinguishable using this 
method. 
 
A second primer pair was developed from –550 bp to –200 bp upstream of the 
first exon of MMP-13. The second primer pair overlapped with one CpG site (located  
–218 bp upstream from the first exon) from the first primer pair (see Table 1.4).  
Table 1.4 2nd Primer Pair Sequence: Target 350 – Forward Primer 
Primer 
Left: aggaagagagTAAGTTATTAAGTTTGGTTTTGGTTT 
Right: cagtaatacgactcactatagggagaaggctAACATCTCTTATTTCAACAAAATCTC 
 
 Table 1.5 Description of CpG sites within primer pair #2 
CpG Name Position Sequence CpGs Base Mass (kDA) 
CpG_Unit_1 327 cac*at 1 1891.192 
CpG_Unit_2 179 c*aat 1 1602.007 
CpG_Unit_3 154 aaaaac*t 1 2589.636 
CpG_Unit_4 57 aaac*acct 1 2838.797 
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Figure 1.1 Illustration of overlap between primer pairs #1 and #2 
Figure showing CpG sites analyzed and overlap of two primer pairs from experiment 1 
(primer pair 1) and experiment 2 (primer pair 2). CpG unit 4 was included in both 
experiments due to overlap of primer pairs. CpG units 1 and 2 from experiment one were 
combined, the mass spectrometer could not measure them individually due to their 
proximity. 
  Following primer design a 96 well Plate (PCR MicroPlate PCR-96-FLT-C, 
Axygen, ThermoFisher) was arranged for bisulphite conversion based on the 
manufacturer’s protocol for Sodium Bisulphite Conversion of Unmethylated Cytosines in 
DNA (from Low-Concentration DNA Solutions) (Epitect Bisulfite Kit, 59104, Qiagen, 
Venlo, Netherlands). Standards of 0% (Human Controls: Low Methylated DNA Control: 
80-8062-HGUM5, EpigenDx, Hopkinton, MA, USA) 50% and 100% methylation 
(Human Controls: High Methylated DNA Control, 80-8061-HGHM5, EpigenDx, 
Hopkinton, MA, USA) were included as a reference. The 50% methylation standard was 
created by mixing a 1:1 volume of 0% methylation standard and 100% methylation 
standard.  
  Following conversion, PCR was performed to amplify converted DNA using 
Platinum Taq DNA Polymerase (600 Rx, Invitrogen, 10966-034, Waltham, 
Massachusetts, USA). PCR experiment was arranged according to the following 
parameters: 
Table 1.6 PCR to amplify Bisulphite Converted DNA  
Reagent 1X (µl) 
H2O 1.32 
10X buffer 0.50 
dNTPs Mix (10 mM) 0.04 
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MgCl2 (50 mM) 0.1 
Taq (Platinum) 0.04 
Total 2 
 
The Eppendorf Mastercycler Gradient (Hamburg, Germany) was utilized for the PCR 
reaction under the following conditions (Table 1.7). 
Table 1.7 PCR conditions for amplification of bisulphite converted DNA 
95 ˚C 2 min   
95 ˚C 30 sec 
45 cycles 56 ˚C* 30 sec 
72 ˚C 1 min 
72 ˚C 5 min   
4 ˚C ∞   
 
Following the PCR reaction, 1 µL of several random samples was run on a 1% 
agarose gel (ultrapure agarose, Invitrogen, Waltham, MA, USA) in Tris-borate-EDTA 
(TBE) buffer at 100 V for approximately fifty minutes on BioRad Power Pac 3000 
(Hercules, CA, USA) to verify presence of converted DNA.  
Following successful bisulphite conversion of DNA, Shrimp alkaline phosphatase 
(SAP) treatment and Transcription/Cleavage reactions were performed using Epityper 
reagent kit (10239, Sequenom, San Diego, CA, USA) according to manufacturer’s 
protocol and resin addition (SpectroCHIP II Resin Kit 2 x 96, 10188, Sequenome, San 
Diego, CA, USA), also according to manufacturer’s protocol. SpectroCHIPs were spotted 
using Sequenom MassARRAY Nanodispenser Model RS1000 and then analyzed by 
Sequenom MassARRAY Analyzer 4 TYP: PHX-1 and EpiTYPER 1.2 software. The 
second experiment was completed using the same protocol but using different DNA 
samples and the second set of primers developed (see Table 1.4). 
 
1.2.6 MMP-13 Gene Expression Analysis 
 
RNA was converted to complementary DNA (cDNA) using Maxima H Minus 
First Strand cDNA Synthesis Kit W/DsDnase (K1682, Thermo Fisher Scientific, 
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Waltham, MA, USA) following manufacturer’s protocol. Presence of target sequence was 
verified by PCR using Platinum Taq DNA polymerase kit (Invitrogen, Waltham, MA, 
USA 18038042) and dNTPs (10297-018, Invitrogen, Waltham, MA, USA). PCR was 
carried out using Eppendorf Mastercycler Gradient (Hamburg, Germany) program using 
the following parameters; initialization phase of five minutes at 94 °C, then 28 repeating 
cycles of one minute at 94 °C for denaturation, one minute at 61 °C for annealing, and 
one minute at 72 °C for elongation followed by ten minutes at 72 °C for final elongation 
and a final hold at 4 °C (see Table 1.8).  
 
Table 1.8 Conditions for PCR for verification of target sequences 
94 ˚C 5 min   
94 ˚C 1 min 
28 cycles 61 ˚C* 1 min 
72 ˚C 1 min 
72 ˚C 10 min   
4 ˚C ∞   
 
Presence of target product was verified by running eight µL of PCR products on a 
1% agarose gel in Tris-borate-EDTA (TBE) buffer at 100 V for forty-five minutes using 
BioRad Power Pac 3000 (Hercules, CA, USA).  
Primers for MMP-13 were designed using Primer Blast 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) (Table 1.9). 
Table 1.9 Primer Pair for MMP-13 Gene Expression Analysis using rt-PCR 
Primer Name Sequence 
MMP13-Q92L AGCTGGACTCATTGTCGGGC 
MMP13-Q92R AGGTAGCGCTCTGCAAACTGG 
 
Gene expression analysis by relative quantification was determined on ABI 
7900HT Fast Real-Time PCR System (LifeTechnologies, Carlsbad, CA, USA) using 
GAPDH as a reference gene. A four point standard curve was established as a reference 
using cDNA dilutions from 0.25 µL, 0.12 µL, 0.06 µL, and 0.03 µL. Reaction was carried 
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out using 10 µL Power SYBR Green PCR Master Mix (4367659, ThermoFisher, 
Waltham, MA, USA), 0.06 µL cDNA, 0.4 µL each forward and reverse primers and 
water was added to a final volume of 20 µL.  Standard mode and conditions were set to 
two minutes at 50 °C followed by initial denaturation phase for 10 minutes at 95 °C and 
forty-five repeating cycles of fifteen seconds at 95 °C and one minute at 60 °C for 
denaturation and annealing respectively.  
Table 1.10 Settings for rt-PCR 
50 ˚C 2 min   
95 ˚C 10 min  95 ˚C* 15 sec 45 cycles 60 ˚C 1 min 
 
1.2.7 Statistics 
 
Statistical analysis was performed using STATA/SE 11.2 (Stata Corp, College 
Station, Texas USA). Mean comparisons of gene expression and methylation levels 
between OA cases and controls were assessed using Student’s t-test and the non-
parametric Mann-Whitney rank-sum test with a significance level defined at alpha = 0.05. 
Spearman’s rank correlation coefficient and significance was calculated to determine the 
relationship between methylation levels in the promoter region and gene expression. 
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1.3 CHAPTER 3: Results 
 
1.3.1 Demographic Information 
 
A total of 78 individuals were included in the analysis: 38 hip OA patients, 10 
knee OA patients and 30 controls. These individuals were chosen randomly, the only 
criteria being that we had obtained multiple cartilage samples during surgery, the DNA 
and RNA extraction experiment was successful and a high concentration and volume was 
obtained. The mean age was 64.2 ±1.36 years for cases and 78.4 ±1.92 for controls. The 
age difference between our cases and control was significant at p = 3.27 x 10-10. The body 
mass index (BMI) was 32.19 ±0.99 kg/m2 for cases and 23.83 ±0.85 kg/m2 for controls. 
This was significantly different at p = 2.11 x 10-9 (see appendix for BMI calculations). A 
total of 53 females and 25 males were included. Of the cases 62.5% were female and 
37.5% were male. From the control group 76.7% were female and 23.3% were male. The 
gender difference between cases and controls was not significant, p = 0.20. OA status was 
confirmed by a surgeon’s assessment and pathological report following surgery. Controls 
were classified as true controls if no signs of arthritis were present in the joint at the time 
of surgery. An additional classification, controls with minor degenerative changes in the 
removed cartilage, was included following interpretation of pathological report. This 
classification was used to indicate individuals with some degeneration of their cartilage. 
This degeneration was determined to be normal age-related erosion and not due to (OA). 
Our analysis indicated that both gene expression and methylation levels demonstrated no 
significant differences between true controls and those with minor degenerative changes. 
Therefore, they were both included in the control category for the overall analysis. Gene 
expression analysis included 53 individuals: 25 hip OA, 7 knee OA and 21 controls. The 
initial methylation analysis was done using DNA from 6 hip OA patients, 4 knee OA 
patients and 5 controls. The second round of methylation analysis included DNA from 62 
individuals: 30 hip OA, 6 knee OA, 26 controls. Of the 62 individuals, 2 controls and 1 
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hip OA patient had been previously included in the first methylation analysis, therefore 
only the measurement from the second run was used for the final analysis. 
 
Table 1.11 Demographic information of cases and controls 
Characteristics Controls 
 
Cases 
 
p-value 
Number of participants 
Sex, n (%) 
     Male 
     Female 
Age at surgery (years), mean ± SD 
BMI (kg/m2), mean ± SD 
30 
 
7 (23.3) 
23 (76.7) 
78.4 ± 1.92 
23.83 ± 0.85 
48 
 
18 (37.5) 
30 (62.5) 
64.2 ± 1.36 
32.19 ± 0.99 
 - 
 
0.2 
 
3.27 x 10-10 
2.11 x 10-9 
 
Age calculated in years at time of surgery ± standard deviation 
BMI calculated in kg/m2 at time of surgery ± standard deviation 
Sex frequency calculated for cases and controls 
P-value calculated by student’s t-test at significance p < 0.05 
 
Odds ratio calculations were also performed for obesity (OR 9.1, 95% CI: 2.7-30.18, p= 
0.0003), hypertension (OR 0.8, 95% CI: 0.3-1.9, p= 0.6) and type 2 diabetes (OR 0.4, 
95% CI: 0.1-1.0, p= 0.04).  
 
1.3.2 Gene Expression 
 
To establish the expression level of MMP-13 we carried out rt-PCR on RNA 
samples extracted from cartilage from hip and knee OA cases and healthy controls. To 
establish our control group the average RQ value from (14) true controls was compared to 
those with minor age-related changes (7), the mean RQ ± standard error was 0.313 ±0.14 
and 0.405 ±0.303 respectively (for sample calculation see Appendix A). The means were 
not significantly different at p = 0.8. Therefore, our two control categories were combined 
as one group. The difference between the mean RQ of knee and hip OA were also 
examined, at 0.903 ±0.28 and 1.75 ±0.44 respectively. This difference was also found to 
be not statistically significant at p =0.3. We therefore combined knee and hip OA patients 
into one group of “cases” in order to increase our sample size and study power. The 
average fold-change for cases was 1.56 ±0.36 and for controls was 0.34 ±0.13. 
Osteoarthritic cartilage was found to have greatly increased expression of MMP-13 by 
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359%, this was a significant difference, p =0.01 based on Student’s T-test (power = 1.00). 
Due to the non-parametric distribution of the gene expression data, the Mann-Whitney 
rank-sum calculation confirmed the significance at p = 0.006 (see Figure 1.3.1).  
 
Figure 1.2 MMP-13 expression results from rt-PCR of cartilage from OA patients (hip 
and knee) compared with healthy controls. 
 
1.3.3 Methylation analysis of MMP-13 
 
The level of methylation in the promoter region of seven CpG sites was 
investigated. The initial experiment included 6 hip OA cases, 4 knee OA cases and 5 
controls. The Ensembl genome browser was used to retrieve the promoter sequence of 
MMP-13. Using the browser we identified an ideal sequence covering 600 base pairs 
upstream of the first exon in the promoter region. Using the identified sequence, a primer 
pair spanning 224 base pairs (the closest primer pair available to the first exon) was 
chosen for the experiment. The primer pair covered 4 CpG units, 2 of which were 
analyzed successfully. Two of the CpG units (designated 1 and 2) were located very close 
together at –103 and –108 upstream of the transcription start site (TSS). Due to their 
proximity the mass spectrometer could not distinguish between the two sites and the 
results reported are based on overlapping signals that cannot be interpreted separately. 
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The other sites were CpG site 3 located at –128 and CpG unit 4 at –218 bp. The mean β 
value of CpG units 1 and 2 in cases was 0.92 ±0.015 and in controls was 0.93 ±0.031. 
Median for patients and controls was 0.94. The difference between the cases and controls 
was not significant at p = 0.78. The mean of CpG unit 3 in cases was 0.35 ±0.11 and in 
controls was 0.38. The median for patients was 0.27 and 0.38 for controls. The standard 
error could not be calculated for controls, only one control for this CpG site reached an 
acceptable threshold for measuring β-value and subsequently a Student’s t-test could not 
be applied. At CpG site 4 the mean for controls was 0.79 ±0.08 and for cases was 0.49 
±0.05, the median was 0.75 for controls and 0.43 for patients. This difference was 
significant at p = 0.005. CpG site 4 was therefore the only site found to be statistically 
significant in the first experiment. Therefore an additional experiment was performed to 
confirm this result and to measure several other CpG sites. 
 
Figure 1.3 Mean β values from initial methylation experiment of CpG sites within the 
promoter region of MMP-13 cases versus controls. 
 
1.3.4 Methylation of MMP-13 Experiment #2 
 
For the subsequent experiment a new primer pair was designed. The development 
procedure was the same. Using Ensembl genome browser a primer pair was designed 
from a 600 base pair promoter region upstream of the first exon. The 350 base pair 
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primers chosen overlapped CpG unit 4 from the previous experiment and also covered 3 
additional CpG sites not previously analyzed. CpG site 1 was located at –487 bp, CpG 2 
at –337 bp, CpG 3 at –317 bp and CpG 4 at –218 bp. The average β value of CpG unit 1 
in cases was 0.80 ±0.037 and controls was 0.81 ±0.032 at p = 0.9 (power = 0.18). CpG 
unit 2 cases had a mean of 0.65 ±0.064 and 0.71 ±0.083 in controls (p = 0.6) (power = 
0.76). CpG unit 3 cases were 0.84 ±0.036 and controls 0.92 ±0.037 (p = 0.1) (power = 
1.00). For CpG site 4 the mean β values for cases was 0.42 ±0.026 and controls 0.52 
±0.023. Of the sites tested only the fourth was found to be statistically different between 
OA cases and healthy controls at p = 0.008 based on Student’s T-test. This CpG site is the 
same as CpG site 4 from the first experiment. 
 
 
Figure 1.4 Mean β values from second methylation experiment of 4 CpG sites within the 
promoter region of MMP-13 cases versus controls. 
 
1.3.5 CpG site 4 combined data from experiment #1 and #2 
 
Based on the analysis, there was a significant difference between mean β values 
from the same CpG site for both runs. In order to obtain a more robust data set we 
combined the methylation data from CpG site 4 from the two experiments. A total of 66 
patients, 33 hip, 6 knee and 26 controls were included. Again, hip and knee OA patients 
were combined as cases, and controls with minor changes were included in the control 
category. The mean β values of the combined data for CpG site 4 for cases was 0.44 
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±0.023 and controls was 0.54 ±0.028. This difference was statistically significant based 
on Student’s t-test at p = 0.006 (power = 1.00).  
 
Figure 1.5 Combined mean β values from CpG site 4 from promoter region of MMP-
13 in cases versus controls. 
 
1.3.6 Correlation between gene expression and methylation 
 
To determine if any correlation exists between the expression of MMP-13 and 
methylation in the promoter region we utilized Spearman’s rank correlation analysis (see 
Table 1.12). Of the seven CpG sites examined, CpG site 2 from the second experiment 
exhibited a statistical significance. This CpG site is located at –337 bp from the TSS. 
However this site did not show a significant difference between cases and controls in the 
methylation analysis. Additionally, CpG 4 was not significantly associated with gene 
expression. 
Table 1.12 Spearman’s rank correlation for all CpG Sites 
CpG site Number of Observations rho p-value 
Exp 1, CpG 1 & 2 8 0.48 0.23 
Exp 1, CpG 3 4 0 1 
Exp 2, CpG 1 34 0.13 0.47 
Exp 2, CpG 2 30 - 0.39 0.035 
Exp 2, CpG 3 41 - 0.30 0.06 
Exp 1 & 2, CpG 4 48 - 0.24 0.1 
Spearman’s rho and statistical significance calculated for each CpG site to 
determine the correlation between gene expression and methylation levels.  
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1.3.7 Confounding Factors 
 
Several potential confounding factors were examined based on our study 
population. OA prevalence is higher in women, older individuals and those who are 
overweight. Therefore, age, BMI and sex were examined as the primary confounding 
variables. Statistical analysis was performed using Spearman’s rank correlation. Briefly, 
it measures the strength of the association between two ranked variables that display a 
monotonic relationship. Scores are ranked and given values between +1 to -1, where +1 
indicates a perfect positive relationship, 0 indicates no association and -1 indicates a 
perfect negative relationship. The closer the r (or rho) value is to zero, the weaker the 
association between ranks. Based on an α value of 0.05 none of these potential 
confounders significantly influenced the results of this study (Table 1.13, Table 1.14). 
Therefore, the methylation results were not adjusted based on any of these confounders. 
 
Table 1.13 Spearman’s rank correlation analysis of confounding factors for 
methylation analysis of CpG site 4 
Confounding 
Factors 
       Cases       Controls 
 Rho p-value Rho p-value 
Age 0.09 0.57 0.29 0.13 
Sex 0.12 0.45 0.11 0.57 
BMI 0.15 0.32 0.25 0.20 
 
 
Table 1.14 Spearman’s rank correlation analysis of confounding factors for gene 
expression 
Confounding 
Factors 
       Cases          Controls 
 Rho p-value Rho p-value 
Age 0.23 0.20 0.16 0.50 
Sex 0.15 0.40 0.13 0.58 
BMI 0.17 0.35 0.03 0.90 
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1.4 CHAPTER 4: Discussion 
 
1.4.1 Gene Expression of MMP-13 
 
Matrix metalloproteinases 1, 8 and 13 are the only mammalian enzymes capable of 
initiating cleavage of type II collagen, a major component of cartilage, at neutral pH 
(Billinghurst et al., 1997). This makes the MMP family essential for normal development 
and turnover of the ECM and has implications for cartilage pathologies (Murphy et al., 
2002). Specifically, MMP-13 is a downstream target gene in the TGF-β signalling 
pathway, suspected to be involved in OA pathogenesis (van der Kraan, 2014). In murine 
models of OA, MMP-13 is over expressed in OA joints when compared to sham-operated 
controls (Bateman et al., 2013). Also, previous studies on humans have demonstrated an 
over-expression of MMP-13 in aged (Wu et al., 2002) and osteoarthritic cartilage (Sakata 
et al., 2014), chondrocytes (Bui et al., 2012) and synovial fluid (Ryu et al., 2012) from 
OA patients. 
To quantify the level of MMP-13 expression in OA cartilage when compared to 
controls we performed rt-PCR. We found the gene expression levels between knees and 
hips to be comparable, with minor variations that were not significant. Although, some 
studies indicate differences in the genes or pathways involved in OA between joints 
(Rushton et al., 2014). MMPs have previously been associated with OA progression in 
both joints (Gonzalez, 2013; Rushton et al., 2014). The present study demonstrates that 
MMP-13 is likely involved in OA pathogenesis in both joints. However, the study has 
only a small number of knee OA patients and verification with a more robust sample size 
is necessary. Gene expression was also similar in healthy controls and controls with 
minor degenerative cartilaginous changes. Those with minor changes had a slightly 
higher expression but it was not significant. These findings suggest that age-related 
degenerative changes in cartilage do not necessarily exhibit an over-expression of MMP-
13 such as that seen in osteoarthritic cartilage, and that the over-expression of the gene is 
specific to the pathology. The overall expression from cases was 359% fold higher than 
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controls. This demonstrates a significant increase in MMP-13 expression in OA patients. 
This finding was verified using the Mann-Whitney rank-sum statistical analysis due to the 
nonparametric distribution of the gene expression data. The expression was not dependent 
on either BMI or sex, indicating that MMP-13 expression is equally up regulated in men 
and women irrespective of their BMI. While there are genes and pathways associated 
with OA specific to women (Lian et al., 2007) and obesity, such as adipokines (Poonpet 
& Honsawek, 2014), these do not appear to be a factor in MMP-13’s association with OA. 
This study supports previous observations that MMP-13 mRNA is present at higher levels 
in cartilage tissue from OA patients when compared to healthy controls. The high level of 
MMP-13 indicates that OA patients are undergoing more significant cartilage 
degeneration and ECM turnover, supporting a potential role for MMP-13 in OA 
pathogenesis. However, the nature of this relationship (whether the up-regulation of 
MMP-13 is a cause or consequence of OA) is unclear. The catabolic erosion of cartilage 
is a dynamic process and MMP-13 plays a key role in its degeneration. This experiment 
provided evidence of altered MMP-13 expression in RNA from osteoarthritic cartilage as 
a necessary step to evaluate the effect DNA methylation could have on the expression of 
this gene. 
 
1.4.2 Methylation Analysis 
 
Methylation is the addition of a methyl group to 5’ cytosine-phosphate-guanidine, 
also called a CpG site. It is a method of epigenetic modification, whereby genes are able 
to respond to environmental stimuli. Previous studies have examined areas of 
hypomethylation in MMP-13 that may correspond with gene expression (Bui et al., 2012). 
By measuring the methylation of seven CpG sites within the promoter region of MMP-13 
we are able to gain a better understanding of its regulation and role in OA. In our study, 
while there were minor changes between methylation levels in knee and hip articular 
cartilage in MMP-13, they were not significantly different. Although not a robust knee 
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sample size, at least for MMP-13 the differences in methylation profiles at these seven 
CpG sites was not significantly different between hip and knee OA.  However, a study by 
den Hollander and colleagues found that epigenetic profiles of knees and hips are distinct 
(den Hollander et al., 2014). They measured the overall epigenetic landscape, and not 
individual CpG sites. It is possible that the disease pathology has made the methylation in 
the MMP-13 promoter comparable in the two joints. The similar methylation level in 
osteoarthritic cartilage from knees and hips allowed us to combine these cases into OA 
patients and perform a larger comparison with the control group.  
We performed two experiments, covering a total of seven CpG sites located in the 
promoter region of MMP-13. Of the seven CpG sites analyzed, only one was found to 
have a significant difference between cases and controls. The site located at –218 from 
the TSS was significantly demethylated in cartilage from OA patients (both hip and knee) 
as compared to controls. This CpG site was included in the experiments from both sets of 
primer pairs, allowing a more robust statistical evaluation of this site. This result supports 
previous experiments that had found hypomethylated CpG sites within the MMP-13 
promoter (Bui et al., 2012; Taylor et al., 2014), and a study by Rushton et al. that 
demonstrated that chondrocytes from cartilage of healthy controls and OA patients had 
different methylation profiles (Rushton et al., 2014). After examining potential 
confounders we determined that age, sex and BMI were not significantly associated with 
methylation at CpG site 4 at p < 0.05.  
Many genes, particularly those associated with transcription regulation, 
development and processes of anatomical structure, tend to become hypermethylated in 
the promoter region with advancing age (Johansson, Enroth, & Gyllensten, 2013). In 
osteoarthritic cartilage this process can become disrupted, and hypomethylation of some 
CpG sites occurs instead, potentially contributing to an up-regulation of MMP-13. One 
theory of the mechanism of OA is that the balance of catabolic and anabolic processes 
becomes disrupted, causing an up-regulation of some catabolic genes while anabolic 
genes are suppressed (Blanco & Rego-Perez, 2014; Roach et al., 2005). Our study 
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supports the up-regulation of the catabolic MMP-13 gene. Pathways known to be 
involved in the regulation of MMPs are TGF-β and ERK/MAP kinase signalling 
pathways, which also suppress the healthy, anabolic expression of type II collagen and 
chondrocyte aggrecan, potentially leading to an OA phenotype (C. G. Chen et al., 2012; 
W. Chen et al., 2015; Goodwin et al., 2010).  
 
1.4.3 Gene expression and methylation 
 
When methylation occurs in the promoter regions of genes it typically represses 
the transcription of the gene thereby silencing it. Most tissue-specific methylation occurs 
in areas of low CpG density, called “shores”, close to CpG islands, and correlates with 
transcriptional repression of the gene (Barter et al., 2012). In order to elucidate the role of 
methylation in regulating MMP-13 expression, we used statistical methods to evaluate the 
correlation between gene expression and methylation at CpG sites in the promoter region 
of MMP-13. Using Spearman’s rank correlation (due to the nonparametric of the gene 
expression data) we tested the correlation between the two and found that none of our 
groups (controls, hip or knees) demonstrated a correlation between methylation at CpG 
site 4 in the promoter region and gene expression. Specifically, while the methylation 
analysis indicated hypomethylation of the CpG site at –218 bp upstream of the first exon, 
this site did not correlate with the expression of MMP-13. The hypomethylation of this 
CpG site cannot, by itself, explain the over-expression of MMP-13.  Interestingly, 
expression did correlate to a different site, CpG 2 from the second experiment but the 
methylation difference between cases and controls was not significant at p > 0.05. It 
seems methylation of these CpG sites alone cannot explain MMP-13’s over-expression at 
the level of 359% measured in this study. Several possible explanations exist. Either we 
did not test the site(s) responsible for the change observed in gene expression in 
osteoarthritic cartilage, or perhaps gene expression corresponds to epigenetic regulation 
from multiple sites. Alternatively, control of gene expression could be achieved through 
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methods other than DNA methylation. Other possible epigenetic mechanisms of 
regulation include miRNAs or histone modification. There is evidence to suggest 
miRNAs could play in a role in MMP-13’s expression (Akhtar et al., 2010; Liang et al., 
2012). Also, regulation of genes could occur through multiple epigenetic mechanisms in 
conjunction. 
 
1.4.4 Study Strengths 
 
The strengths of this study include the use of human OA cartilage. Due to the 
resilient nature of cartilage, it can be difficult to manipulate or utilize for experiments. As 
such, many studies use murine models or cultured OA chondrocytes. The use of cartilage 
taken directly from osteoarthritic joints can more accurately reflect the environment 
within the joint and the genes involved in a way that tissue culture cannot. Furthermore, 
epigenetic landscapes are different depending on the tissue used and could be altered in a 
tissue culture in unknown ways. Therefore, it was advantageous to use one tissue type, 
taken directly from a human joint for the analysis. 
Another strength is the use of DNA and RNA extracted from the same cartilage 
sample. As far as I can tell this is the first study to examine MMP-13 using DNA and 
RNA from the same cartilage sample. There are indications that even within the same 
joint, cartilage taken from different sections can reflect differing gene expression or 
methylation patterns (Aicher & Rolauffs, 2014; Moldovan et al., 1997). Therefore, using 
DNA and RNA extracted from the same tissue specimen is especially useful for 
correlation analysis and further insight into the genes and epigenetic mechanisms 
involved in pathogenesis.  
While the role of MMP-13 in OA has been previously examined in other 
populations, this is the first study in the Newfoundland population. The unique population 
genetics and high prevalence of OA in NL make it an advantageous study population to 
use. 
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1.4.5 Study Limitations 
 
While cartilage is often used to study the joint environment, it does not necessarily 
reflect what is occurring in all tissues involved in OA. Bone, cartilage, synovium and 
ligaments all contribute to disease progression as a “whole-joint” (Hugle et al., 2012). 
However, it is currently unknown which tissues commence OA progression or the extent 
to which they all contribute (Cox, van Donkelaar, van Rietbergen, Emans, & Ito, 2012; 
Pitsillides & Beier, 2011). However, analysis of OA progression using a whole joint from 
human patients is difficult with current methods. Therefore, cartilage tissue, considered to 
be actively involved in the disease process, is frequently used for OA studies. 
Furthermore, we used mRNA and DNA to study gene expression and methylation. 
However, protein levels were not examined in this analysis. Studying DNA and mRNA 
expression with corresponding protein levels would have improved our analysis and 
knowledge of the regulation of MMP-13. 
 The number of cases versus controls utilized was not equal, this may bias the 
results as the methylation levels in cases may have been more accurately calculated. As 
well, a more robust sample size could have been used. Although most CpG sites were 
sufficiently powered, CpG unit 1 in this analysis was underpowered. 
A complication of studying methylation profiles is that they do not always 
correlate directly to gene expression (den Hollander et al., 2014). Epigenome-wide 
experiments can inform us as to what areas may correspond to expression (den Hollander 
et al., 2014), and verification by studying the effects of single CpG sites is important 
(Vrtacnik et al., 2014). Both methods can provide novel information about genes or 
pathways and their regulation. This study measured seven CpG sites within the promoter 
region, up to 600 base pairs upstream from the TSS, it is possible that studying 
methylation throughout the gene or from related genes and pathways might provide a 
more complete picture of MMP-13’s involvement in OA.  
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1.5 CHAPTER 5: Conclusions 
 
1.5.1 Significance of this Study 
 
Osteoarthritis is a leading cause of pain and disability worldwide. As the most 
common form of arthritis, it currently affects approximately one-in-five Canadians 
(Arthritis Alliance of Canada, 2011). Despite this high prevalence and increasing 
incidence, the aetiology and pathogenesis are poorly understood. Also, while over-the-
counter supplements exist, their effects are controversial, and as of yet no disease 
modifying osteoarthritis medications have been approved by the FDA. Furthermore, no 
biomarkers or methods for early detection are available. Due to the significant 
socioeconomic burden and increasing prevalence of OA, in excess of what would be 
expected from the obesity epidemic and an aging population, research into the genetics 
and epigenetics of OA is necessary. Enhancing our knowledge and subsequently 
developing therapies or diagnostics requires further research into genes such as MMP-13, 
and their regulation.  
 
1.5.2 Future Directions 
 
Next steps could include testing other genes suspected to play a catabolic role in 
ECM turnover and cartilage degeneration in OA, such as other MMPs, for a relationship 
between methylation and gene expression.  
 Further investigation of CpG site 2, located – 337 bp from TSS is required 
to verify its correlation with MMP-13 gene expression. Although the methylation level at 
this site was not significantly different between cases and controls, it was lower in cases. 
Indicating this site could be involved in regulating gene expression. Validation by testing 
with a larger sample pool could be useful. As well, the age of our controls was much 
higher than cases, the study could benefit from a matching case control study. 
Using a grading scale such as the K-L scale to measure patient and control 
samples and comparing them to gene expression and methylation may yield a pattern 
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reflective of histological grading. There is evidence from previous studies to suggest there 
may be correlation between methylation of CpG sites and histologic severity (Jeffries et 
al., 2014). It would be interesting to experimentally verify if this correlation occurs with 
gene expression or methylation of MMP-13. Furthermore, this experiment could shed 
light onto the cause/consequence relationship between MMP-13 and OA. 
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2 PART II: BURDEN OF RISK ALLELES FOR COMPLEX 
TRAITS IN THE NEWFOUNDLAND AND LABRADOR 
POPULATION 
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2.1 CHAPTER 1. Introduction 
 
2.1.1 Genetics in Founder Populations 
 
A small proportion of individuals from one population migrating to a new location 
and establishing a colony usually experience a loss of genetic diversity, this is known as a 
“founder effect”. A random sample of alleles is removed from the original population 
with the migrants and ends up in the new population. As a result of this effect, the new 
population often has a distinct genetic profile, with less genetic variation than the original 
population. Allele frequencies at the expansion front will have higher variance, and 
alleles are more likely to become fixed or lost (Peter & Slatkin, 2015). The founder 
population may also experience a population bottleneck, increased sensitivity to genetic 
drift, low genetic variation and an increase of inbreeding. In human populations, 
numerous factors, most notably geographic isolation, can result in a founder effect. Other 
factors that can influence isolation are social status and religion, among others.  
Consequences of a founder effect can include higher prevalences of certain 
genetic conditions and lower prevalences of others due to the loss of genetic variation. 
There is an ongoing debate as to whether founder populations truly exhibit an excess 
burden of disease due to deleterious variant alleles. Lohmueller et al. suggested that 
European populations have more deleterious variants as compared to African American 
individuals (Lohmueller et al., 2008). Utilizing a computer simulation they found 
bottlenecked populations (European Americans in this case) were found to have about 
26% more homozygous damaging genotypes and an excess of non-synonymous SNPs 
(Lohmueller et al., 2008). The findings support the “Out-of-Africa” bottleneck theory, 
suggesting that bottlenecked populations (European populations in this case) most likely 
accumulate more deleterious variants following the event (Lohmueller et al., 2008). In 
contrast, a recent study suggests that Europeans and West Africans have comparable 
burdens of deleterious alleles (Simons, Turchin, Pritchard, & Sella, 2014). While 
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evidence suggests bottleneck populations could harbour more deleterious variants, this 
theory is disputed. 
Many current examples of founder population have been identified. Perhaps the 
best-known example of genetic isolation driving a high incidence of genetic disorders is 
in the Ashkenazi Jew population, which has been extensively studied. Ashkenazi Jews are 
known to have a higher prevalence of Tay-Sachs and cancer susceptibility (particularly 
BRCA 1 and 2 mutations) (Carmeli, 2004). Approximately 1 in 4 people of Ashkenazi 
Jew ethnicity is a carrier of either: Bloom Syndrome, Canavan disease, Cystic Fibrosis, 
Familial Dysautonomia, Fancomi Anemia, Gaucher disease, mucolipidosis IV, Niemann-
Pick disease, Tay-Sachs or Torsion dystonia (National Cancer Institute (NCI), 2014). The 
Finnish population is also often used as a classic example of a founder effect with higher 
rates of recessive Mendelian conditions such as megaloblastic anaemic 1 (Aminoff et al., 
1999; Savukoski et al., 1998). These high rates of disease are due to higher incidences of 
specific deleterious mutations within the population. At least 35 disease genes have been 
identified as enriched in the Finnish population (Peltonen, Jalanko, & Varilo, 1999). A 
cluster of families with progressive epilepsy with mental retardation (EPMR) 
(Tahvanainen et al., 1994) live on the Eastern border and a similar cluster of the variant 
form of late infantile neuronal ceroid lipofuscinosis (vLINCL) cases on the Western 
coastline have been described (Peltonen et al., 1999). On the other hand, some disease 
alleles have become almost non-existent in Finnish populations, for example 
phenylketonuria, galactosemia, maple syrup disease and cystic fibrosis (Peltonen et al., 
1999). 
Another example, a small community in the Netherlands with common ancestry, 
has been found with several genetic disorders that are more common than in surrounding 
areas. Due to social and religious separation, the community is isolated and has been 
described as genetically homogeneous. Four rare disorders, pontocerebellar hypoplasia 
type 2 (PCH2), fetal akinesia deformation sequence (FADS), rhizomelic 
chondrodysplasia punctata type 1 (RCDP1), and osteogenesis imperfecta (OI) type IIB/ 
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III have recently been found in multiple patients from this village, driven to higher 
prevalence by a founder effect (Mathijssen et al., 2015). Marchi et al. recently identified 
the first proof of a founder effect in Northern Europe and were able to narrow down the 
timing of the occurrence to an event that had taken place nine generations previously 
(Marchi et al., 2014). They utilized microsatellite markers of β –globin to identify variant 
carriers in North England sharing a common haplotype for β –Thalassemia (Marchi et al., 
2014).  
These examples of high disease prevalence in founder populations are not 
observed in out-bred populations, where these conditions have a lower incidence and a 
wider array of mutated regions, indicating no single common ancestor (Marchi et al., 
2014). In isolated populations the prevalence of genetic disorders can be relatively high. 
The high prevalences are likely driven by one or a few specific founder mutations in a 
gene that has spread throughout the population. Many successful studies have discovered 
novel rare variants that have become enriched in such populations, making founder 
populations a good resource for studying genetic conditions. These elevated disease 
prevalences have been found to mostly be consequences of a historic founder effect, 
population bottlenecks, genetic drift or an increase in inbreeding. 
 
2.1.2 Settlement History of Newfoundland & Labrador 
 
Newfoundland’s unique settlement history and population structure make it a 
valuable location for studying population genetics. Of the approximate 520,000 current 
Newfoundland residents, approximately 80-90% can trace their ancestry to a group of 
around 20,000 – 30,000 settlers from South West England and South East Ireland in the 
1700 and 1800’s (Mannion, 1977). Although a small proportion of French and Basque 
descendants remain as well (Mannion, 1977). Early native groups, the Beothuk Native 
Americans, Maritime Archaic Indians, Paleo Eskimos, as well as Norse settlers inhabited 
Newfoundland in the past but no permanent communities remain (Rowe, 1980), though 
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there are considerable numbers of Mi’kMaq residing in NL today. After John Cabot’s 
expedition to Newfoundland in 1497, overwintering establishments were constructed to 
support the fishing trade. These settlements were seasonal due to the harsh winters but are 
recorded as early as 1527 (Pope, Carr, Smith, & Marshall, 2011). At that time, 
Newfoundland had an abundance of natural resources and colonization was strictly 
controlled by England. However, evidence of permanent settlements began in 1621 from 
English immigrants and by 1675, Irish Catholics immigrants were documented in St. 
John’s (Pope et al., 2011). At that time, English Protestants inhabited over 30 settlements 
along the Avalon Peninsula of Eastern Newfoundland. The settlements were primarily 
founded by less than five families originally from localized regions of southwest England 
(Mannion, 1977). By 1753 all major communities along the Avalon Peninsula also had 
large Irish communities (O'Neill, O'Neill, & O'Neill, 2003; Rowe, 1980). As more people 
immigrated, settlements and out ports spread further inland along waterways and bays, 
supported by the healthy fishing trade. Throughout the 17th-20th centuries, there was 
limited contact between settlements due to religious, social and geographic barriers 
(Mannion, 1977). Two main religions were present in Newfoundland at the time, the 
Anglicans and Catholics. The animosity between them made relationships between 
individuals from different religious communities rare. Historically, out-ports were small 
and isolated and most offspring remained near the original settlements (Bear et al., 1987). 
Of the outport populations, only 1 – 8% of the population were not originally from the 
area, and the majority of births were to parents from the same community (Bear et al., 
1987). As a result, Newfoundland has had large family sizes, small settlement populations 
and minimal dispersion between out-ports, resulting in a high degree of genetic 
homogeneity and an abundance of several monogenic disorders (Crawford et al., 1995). 
NL has been utilized as a resource for identifying genes associated with monogenic 
disorders and is now of interest for studying genes implicated in common and complex 
diseases (Rahman et al., 2003).  
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2.1.2.1 Genetic conditions in Newfoundland 
Newfoundland’s unique settlement history has driven research into its genetic 
architecture and associated medical conditions. At first, this research in Newfoundland 
concentrated on rare medical conditions and later on genetic variation (L. J. Martin et al., 
2000). For example, a study by Crawford and colleagues in 1995 examined red cell 
antigens and calculated gene frequencies and describe Burgeo, South Ramea and Fogo 
Island as being populations that had differing genetic structures (Crawford et al., 1995) 
and had ultimately experienced a loss of heterogeneity with respect to the source 
population (Pope et al., 2011). In Newfoundland, a number of diseases are considered 
more prevalent when compared to out-bred populations, type 1 diabetes (40/100,000 
compared to the general population at 7-15/100,000), Lynch syndrome (Stuckless et al., 
2007), hereditary diffuse gastric cancer syndrome (Kaurah et al., 2007), psoriasis and 
some cardiomyopathies, are all measured at higher rates in the Newfoundland population 
(Kosseim et al., 2013). Evidence for other diseases enriched in the Newfoundland 
population due to the founder effect include several autosomal dominant disorders such as 
arrhythmogenic right ventricular dysplasis type 5 (Merner et al., 2008) and familial forms 
of pulmonary fibrosis (Fernandez et al., 2012). Xie et al. describe a very high prevalence 
of mild haemophilia type A at a rate of 44 in 3,300 males in isolated populations in rural 
Newfoundland. This is an extremely high rate as compared to out-bred populations (Xie, 
Zheng, Leggo, Scully, & Lillicrap, 2002). The same mutation, a missense mutation 
(Val2016Ala) had previously been described in five other patients, all from areas around 
London UK. The mutation most likely arose independently in the two populations and 
expanded in Newfoundland through a founder effect (Xie et al., 2002). Further evidence, 
Doucette et al. describe a rare, severe retinal disorder called achromatopsia in 
Newfoundlanders that had previously been described at a high rate (4-10%) in another 
founder population from the Pacific Islands. They determined that the large family size 
and isolation of communities along the coast of Newfoundland had resulted in higher than 
expected inbreeding coefficient and a high rate of disease. Furthermore, unrelated patients 
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shared identical alleles suggesting a likely common ancestor. By reconstructing the 
haplotype they determined that 80% of achromatopsia alleles identified were the result of 
a founder effect in the Newfoundland population (Doucette et al., 2013). These examples 
of rare genetic conditions more prevalent in Newfoundland have been identified to be a 
result of the founder effect during the settling of NL.  More recently, a study to measure 
the loss of genetic variation due to a founder effect, drift and inbreeding in Newfoundland, 
was undertaken by Pope and colleagues. They studied microsatellite loci and complete 
mitochondrial DNA (mtDNA) genomes from 27 individuals of known matrilineal 
ancestry (Pope et al., 2011). They found a high degree of microsatellite diversity (HE = 
0.763) and a significant degree of inbreeding (FIS = 0.0174) (Pope et al., 2011). Thus, the 
observed increase in disease prevalence in NL may also be highly influenced by 
inbreeding and large family sizes.  
 
2.1.3 Genome-Wide Association Studies  
 
Genome-wide association studies (GWAS) have become increasingly useful for 
identifying allele variants associated with given traits. These traits can include eye colour 
or hair colour, or they could be associated with an increased risk for disease such as 
cancer or arthritis. The introduction of population-scale whole-genome data sets has 
enhanced our capabilities to identify or interpret genetic variants in the human population. 
Genome-wide association studies (GWAS) examine the genome for common genetic 
polymorphisms to determine potential associations with given phenotypic characteristic. 
The principle idea behind GWAS is that a mutation in a common ancestor entered the 
population and spread. This process has resulted in many, common genetic variants in the 
population. These alleles, now prevalent, generally have a small effect or low penetrance 
and may not have equal impacts on gene function.  GWA studies have successfully 
identified thousands of single nucleotide polymorphism (SNPs) associated with a variety 
of complex diseases (Welter et al., 2014). In addition, these studies provide insight into 
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common pathways or genes not previously implicated in disease processes by other 
methods of analysis. The presence of these multiple low penetrance polymorphisms in the 
general population could explain some of the missing heritability of certain complex 
diseases. 
 Other theories of missing heritability include rare variants of large effects, rare 
combinations of common variants, parent-of-origin effects, or epigenetics (Eichler et al., 
2010). Parent of origin effects have been described in cancer and for type 1 and 2 
diabetes, where variants have been discovered that can either confer or reduce risk 
depending on the parent of origin (Kong et al., 2009). These effects are difficult to 
evaluate, and could be underestimated in models that do not include parental origin 
(Eichler et al., 2010). Epigenetics, the heritable changes that alter gene expression without 
affecting the underlying DNA sequence, can also contribute to heritability. The 
environmentally induced epigenetic change can be transmitted to one of more 
generations, as an “epigenetic persistence of genetic memory” (Eichler et al., 2010). For 
example, a paternal grandmother who experienced sharp changes in food supply during 
childhood confers an increased risk of cardiovascular mortality to her female 
grandchildren (Bygren et al., 2014). Another possibility is that large variants, individually 
rare but common in the general population exist. In fact, these large deletions and 
duplications result in many of the genetic differences observed in humans (Sebat et al., 
2004). A study conducted by Itsara et al. identified large variants in many individuals, 
variants larger than 500 kb in 5% – 10% of individuals and variants greater than 1 Mb in 
2% (Itsara et al., 2009). Up to 8% of people are estimated to carry a large duplication or 
deletion greater than 500 kb and occurring at a frequency of < 0.05% (Eichler et al., 
2010). While these rare variants are common, 1% carry >1 Mb, they are generally 
considered deleterious and have been implicated in several conditions such as 
neurological disease, schizophrenia, mental delays (Itsara et al., 2009) and autism (Sebat 
et al., 2007). 
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Most variants discovered through GWAS are associated with only a small 
increased risk of disease and have a small predictive value but the magnitude of their 
attributable risk may be large due to their frequency (Manolio et al., 2009b). In most 
cases of common complex disorders the combined contribution of loci to disease 
variation is often <10% (Bjorkegren, Kovacic, Dudley, & Schadt, 2015). For example, the 
153 known coronary artery disease (CAD)-associated variants explain less than 10.6% of 
the genetic variation observed across the population (Bjorkegren et al., 2015). Another 
way to assess heritability is to consider all measured SNPs together. A study by Yang et 
al. utilized a linear model to explain the complex trait of height by estimating the variance 
explained by all height-associated SNPs together (Yang et al., 2010). When applying this 
“polygenic” model to height 294, 831 SNPs explained as much as 45% of height 
variance, a significant increase relative to the 5% explained by published individual SNPs 
(Yang et al., 2010). Currently, there is a wide spectrum of identified SNPs corresponding 
to various complex diseases. The approach of combining individual SNPs associated with 
complex diseases could increase the predictive value of risk alleles discovered through 
GWAS.  
Additionally, these association studies can benefit from populations in tight 
linkage disequilibrium (LD). LD is the non-random association of alleles that likely arose 
in a single, common ancestor. In association studies, studying tightly linked variants can 
conserve resources. Genetically isolated populations, particularly those founded recently 
could have longer stretches of LD than other populations. Populations with descendants 
from a small number of founders, occurring relatively recently exhibit extensive LD with 
few gaps (Service et al., 2006). In theory, these isolated populations could achieve better 
genome coverage or require fewer markers for association studies (Service et al., 2006). It 
is suggested that association studies from these populations could be more useful than 
out-bred populations (Service et al., 2006). Assessing the excess disease burden of 
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deleterious variants in a bottleneck population can offer many advantages to elucidating 
the burden of disease in these populations and others. 
 
2.1.4 Founder Populations as Models for Studying Genetic Disease 
 
Most complex diseases have a strong heritable component, but identifying all 
potential genetic variants has been difficult. An important question is why these common 
disease-associated variants are so prevalent in the human genome. A current theory 
suggests that such diseases arose due to the accumulation of mildly detrimental variant 
alleles in the human genome. In theory, genetically isolated populations, having 
undergone a recent bottleneck, could offer advantages to studying complex disease due to 
the higher frequency of certain risk variants present in such populations. A recent study 
by Lim and colleagues used exome sequencing of a Finnish population to compare 
variant alleles to other similar European populations. They reported more unusually 
strong acting alleles and variants at higher frequencies in the Finnish population, up to 
1% for highly penetrant and lethal conditions (Lim et al., 2014; Polvi et al., 2013). They 
proposed that while the bottleneck removed most rare variants, the ones that were still 
present had become substantially elevated in frequency and that the Finns have an 
enrichment of low-frequency (0.5% – 5%) loss-of-function (LoF) variants (de la Chapelle 
& Wright, 1998; Lim et al., 2014). This observation led them to pursue potential health-
related consequences of the deleterious low frequency alleles with significant results. For 
example, a nonsense variant in the Translation Elongation Factor, Mitochondrial gene 
(TSFM) was present at 1.2% allele frequency in the Finn population, but was absent in the 
out-bred European population. Furthermore, this variant was not found in a homozygous 
state in over 36,000 Fins, and two families with Finnish mitochondrial disease were 
identified with compound heterozygosity of this nonsense variant (each family had a 
different second hit in the TSFM gene) (Lim et al., 2014). This suggests that a loss of this 
gene is severely detrimental in humans, and that a complete loss could result in 
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embryonic lethality, or severe early childhood disease (Lim et al., 2014). The high 
prevalence of this allele in the Finnish population is likely a consequence of the 
population bottleneck, where alleles were drawn at random from rare variants from the 
original population and spread at a higher frequency in the new population. While the 
out-bred population had higher proportions of LoF variants, they were either selected 
against or arose recently, keeping the frequencies very low.  
Founder populations such as the Finnish population also provide good resources 
for GWA studies of complex traits due to synthetic associations. Synthetic associations 
can be defined as multiple rare variants that occur more frequently in association with one 
allele at a common SNP than with the other (Goldstein, 2009). Dickson et al. postulate 
that multiple low-frequency variants spanning large regions of the genome may account 
for some observed disease-association (Dickson, Wang, Krantz, Hakonarson, & 
Goldstein, 2010). The causal variants underlying GWAS associations are not necessarily 
frequent as GWA studies can find associations resulting from SNPs in partial linkage 
disequilibrium to rare mutations with strong effect. Thus, founder populations are useful 
study populations due to an enrichment of mutations with a strong effect that are 
otherwise rare in outbred populations. 
A recent study using whole-exome sequencing of a founder population of French-
Canadians that had experienced a bottleneck less than 20 generations ago was done by 
Casals et al. They discovered reduced levels of diversity, higher homozygosity, an excess 
of rare variants and a higher proportion of putatively damaging functional variants in the 
founder population (Casals et al., 2013). The authors hypothesize this finding could 
partially explain the increased incidence of genetic disease in the group (Casals et al., 
2013).  
Another recent study of European Romanis, who recently underwent a population 
bottleneck resulting in a higher prevalence of several diseases, was conducted by 
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Mendizabal et al. Researchers tested SNPs associated with several metabolic and 
cardiovascular disorders previously reported at a high prevalence in the Romani and 
compared the average risk allele frequencies from the Romani population to an outbred 
European population (Mendizabal, Lao, Marigorta, Kayser, & Comas, 2013). The 
Romani population exhibited excess homozygosity and had higher than average risk 
alleles frequencies when compared to other European populations for four of the five 
cardiovascular/metabolic conditions tested, with one reaching a significant difference 
(Mendizabal et al., 2013). The results also indicated the genetic risk for these conditions 
matched the known pattern of morbidity, suggesting common risk alleles discovered by 
GWAS (at a MAF of greater than 5%) could somewhat explain the higher disease 
prevalence in the founder Romani population (Mendizabal et al., 2013).  
A study by Lohmueller et al. found that each person likely carries several hundred 
potentially damaging SNPs (Lohmueller et al., 2008). Apparently healthy individuals can 
have many disadvantageous variants in their genome without showing any obvious ill 
effects, possibly due to the late onset of the disease or mild clinical phenotype. It is now 
suspected that up to 10% of functional genes in the human genome varies between 
individuals, with only minor health consequences (Xue et al., 2012). Xue et al. found that 
the CEU population from the 1000 Genomes Project website, genotyped from healthy 
adult residents of Utah with Northern and Western European ancestors, had ~12,000 
derived missense-alleles per individual. By assessing the number of potentially 
deleterious variants in healthy humans populations they found an average individual 
might eventually be found to carry upwards of 400 damaging variants and more than 2 
disease-causing ones. Each individual likely has up to 515 missense substitutions, 
approximately 60 of which were homozygous and predicted to be highly damaging, and 
many more disease-associated SNPs (Xue et al., 2012). The high numbers of disease 
associated SNPs in apparently healthy individuals gives credence to the common variant, 
common ancestor hypothesis of complex disease. Where each individual harbours many 
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disease-associated SNPs but due to low-penetrance or late onset, do not have the disease. 
Kryukov et al. propose that the high incidence rate of complex diseases suggests 
high cumulative frequencies of medically deleterious variants are probably present in the 
human population (Kryukov, Pennacchio, & Sunyaev, 2007). Up to 70% of low-
frequency missense alleles are mildly deleterious and associated with a small 
heterozygous fitness loss (Kryukov et al., 2007). Why such high numbers of detrimental 
SNPs occur is potentially due to several factors; the complex-disease associated 
polymorphisms present now were potentially evolutionarily advantageous. This is either 
because of late-onset disease, or a changing direction of selection, the “thrifty-gene 
hypothesis”. For example, genes that predispose modern humans to obesity possibly rose 
to high frequency in early human history due to selective advantages during times of food 
scarcity. Another theory is that balancing selection, maintaining a population of 
heterozygotes, is advantageous. For example, the haemoglobin mutation causing sickle-
cell anemia in homozygous individuals is protective against malaria in heterozygotes. 
Another possibility is that the negative effect of a mutation on a trait is balanced by the 
positive effect on another, so called “antagonistic pleitropy”. There are many 
polymorphisms in the GWAS database that offer a protective effect on one hand but a 
detrimental effect on a different disease. A mutation-selection hypothesis states a balance 
between a high rate of deleterious mutations is balanced by purifying selection (Kimura 
& King, 1979). Among de novo missense mutations in human proteins, it is estimated that 
approximately 20% are strongly detrimental, while 53% are mildly deleterious and the 
27% are effectively neutral (Kryukov et al., 2007). 
A current hypothesis is that many, low-penetrance polymorphisms exist in the 
human genome and exert a mild, increased predisposition to complex disease. Studying 
the proportion of such common variants in certain populations, particularly founder 
populations with known increased prevalence of disease, can provide insight into the 
history or burden of such diseases and may help inform public health policies for the 
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population. 
 
2.1.5 Hypothesis 
 
 Founder populations have inherent genetic consequences such as increased 
sensitivity to genetic drift, population bottlenecks, inbreeding and increased prevalence of 
founder mutations. Newfoundland, a known founder population, has experienced some of 
these genetic effects. They are predicted to have modern-day genetic consequences for 
Newfoundlanders in terms of increased burden of disease. This theory is supported by 
numerous studies of diseases with known mutations present at higher frequencies in the 
Newfoundland population. Based on the hypothesis that complex-diseases are 
attributed to many low-penetrance SNPs, I hypothesize that a founder effect 
contributed to a high rate of some risk variants in the Newfoundland population and 
this may contribute to increased rates of certain complex diseases.   
 
2.1.6 Objectives 
 
The objectives for this study include: 
1. Predicting the prevalence of complex diseases in the Newfoundland and 
Labrador founder population based on the mean frequencies of disease-
associated SNPs as compared to an out-bred population of European ancestry. 
2. Comparing the prevalence of disease in NL with the national statistics from the 
rest of Canada in an effort to support the disease burden predictions from mean 
frequencies of risk variants.  
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2.2 CHAPTER 2. Materials and Methods 
 
2.2.1 Study Population 
 
A total of 494 individuals were included in the study, recruited by random digital 
dialling across Newfoundland and Labrador as control participants of a colorectal cancer 
(CRC) research study (Woods et al., 2005). The only inclusion criterion was that the 
individual had not been diagnosed with colorectal cancer at any point in their life. The 
study was conducted from 2001-2003; blood samples and health information were 
collected from participants. DNA was extracted from the participants and genotyped 
using an Affymetrix Axiom Genome-Wide Array (Santa Clara, CA, USA) at the USC 
Norris Comprehensive Cancer Centre (LA, USA). The array covered 1.3 million SNPs 
and samples were then subject to quality control as follows. Unintended replicate samples 
were removed. Improper genotype to reported sex and individuals with missing genotype 
at ≥ 3 % were removed. Two “wells” were used for each genotype sample, labeled “peg 
A” and “peg B” to increase the number of SNPs tested, because a limited number of 
SNPs can be tested in each well. Some overlap of SNPs existed between the wells, which 
was removed later in the QC process. SNPs with poor quality were removed as per 
Affymetrix recommended guidelines as follows; SNP call rate <95 %, Fisher’s Linear 
Discriminant and SNPs out of Hardy-Weinberg Equilibrium at < 0.0001 and duplicates. 
Overlapping SNPs between peg A and B with concordance < 95 % and >1 mismatch and 
study replicates with a lower call rate were removed. Pegs A and B were then merged 
using PLINK (Purcell, 2007) (http://pngu.mgh.harvard.edu/~purcell/plink/). PLINK was 
then used to estimate IBD and find related individuals. We used STRUCTURE 
(http://pritchardlab.stanford.edu/structure.html) to identify and remove individuals with 
European ancestry < 80 %. In total, 1 individual was removed for improper genotype to 
reported sex and 16 samples were removed from both peg A and peg B due to study 
replicates with a low call rate. A total of 9552 SNPs from peg A and 17761 SNPs from 
peg B were removed due to poor quality as per Affymetrix guidelines, 1143 peg A SNPs 
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and 1906 peg B SNPs were then removed due to replicate concordance. Following 
merging of peg A and peg B, 2072 duplicate SNPs were removed.  
GTOOL (V0.75) software was used to transform the data to a format recognizable 
by the IMPUTE2 program (PED to GEN conversion)  
(http://www.well.ox.ac.uk/~cfreeman/software/gwas/gtool.html) (Freeman & Marchini, 
2007). The computer program IMPUTE2 (Pritchard, Stephens, & Donnelly, 2000) 
(https://mathgen.stats.ox.ac.uk/impute/impute_v2.html) was then utilized to impute the 
whole genome data set. Briefly, the program uses a fine-scale recombination map and 
reference panel to fill in missing genotypes allowing for more SNPs to be tested for 
association and increasing study power.  
A genetically similar out-bred population from Utah was used as a comparison to 
the NL population. The CEPH population, collected from 90 individuals in 1980 for the 
HapMap International Project, was taken from US Utah residents with ancestry from 
Northern and Western Europe (International HapMap Consortium, 2003).  This 
population will be referred to as the “CEU” population. The CEU samples from Hapmap3 
were genotyped on the Affymetrix Human SNP array 6.0 and the Illumina Human 1M-
single Beadchip (International HapMap Consortium, 2003). Genotype data were 
downloaded from the International HapMap Project website 
(http://hapmap.ncbi.nlm.nih.gov).  
 
 
2.2.2 Disease Associated Single Nucleotide Polymorphisms 
 
The NIH National Human Genome Research Institute’s catalog of published 
Genome-Wide association studies (https://www.genome.gov/26525384) was used to 
compile a list of SNPs for the study (Hindorff et al., 2015). As of February 2015 the 
catalogue included 2111 publications and 15,396 SNPs that associate with various traits. 
The search for relevant SNPs from the GWAS catalogue was restricted to those reaching 
genome-wide significance, at p < 10-8. This narrowed the list to 6,984 SNPs. The results 
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were downloaded and further filtered. SNPs that were not found in Caucasian populations 
(of European descendent) were excluded, further narrowing the list to 4,435 SNPs. Many 
non-disease associated SNPs were present in the list, including traits such as aging, 
alcohol consumption, birth weight, educational attainment, etc. These traits, as well as 
those of personal characteristics such eye colour or biomarkers of disease, were removed. 
Next, SNPs with multiple haplotypes or reaching genome-wide significance through 
association with more than one disease or condition were removed. Only those SNPs 
associated with one specific disease reaching genome-wide significance in a Caucasian 
population were included. A final list of approximately 1,800 SNPs was used for 
comparison between populations (Figure 2.1). However, certain allele frequencies were 
not available from either the NL or CEU data for some of the SNPs. Therefore, they were 
not included in the analysis. Of the 1,800 SNPs used in the final analysis, allele 
frequencies from both the CEU population and the NL population were available for only 
1,391. The disease-associated variants were determined based on information from the 
original publication describing the association or from the GWAS catalogue database. 
The online mendelian inheritance in man (OMIM) (McKusick-Nathans Institute of 
Genetic Medicine, John Hopkins University (Baltimore, MD), 2015) and Ensembl (v. 80) 
(Cunningham et al., 2015) databases were also used when necessary. 
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Figure 2.1 Summary of SNP filtering process 
 
 
2.2.3 Comparison Analysis 
 
Information for an initial 4,435 SNPs downloaded from the GWAS catalogue, as 
previously mentioned (Figure 2.1), were extracted from the imputed NL population file. 
The data included SNP rs ID, chromosome location, associated disease, allele frequency 
and total allele counts. All SNPs reported in the GWAS catalogue for a specific disease 
were grouped into one category. Then, the risk alleles for all SNPs associated with that 
disease (as recorded in the GWAS catalogue) were determined and the mean frequencies 
and standard errors were calculated using STATA/SE 11.2 (Stata Corp, College Station, 
Texas, USA). For example, all SNPs associated with coronary artery disease were placed 
Final	  Result:	  1,391	  SNPs	  	  
Result:	  1,800	  SNPs	  Removed	  those	  SNPs	  with	  missing	  frequency,	  either	  in	  NL	  or	  CEU	  
4,435	  SNPs	  from	  Caucasian	  populations	  Removed	  non-­‐disease	  traits	   Removed	  multi	  SNP	  haplotypes	  or	  	  gene	  X	  gene	  interactions	  
6,984	  SNPs	  reached	  genome-­‐wide	  signiaicance	  Filtered	  only	  those	  from	  caucasian	  populations	  
GWAS	  Catalogue:	  15,	  396	  SNPs	  Restricted	  to	  genome-­‐wide	  signiaicance,	  p	  <	  10-­‐8	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in one category and the mean frequency and standard error were calculated for the risk 
alleles for each SNP. Each disease has been grouped further by anatomical region or 
disease type for simplicity. For example, all neurological diseases were grouped and 
graphed together (the SNP calculations were not combined, they were kept as distinct 
means for each disease). The mean frequencies of disease-associated alleles from the NL 
population were then compared to mean frequencies of the CEU population for each 
disease. The Wilcoxon rank-sum test was used to evaluate the difference between mean 
risk-allele frequencies from the NL and CEU populations to test whether there was a 
significant difference between populations. The statistical significance was defined at p 
<0.05 by STATA software. A summary of SNPs in LD that were used in the same mean 
frequency calculations are included. LD was verified using pairwise SNP Annotation and 
Proxy Search (Version 2.2, Pairwise LD function) (A. D. Johnson et al., 2015) 
(http://www.broadinstitute.org/mpg/snap/ldsearchpw.php). Finally, a comparison is 
drawn between the mean frequencies of disease alleles in NL and the provincial statistical 
prevalence of the disease. The provincial statistical average was then compared to the 
national average. The Canadian national average is used as a comparison population due 
to the environmental similarity and geographic proximity.  
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2.3 CHAPTER 3. Results 
 
A total of 1,391 SNPs and 146 disease conditions were included in the final 
analysis. All SNPs, frequencies and disease-associations are reported in table format. Due 
to low statistical power, only those diseases with frequencies available from four or more 
SNPs were used for statistical calculations. Mean frequencies and standard errors are 
displayed in graphs of mean frequency comparisons.  
 
2.3.1 Autoimmune Conditions 
 
 
 
 Figure 2.2 Mean risk allele frequencies of autoimmune conditions 
“Allergic S” is allergic sensitization, “PB cirrhosis” is primary biliary cirrhosis, “S-R 
allergy” is self-reported allergy, “S. sclerosis” is systemic sclerosis and “SLE” is systemic 
lupus erythematosus. 
 
Table 2.1 SNPs association with autoimmune disorders 
Disease SNP ID Risk Allele Frequency 
NL population 
Risk Allele Frequency 
CEU Population 
Allergic 
Sensitization 
rs2155219 
 
0.498 
 
0.487 
 
 rs1059513 0.879 0.920 
 rs10056340 0.197 0.183 
 rs3771175 0.860 0.880 
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 rs17616434 0.742 0.779 
 rs9865818 0.422 0.433 
 rs4410871 0.281 0.290 
 rs17454584 0.241 0.250 
    
Total Mean 
Frequencies 
N= 8  
0.515 
 
0.528 
    
Self-
reported 
allergy 
rs10189629 
 
0.143 
 
0.107 
 
 rs10497813 0.472 0.451 
 rs9860547 0.432 0.460 
 rs2101521 0.238 0.196 
 rs7720838 0.385 0.344 
 rs1438673 0.454 0.491 
 rs7032572 0.150 0.140 
 rs9303280 0.475 0.500 
 rs6021270 0.058 0.059 
Total Mean 
Frequencies 
N= 9  
0.312 
 
0.305 
 
Systemic 
lupus 
erythematosus rs7574865 0.252 0.234 
 
rs12531711 0.880 0.876 
 
rs13277113 0.238 0.235 
 
rs10488631 0.120 0.124 
 
rs9888739 0.104 0.095 
 
rs5029939 0.025 0.027 
 
rs3821236 0.206 0.217 
 
rs4963128 0.696 0.671 
 
rs6445975 0.321 0.248 
 
rs12537284 0.154 0.133 
 
rs3131379 0.107 0.080 
 
rs11574637 0.128 0.142 
 
rs10516487 0.668 0.748 
Total Mean 
Frequencies N= 13 0.300 0.295 
 
Systemic 
sclerosis rs11642873 0.793 0.779 
 
rs10488631 0.120 0.124 
 
rs2233287 0.093 0.058 
 
rs7574865 0.252 0.234 
 
rs2056626 0.625 0.59 
 
rs3821236 0.206 0.217 
Total Mean 
Frequencies N= 6 0.348 0.334 
 
 A pair of SNPs was found in LD for SLE, rs12531711/rs10488631 (r2 = 1.0, D’ = 
1.0).  
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2.3.2 Brain and Neurological Conditions 
 
 
Figure 2.3 Mean risk allele frequencies of brain and neurological conditions.  
“Alzheimer’s” is Alzheimer’s disease, “LO AD” is late-onset Alzheimer’s disease, 
“Migraine” is migraine headaches, “P S palsy” is progressive supranuclear palsy, 
“Parkinson’s” is Parkinson’s disease, “Restless legs” is restless leg syndrome 
 
Table 2.2 SNPs associated with brain and neurological conditions 
Disease SNP ID 
Risk Allele Frequency 
NL population 
Risk Allele Frequency 
CEU population 
Alzheimer's 
disease rs7561528 0.356 0.366 
 
rs1562990 0.580 0.509 
 
rs157580 0.360 0.371 
 
rs536841 0.683 0.656 
 
rs744373 0.293 0.317 
 
rs3764650 0.097 0.107 
 
rs3818361 0.167 0.255 
 
rs2075650 0.139 0.161 
 
rs11136000 0.607 0.647 
 
rs3851179 0.613 0.585 
 
rs2075650 0.139 0.161 
 
rs6859 0.432 0.446 
Total Mean 
Frequencies N= 12 0.372 
 
0.382 
 
Alzheimer's 
disease  
(late onset) rs6656401 
 
 
0.160 
 
 
0.241 
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rs10948363 0.263 0.280 
 
rs11771145 0.638 0.652 
 
rs9331896 0.605 0.638 
 
rs10792832 0.612 0.583 
 
rs2718058 0.604 0.643 
 
rs1476679 0.746 0.683 
 
rs17125944 0.090 0.080 
 
rs11218343 0.963 0.969 
 
rs10498633 0.798 0.813 
 
rs9349407 0.263 0.275 
 
rs11767557 0.784 0.797 
 
rs4938933 0.585 0.505 
 
rs3865444 0.654 0.679 
 
rs6701713 0.167 0.255 
 
rs7561528 0.355 0.366 
 
rs561655 0.351 0.375 
 
rs744373 0.293 0.317 
 
rs12989701 0.162 0.152 
 
rs4420638 0.182 0.183 
Total Mean 
Frequencies N=20 
 
0.464 
 
0.474 
 
Disease SNP ID 
Risk Allele Frequency 
NL population 
Risk Allele Frequency 
CEU population 
Migraine rs2651899 0.408 0.416 
 
rs12134493 0.129 0.124 
 
rs6741751 0.889 0.858 
 
rs11759769 0.198 0.237 
 
rs4379368 0.082 0.088 
 
rs11172113 0.604 0.633 
 
rs6478241 0.392 0.389 
 
rs9349379 0.633 0.628 
rs3790455 0.346 0.341 
 rs7640543 0.349 0.376 
 rs10166942 0.800 0.829 
 rs1835740 0.246 0.230 
Total Mean 
Frequencies N= 12 0.423 0.429 
 
Progressive 
supranuclear 
palsy rs1411478 0.386 0.473 
 
rs7571971 0.260 0.267 
 
rs1768208 0.251 0.295 
 
rs12203592 0.788 0.841 
Total Mean 
Frequencies N= 4 0.421 0.469 
 
Parkinson's 
disease rs11248060 0.094 0.124 
 
rs356220 0.453 0.403 
 
rs12456492 0.314 0.319 
 
rs10513789 0.816 0.757 
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rs6812193 0.646 0.602 
 
rs34372695 0.032 0.031 
 
rs11724635 0.553 0.500 
 
rs356219 0.350 0.425 
 
rs1491942 0.185 0.192 
 
rs11248051 0.083 0.111 
 
rs2736990 0.439 0.469 
 
rs199533 0.774 0.805 
Total Mean 
Frequencies N= 12 0.395 0.395 
 
Restless legs 
syndrome rs2300478 0.235 0.237 
 
rs9357271 0.806 0.765 
 
rs1975197 0.185 0.190 
 
rs12593813 0.642 0.705 
 
rs6747972 0.442 0.398 
 
rs3104767 0.605 0.602 
 
rs4626664 0.164 0.127 
 
rs3923809 0.723 0.726 
 
rs9296249 0.808 0.770 
Total Mean 
Frequencies N= 9 0.512 0.502 
    Musician's 
dystonia  rs11655081 0.050 0.053 
    
Creutzfeldt-
Jakob disease 
(variant) rs6107516 0.738 0.757 
Creutzfeldt-
Jakob disease rs1799990 0.644 0.655 
 
 Two SNPs are in LD for Parkinson’s, rs11248060/rs11248051 (r2 = 0.884, D’ 
=1.0) and for restless legs syndrome, rs9357271/rs9296249 (r2 = 0.976, D’ = 1.0). 
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2.3.3 Arthritis 
 
 
Figure 2.4 Mean risk allele frequencies of forms of arthritis.  
“AS” is ankylosing spondylitis, Gout, “OA” is osteoarthritis and “RA” is rheumatoid 
arthritis 
 
 
Table 2.3 SNPs associated with types of arthritis 
 
Disease SNP ID 
Risk Allele Frequency 
NL population 
Risk Allele Frequency 
CEU population 
Ankylosing 
spondylitis  rs11209026 0.939 0.959 
 rs2297909 0.695 0.658 
 rs10865331 0.414 0.288 
 rs30187 0.360 0.310 
 rs378108 0.427 0.496 
 rs11249215 0.494 0.482 
 rs11616188 0.419 0.433 
 rs27434 0.227 0.191 
 rs2242944 0.607 0.608 
Total Mean 
Frequencies N= 9 0.509 0.492 
Gout rs4475146 0.221 0.246 
 rs1481012 0.892 0.898 
 rs2231142 0.108 0.111 
 rs734553 0.760 0.739 
 rs2231142 0.108 0.111 
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Rheumatoid 
Arthritis rs2476601 0.907 0.882 
 
rs653178 0.480 0.438 
 
rs1893217 0.183 0.116 
 
rs1953126 0.354 0.380 
 
rs7574865 0.252 0.236 
 
rs2298428 0.189 0.165 
 
rs934734 0.476 0.442 
 
rs6859219 0.795 0.830 
 
rs874040 0.283 0.295 
 
rs3093023 0.399 0.410 
 
rs10488631 0.120 0.121 
 
rs11676922 0.425 0.457 
 
rs951005 0.870 0.821 
 
rs706778 0.424 0.406 
 
rs6920220 0.248 0.158 
 
rs4810485 0.250 0.246 
 
rs13017599 0.358 0.375 
 
rs231735 0.483 0.487 
 
rs2736340 0.236 0.241 
rs6679677 0.092 0.116 
 
rs10499194 0.739 0.825 
 
rs3761847 0.423 0.473 
 
rs660895 0.245 0.277 
Total Mean 
Frequencies N= 23 0.273 0.306 
 
A pair of SNPs in LD were included in the mean calculation for gout; 
rs1481012/rs2231142 (r2 = 0.92, D’ = 1.0) and for RA: rs2476601/rs6679677 (r2 = 1.0, 
D’ = 1.0). 
  
Total Mean 
Frequencies N= 5 0.418 0.421 
Disease SNP ID 
Risk Allele Frequency 
NL population 
Risk Allele Frequency 
CEU population 
Osteoarthritis 
(hip) rs6094710 0.038 0.033 
 
rs3757837 0.141 0.079 
Osteoarthritis rs11177 0.389 0.339 
 
rs12982744 0.432 0.375 
Total Mean 
Frequencies N=4 0.250 0.207 
    
Psoriatic 
arthritis rs12188300 0.076 0.112 
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2.3.4 Bone Conditions 
 
 
Figure 2.5 Mean risk allele frequencies of bone conditions.  
 
Table 2.4 SNPs associated with disorders of the bone 
 
Disease SNP ID 
Risk Allele Frequency 
NL population 
Risk Allele Frequency 
CEU population 
Osteoporosis-
related 
phenotypes rs2062375 0.441 0.467 
    
Orofacial clefts rs560426 0.573 0.504 
 rs861020 0.214 0.221 
 rs987525 0.232 0.221 
 rs7078160 0.171 0.168 
 rs13041247 0.598 0.597 
 rs742071 0.417 0.446 
 rs8001641 0.512 0.549 
Total Mean 
Frequencies N= 7 0.388 0.387 
    
Paget's disease rs10494112 0.202 0.173 
 rs4294134 0.846 0.848 
 rs2458413 0.578 0.535 
 rs1561570 0.570 0.535 
 rs10498635 0.821 0.863 
 rs5742915 0.573 0.504 
 rs3018362 0.367 0.371 
 72 
 rs2957128 0.417 0.403 
 rs484959 0.544 0.553 
Total Mean 
Frequencies N= 9 0.547 0.532 
    
Disc 
degeneration 
(lumbar) rs17034687 0.922 0.908 
    
Sagittal 
craniosynostosis rs1884302 0.355 0.341 
 rs10262453 0.693 0.711 
    
Osteosarcoma rs1906953 0.147 0.095 
    
 
 No SNPs in LD were included in the same mean risk frequency calculations. 
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2.3.5 Common Types of Cancer 
 
 
Figure 2.6 Mean risk allele frequencies of common forms of cancer.  
Bladder cancer, Breast cancer, “CR ca.” is colorectal cancer, Ovarian cancer, prostate 
cancer, “Testicular GC Ca.” is testicular germ cell cancer, “Testicular GC tumour” is 
testicular germ cell tumour.  
 
 
Table 2.5 SNPs associated with common types of cancer 
Disease SNP ID 
Risk Allele Frequency 
NL population 
Risk Allele Frequency 
CEU population 
Renal cell 
carcinoma rs718314 0.240 0.217 
 
rs7579899 0.381 0.354 
 
rs7105934 0.900 0.942 
    Bladder 
cancer rs10936599 0.752 0.730 
 
rs710521 0.732 0.686 
 
rs798766 0.199 0.199 
 
rs401681 0.537 0.566 
 
rs1495741 0.772 0.712 
 
rs9642880 0.457 0.425 
 
rs8102137 0.345 0.292 
 
rs1014971 0.697 0.655 
 
rs7238033 0.418 0.350 
 
rs17674580 0.335 0.292 
 
rs2294008 0.416 0.420 
 74 
Total Mean 
Frequencies N= 11 0.515 0.484 
 
Breast 
cancer rs4245739 0.274 0.305 
 
rs10069690 0.255 0.301 
 
rs2046210 0.352 0.288 
 
rs10771399 0.881 0.833 
 
rs3803662 0.245 0.248 
rs8170 0.209 0.216 
 
rs616488 0.656 0.668 
 
rs4849887 0.910 0.889 
 
rs16857609 0.242 0.293 
 
rs6762644 0.401 0.425 
 
rs6828523 0.875 0.912 
 
rs1432679 0.478 0.411 
 
rs11242675 0.626 0.650 
 
rs204247 0.472 0.482 
 
rs720475 0.725 0.737 
 
rs9693444 0.334 0.319 
 
rs6472903 0.830 0.796 
 
rs11780156 0.164 0.155 
 
rs7072776 0.270 0.270 
 
rs3903072 0.528 0.573 
 
rs11820646 0.570 0.544 
 
rs17356907 0.690 0.708 
 
rs2236007 0.809 0.786 
 
rs2588809 0.158 0.183 
 
rs941764 0.359 0.339 
 
rs17817449 0.592 0.540 
 
rs13329835 0.211 0.181 
 
rs527616 0.658 0.633 
 
rs4808801 0.635 0.655 
 
rs3760982 0.480 0.460 
 
rs132390 0.030 0.017 
 
rs6001930 0.074 0.102 
 
rs11249433 0.414 0.425 
 
rs13387042 0.500 0.562 
 
rs4973768 0.473 0.438 
 
rs889312 0.283 0.308 
 
rs17530068 0.232 0.219 
 
rs3757318 0.073 0.067 
 
rs13281615 0.386 0.458 
 
rs865686 0.596 0.606 
 
rs10995190 0.866 0.872 
 
rs704010 0.387 0.433 
 
rs2981579 0.442 0.465 
 
rs3817198 0.280 0.327 
 
rs614367 0.167 0.185 
 
rs1292011 0.575 0.606 
 
rs999737 0.735 0.739 
 
rs6504950 0.705 0.693 
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rs2823093 0.741 0.728 
 
rs2943559 0.087 0.071 
 
rs11814448 0.009 0.033 
 
rs4415084 0.402 0.376 
 
rs1562430 0.574 0.647 
 
rs1219648 0.429 0.465 
 
rs3112612 0.396 0.407 
Total Mean 
Frequencies N= 55 0.450 0.455 
    
Breast 
cancer 
(male) rs1314913 0.139 0.155 
 
rs3803662 0.245 0.248 
 
Colorectal 
cancer rs6983267 0.455 0.487 
 
rs4939827 0.457 0.473 
 
rs1321311 0.233 0.310 
 
rs3824999 0.500 0.487 
 
rs5934683 0.340 0.343 
 
rs6691170 0.363 0.389 
 
rs11169552 0.752 0.810 
 
rs4925386 0.691 0.644 
 
rs6687758 0.178 0.208 
 
rs10411210 0.902 0.916 
 
rs961253 0.407 0.403 
 
rs4444235 0.476 0.442 
 
rs7014346 0.403 0.310 
 
rs3802842 0.284 0.235 
 
rs10795668 0.337 0.323 
 
rs16892766 0.931 0.894 
Total Mean 
Frequencies  0.482 0.480 
 
Ovarian 
cancer rs3814113 0.661 0.628 
 
rs10088218 0.867 0.875 
 
rs2072590 0.287 0.362 
 
rs7651446 0.043 0.049 
 
rs8170 0.209 0.216 
 
rs9303542 0.293 0.269 
 
rs11782652 0.939 0.892 
 
rs757210 0.659 0.567 
 
rs2072590 0.287 0.362 
Total Mean 
Frequencies N= 9 0.472 0.469 
    
Endometrial 
cancer rs4430796 0.483 0.491 
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Disease SNP ID 
Risk Allele Frequency 
NL population 
Risk Allele Frequency 
CEU population 
Prostate 
cancer rs4245739 0.726 0.695 
 
rs3771570 0.156 0.142 
 
rs7611694 0.574 0.584 
 
rs1894292 0.452 0.460 
 
rs2273669 0.153 0.150 
 
rs1933488 0.598 0.597 
 
rs12155172 0.226 0.226 
 
rs11135910 0.166 0.173 
 
rs3850699 0.733 0.730 
 
rs11568818 0.521 0.531 
 
rs8008270 0.818 0.792 
 
rs7141529 0.484 0.478 
 
rs684232 0.340 0.367 
 
rs11650494 0.081 0.090 
 
rs7241993 0.685 0.700 
 
rs6062509 0.731 0.673 
 
rs2405942 0.818 0.769 
 
rs11672691 0.776 0.721 
 
rs10187424 0.537 0.553 
 
rs7584330 0.225 0.261 
 
rs10936632 0.516 0.517 
 
rs2242652 0.799 0.850 
 
rs10875943 0.282 0.283 
 
rs902774 0.140 0.142 
 
rs651164 0.674 0.655 
 
rs1016343 0.222 0.261 
 
rs12621278 0.935 0.960 
 
rs17021918 0.641 0.646 
 
rs7679673 0.640 0.624 
 
rs1512268 0.411 0.420 
 
rs7127900 0.166 0.235 
 
rs5759167 0.516 0.549 
 
rs12500426 0.432 0.460 
 
rs3123078 0.547 0.580 
 
rs7130881 0.169 0.190 
 
rs7501939 0.618 0.566 
 
rs1327301 0.358 0.373 
 
rs10934853 0.274 0.239 
 
rs445114 0.652 0.619 
 
rs8102476 0.569 0.504 
 
rs11228565 0.198 0.248 
 
rs10993994 0.409 0.341 
 
rs2735839 0.856 0.863 
 
rs7931342 0.509 0.531 
 
rs9364554 0.315 0.274 
 
rs6465657 0.511 0.509 
 
rs5945619 0.352 0.385 
 
rs6983267 0.455 0.487 
 
rs4242384 0.106 0.071 
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rs5945572 0.360 0.379 
 
rs721048 0.170 0.137 
 
rs10896449 0.519 0.532 
 
rs4242382 0.106 0.071 
 
rs4430796 0.483 0.491 
 
rs1859962 0.483 0.473 
 
rs16901979 0.035 0.031 
 
rs1447295 0.106 0.071 
Total Mean 
Frequencies N= 57 0.444 0.443 
 
 
 
 
Testicular 
germ cell 
tumour rs9905704 0.668 0.699 
 
rs12699477 0.408 0.292 
 
rs4888262 0.512 0.553 
 
rs4624820 0.521 0.563 
 
rs995030 0.202 0.186 
 
rs2720460 0.615 0.628 
 
rs8046148 0.766 0.757 
 
rs2839186 0.438 0.398 
 
rs4635969 0.192 0.191 
 
rs755383 0.613 0.621 
 
rs2900333 0.593 0.688 
Total Mean 
Frequencies N= 11 0.503 0.507 
    
Testicular 
germ cell 
cancer rs2736100 0.478 0.473 
 
rs3782181 0.790 0.801 
 
rs4624820 0.521 0.563 
 
rs4635969 0.192 0.191 
 
rs755383 0.613 0.621 
 
rs2900333 0.593 0.688 
Total Mean 
Frequencies N= 6 0.531 0.556 
    
Testicular 
Cancer rs4474514 0.791 0.801 
 
rs7040024 0.754 0.783 
 
rs755383 0.613 0.621 
   
Upper aero-
digestive 
tract 
cancers rs1229984 0.021 0.000 
 rs971074 0.882 0.868 
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 Upper aero-digestive tract cancers include cancers of the lips, tongue, major 
salivary glands, gums and adjacent oral cavity tissues, floor of the mouth, tonsils, 
oropharynx, nasopharynx, hypopharynx and other oral regions, nasal cavity, accessory 
sinuses, middle ear, and larynx. 
 For breast cancer, two SNPs were in LD rs2981579/rs1219648 ( r2 = 0.916, D’ = 
0.965). Several SNPs were in LD for prostate cancer calculations, rs7931342/rs10896449 
(r2 = 0.966, D’ = 1.0), rs4242384/rs4242382 (r2 = 1.0, D’ = 1.0), rs4242384/rs1447295 
(r2 = 1.0, D’ = 1.0), and rs4242382/ rs1447295 (r2 = 1.0, D’ = 1.0). 
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2.3.6 Renal and Digestive Tract Disorders 
 
 
 
Figure 2.7 Mean risk allele frequencies of renal and digestive tract disorders.  
“Celiac” is celiac disease, “Chronic kidney Dis” is chronic kidney disease”, “Crohn’s” is 
crohn’s disease and “U C” is ulcerative colitis. 
 
Table 2.6 SNPs associated with renal and digestive tract disorders 
 
Disease SNP ID 
Risk Allele Frequency 
NL population 
Risk Allele Frequency 
CEU population 
Celiac 
disease rs2816316 0.192 0.199 
 
rs13003464 0.412 0.385 
 
rs917997 0.237 0.204 
 
rs13010713 0.421 0.434 
 
rs4675374 0.197 0.186 
 
rs13098911 0.076 0.076 
 
rs17810546 0.130 0.100 
 
rs1464510 0.470 0.456 
 
rs13151961 0.880 0.866 
 
rs2327832 0.248 0.155 
 
rs1738074 0.416 0.465 
 
rs653178 0.480 0.438 
 
rs1893217 0.183 0.115 
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rs3748816 0.698 0.664 
 
rs10903122 0.514 0.513 
 
rs296547 0.653 0.628 
 
rs17035378 0.748 0.695 
 
rs13314993 0.451 0.469 
 
rs11712165 0.388 0.412 
 
rs10806425 0.434 0.362 
 
rs802734 0.310 0.292 
 
rs9792269 0.762 0.752 
 
rs1250552 0.514 0.544 
 
rs11221332 0.190 0.212 
 
rs4819388 0.716 0.752 
 
rs13015714 0.236 0.204 
 
rs6822844 0.878 0.854 
Total Mean 
Frequencies N= 27 0.438 0.423 
 
Kidney stones rs219780 0.768 0.855 
    Chronic 
kidney disease rs3925584 0.551 0.522 
 
rs267734 0.230 0.208 
 
rs1260326 0.422 0.420 
 
rs13538 0.250 0.208 
 
rs347685 0.289 0.265 
 
rs6420094 0.325 0.367 
 
rs881858 0.325 0.292 
 
rs7805747 0.305 0.296 
 
rs4744712 0.387 0.390 
 
rs653178 0.520 0.562 
 
rs626277 0.421 0.381 
 
rs1394125 0.343 0.350 
 
rs12460876 0.403 0.417 
 
rs2279463 0.149 0.124 
 
rs6465825 0.414 0.442 
 
rs10774021 0.300 0.305 
 
rs491567 0.237 0.200 
 
rs9895661 0.169 0.186 
 
rs4293393 0.828 0.823 
 
rs12917707 0.827 0.850 
rs17319721 0.439 0.420 
 rs2467853 0.378 0.331 
Total Mean 
Frequencies N= 22 0.336 C0.330 
    
Gallstones rs11887534 0.059 0.085 
 
Disease SNP ID 
Risk Allele Frequency 
NL population 
Risk Allele Frequency 
CEU population 
Crohn's 
disease rs17391694 0.854 0.881 
 
rs6679677 0.908 0.885 
 
rs3897478 0.911 0.903 
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rs9286879 0.253 0.204 
 
rs1728918 0.298 0.281 
 
rs10865331 0.414 0.288 
 
rs6716753 0.184 0.212 
 
rs12994997 0.551 0.575 
 
rs13126505 0.084 0.076 
 
rs10065637 0.796 0.814 
 
rs7702331 0.624 0.593 
 
rs17695092 0.681 0.712 
 
rs12663356 0.543 0.597 
 
rs9491697 0.443 0.473 
 
rs13204742 0.129 0.146 
 
rs212388 0.425 0.438 
 
rs864745 0.481 0.487 
 
rs6651252 0.869 0.876 
 
rs3764147 0.218 0.243 
 
rs16967103 0.185 0.241 
 
rs2945412 0.562 0.584 
 
rs2024092 0.203 0.212 
 
rs4802307 0.671 0.717 
 
rs516246 0.508 0.531 
 
rs2284553 0.605 0.558 
 
rs2076756 0.263 0.323 
 
rs11209026 0.939 0.959 
 
rs3792109 0.559 0.580 
 
rs10761659 0.537 0.553 
 
rs1250550 0.640 0.633 
 
rs4902642 0.583 0.603 
 
rs181359 0.206 0.168 
 
rs1819658 0.818 0.796 
 
rs12720356 0.108 0.124 
 
rs7517810 0.253 0.204 
 
rs3810936 0.712 0.642 
 
rs2062305 0.447 0.487 
 
rs10495903 0.141 0.146 
 
rs7423615 0.177 0.205 
 
rs17293632 0.216 0.230 
 
rs12521868 0.430 0.397 
 
rs4809330 0.723 0.664 
 
rs2476601 0.907 0.883 
 
rs1893217 0.183 0.115 
 
rs11742570 0.628 0.646 
 
rs694739 0.652 0.584 
 
rs6738825 0.481 0.456 
 
rs4409764 0.497 0.455 
 
rs11167764 0.780 0.783 
 
rs11564258 0.023 0.027 
 
rs713875 0.456 0.385 
 
rs3197999 0.258 0.261 
 
rs2413583 0.851 0.854 
 
rs10758669 0.385 0.366 
 
rs7714584 0.070 0.044 
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rs12722489 0.846 0.827 
 
rs151181 0.403 0.372 
 
rs2058660 0.237 0.192 
 
rs6556412 0.336 0.319 
 
rs2797685 0.168 0.186 
 
rs3024505 0.153 0.181 
 
rs2838519 0.398 0.420 
 
rs2872507 0.449 0.473 
 
rs740495 0.269 0.259 
 
rs780093 0.404 0.394 
 
rs8005161 0.085 0.140 
 
rs281379 0.525 0.559 
 
rs102275 0.318 0.351 
 
rs2549794 0.430 0.429 
 
rs13428812 0.317 0.314 
 
rs1998598 0.321 0.305 
 
rs12242110 0.290 0.319 
 
rs359457 0.559 0.606 
 
rs415890 0.497 0.491 
 
rs3091315 0.720 0.690 
 
rs4077515 0.453 0.482 
 
rs10181042 0.434 0.412 
 
rs7927997 0.392 0.388 
 
rs1847472 0.625 0.692 
 
rs13073817 0.373 0.372 
 
rs17309827 0.632 0.646 
 
rs736289 0.619 0.664 
 
rs1736020 0.572 0.589 
 
rs4871611 0.627 0.619 
 
rs10045431 0.696 0.757 
 
rs2301436 0.435 0.456 
 
rs744166 0.612 0.549 
 
rs7746082 0.255 0.311 
 
rs2274910 0.699 0.634 
 
rs11584383 0.701 0.668 
 
rs6908425 0.804 0.823 
 
rs1456893 0.685 0.650 
 
rs1551398 0.626 0.619 
 
rs17582416 0.325 0.383 
 
rs7927894 0.391 0.394 
 
rs11175593 0.022 0.027 
 
rs1736135 0.568 0.580 
 
rs762421 0.396 0.412 
 
rs11465804 0.946 0.955 
 
rs3828309 0.550 0.571 
 
rs4613763 0.128 0.168 
 
rs2188962 0.433 0.402 
 
rs11747270 0.070 0.049 
 
rs4263839 0.713 0.637 
 
rs11190140 0.500 0.460 
 
rs2542151 0.183 0.115 
 
rs10995271 0.386 0.450 
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rs17221417 0.309 0.350 
 
rs11805303 0.317 0.292 
 
rs10210302 0.551 0.580 
 
rs17234657 0.128 0.168 
 
rs1373692 0.629 0.646 
Total Mean 
Frequencies N= 112 0.463 0.463 
 
Disease SNP ID 
Risk Allele Frequency 
NL population 
Risk Allele Frequency 
CEU population 
Ulcerative 
colitis rs10797432 0.551 0.535 
 
rs6426833 0.561 0.509 
 
rs2816958 0.902 0.914 
 
rs17229285 0.471 0.438 
 
rs3774959 0.397 0.367 
 
rs254560 0.418 0.363 
 
rs6927022 0.499 0.482 
 
rs798502 0.673 0.712 
 
rs4380874 0.463 0.438 
 
rs4728142 0.435 0.398 
 
rs561722 0.644 0.699 
 
rs11150589 0.496 0.456 
 
rs7210086 0.803 0.792 
 
rs1126510 0.384 0.354 
 
rs6017342 0.502 0.562 
 
rs11209026 0.939 0.959 
 
rs1801274 0.470 0.491 
 
rs3024505 0.153 0.181 
 
rs7608910 0.414 0.379 
 
rs4676406 0.535 0.544 
 
rs9822268 0.289 0.259 
 
rs4510766 0.612 0.562 
 
rs6584283 0.523 0.562 
 
rs7134599 0.420 0.394 
 
rs2872507 0.449 0.473 
 
rs2836878 0.712 0.712 
 
rs734999 0.550 0.535 
 
rs35675666 0.803 0.833 
 
rs7524102 0.845 0.814 
 
rs2310173 0.478 0.420 
 
rs11676348 0.466 0.425 
 
rs267939 0.350 0.393 
 
rs6451493 0.628 0.646 
 
rs6871626 0.330 0.367 
 
rs943072 0.106 0.080 
 
rs6920220 0.248 0.165 
 
rs10758669 0.385 0.366 
 
rs4246905 0.738 0.676 
 
rs10781499 0.455 0.487 
 
rs12261843 0.249 0.283 
 
rs907611 0.294 0.319 
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rs2155219 0.499 0.487 
 
rs17085007 0.188 0.150 
 
rs941823 0.746 0.779 
 
rs16940202 0.157 0.164 
 
rs2297441 0.791 0.752 
 
rs1297265 0.547 0.562 
 
rs2838519 0.398 0.42 
 
rs7554511 0.708 0.673 
 
rs17207986 0.069 0.058 
 
rs7809799 0.045 0.076 
 
rs4654925 0.461 0.467 
 
rs3024493 0.152 0.169 
 
rs1317209 0.172 0.137 
 
rs2201841 0.685 0.704 
 
rs10800309 0.309 0.296 
 
rs13003464 0.412 0.385 
 
rs3197999 0.258 0.261 
 
rs4957048 0.782 0.757 
 
rs1558744 0.434 0.403 
 
rs9858542 0.289 0.257 
 
rs3806308 0.633 0.602 
Total Mean 
Frequencies N= 62 0.473 0.465 
 
Disease SNP ID 
Risk Allele Frequency 
NL population 
Risk Allele Frequency 
CEU population 
Barrett's 
esophagus rs9936833 0.402 0.375 
Infantile 
hypertrophic 
pyloric 
stenosis rs11712066 0.763 0.774 
 rs573872 0.182 0.168 
 rs29784 0.487 0.469 
Eosinophilic 
esophagitis 
(paediatric) rs3806932 0.600 0.549 
Hypospadias rs1934179 0.335 0.337 
 
A number of SNPs in LD were included in the mean risk allele calculation analysis (see 
table 2.7). 
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Table 2.7 Renal and Digestive Tract Disorders – SNPs in LD 
 
Disease SNP Proxy r2 D’ 
Crohn’s 
Disease rs6679677 rs2476601 1 1 
 rs9286879 rs7517810 1 1 
 rs6716753 rs7423615 0.975 1 
 rs12994997 rs3792109 0.983 1 
 rs12994997 rs10210302 0.983 1 
 rs12994997 rs3828309 0.949 0.982 
 rs2076756 rs17221417 0.892 1 
 rs11209026 rs11465804 0.905 1 
 rs3792109 rs3828309 0.932 0.982 
 rs12521868 rs2188962 1 1 
 rs1893217 rs2542151 1 1 
 rs11742570 rs1373692 0.964 0.982 
 rs4409764 rs11190140 0.966 0.983 
 rs11564258 rs11175593 1 1 
 rs7714584 rs11747270 0.905 1 
 rs2838519 rs762421 0.965 1 
 rs7927997 rs7927894 1 1 
 rs1736020 rs1736135 0.966 1 
 rs4871611 rs1551398 1 1 
 rs11209026 rs11465804 0.905 1 
 rs10210302 rs3792109 0.965 0.983 
 rs3828309 rs10210302 0.932 0.982 
 rs4613763 rs17234657 1 1 
     
Ulcerative 
colitis rs13003464 rs7608910 1 1 
 rs3197999 rs9858542 0.956 0.978 
 rs13003464 rs7608910 1 1 
 rs10797432 rs734999 0.966 0.983 
 rs9822268 rs9858542 1 1 
 rs9822268 rs3197999 0.956 0.978 
 rs7134599 rs1558744 0.931 0.982 
     
Celiac Disease rs917997 rs13015714 1 1 
 rs13151961 rs6822844 0.868 0.964 
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2.3.7 Metabolic syndrome and associated traits 
 
 
 
Figure 2.8 Mean risk allele frequencies of metabolic syndrome and associated traits.  
“Metabolic S.” is metabolic syndrome, obesity, “Obesity ex.” is all obesity (extreme) 
combined, “T 1 D” is type 1 diabetes and “T 2 D” is type 2 diabetes 
 
Table 2.8 SNPs associated with metabolic syndrome and associated traits 
Disease SNP ID 
Risk Allele Frequency 
NL population 
Risk Allele Frequency 
CEU population 
Metabolic 
syndrome rs560887 0.722 0.674 
 
rs6947830 0.519 0.518 
 
rs3757840 0.491 0.491 
 
rs1127065 0.556 0.567 
 
rs10830962 0.374 0.389 
 
rs673548 0.810 0.795 
 
rs268 0.290 0.004 
 
rs1883025 0.272 0.199 
 
rs10838681 0.675 0.730 
 
rs1532085 0.635 0.588 
 
rs247617 0.658 0.659 
 
rs8060686 0.832 0.867 
 
rs780094 0.403 0.394 
 
rs13226650 0.786 0.810 
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rs7841189 0.901 0.863 
 
rs964184 0.143 0.121 
 
rs9940128 0.440 0.487 
 
rs295 0.775 0.767 
 
rs2266788 0.073 0.084 
 
rs2075290 0.078 0.043 
 
rs10790162 0.075 0.042 
 
rs173539 0.650 0.633 
Total Mean 
Frequencies N= 29 0.507 0.488 
    
 
Metabolic 
syndrome 
(bivariate 
traits) rs1387153 0.712 0.728 
 
rs3764261 0.658 0.655 
 
rs9939224 0.800 0.822 
 
rs301 0.224 0.252 
 
rs10830956 0.713 0.717 
 
rs2197089 0.461 0.442 
 
rs11820589 0.065 0.051 
Total Mean 
Frequencies N= 7 0.519 0.524 
    
 
Obesity rs17024258 0.022 0.042 
 
rs4735692 0.597 0.558 
 
rs8043757 0.408 0.450 
 
rs6711012 0.825 0.854 
 
rs10938397 0.441 0.446 
 
rs633715 0.225 0.243 
 
rs2030323 0.781 0.783 
 
rs2206277 0.197 0.096 
 
rs7138803 0.396 0.345 
 
rs10182181 0.491 0.469 
 
rs7141420 0.540 0.553 
 
rs7531118 0.522 0.567 
 
rs1800437 0.809 0.825 
 
rs9816226 0.832 0.851 
 
rs7498665 0.406 0.381 
 
rs8028313 0.765 0.780 
 
rs2307111 0.633 0.647 
 
rs11042023 0.638 0.681 
 
rs887912 0.288 0.319 
 
rs12446632 0.849 0.858 
 
rs1514177 0.413 0.460 
 
rs7185735 0.408 0.442 
 
rs10189761 0.829 0.854 
 
rs11152213 0.232 0.283 
 
rs2207139 0.189 0.102 
 
rs13130484 0.442 0.429 
 
rs3101336 0.614 0.637 
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rs10423928 0.809 0.824 
 
rs9568867 0.125 0.10 
 
rs1516725 0.874 0.908 
 
rs2112347 0.656 0.619 
 
rs11639988 0.849 0.858 
 
rs7184597 0.332 0.271 
 
rs1421085 0.418 0.460 
 
rs1558902 0.418 0.450 
 
rs10871777 0.232 0.270 
 
rs2568958 0.614 0.637 
 
rs12446554 0.849 0.867 
 
rs13078807 0.206 0.226 
 
rs10875976 0.456 0.451 
 
rs6731302 0.413 0.438 
 
rs2370983 0.640 0.704 
 
rs9568856 0.125 0.126 
 
rs9299 0.657 0.633 
 
rs2116830 0.802 0.770 
 
rs988712 0.762 0.754 
 
rs17817449 0.408 0.460 
 
rs17782313 0.231 0.265 
 
rs1424233 0.520 0.558 
Total Mean 
Frequencies N= 49 0.514 0.523 
    Obesity 
(early onset 
extreme) rs476828 0.233 0.270 
 
rs12463617 0.828 0.881 
 
rs1993709 0.807 0.851 
 
rs1957894 0.078 0.083 
 
rs11208659 0.086 0.062 
 
rs564343 0.427 0.372 
 
rs11109072 0.043 0.028 
 
rs17700144 0.205 0.248 
 
rs1421085 0.418 0.460 
 
rs1558902 0.418 0.450 
 
rs10871777 0.232 0.270 
Total Mean 
Frequencies N= 11 0.343 0.361 
    Adiposity rs987237 0.195 0.164 
    Obesity 
(extreme) rs9941349 0.425 0.473 
 
Type 1 
diabetes rs539514 0.493 0.483 
 
rs478222 0.602 0.627 
 
rs924043 0.858 0.894 
 
rs2304256 0.697 0.679 
 
rs941576 0.571 0.535 
 
rs11755527 0.486 0.429 
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rs947474 0.169 0.155 
 
rs3825932 0.329 0.305 
 
rs6679677 0.092 0.115 
 
rs3087243 0.433 0.460 
 
rs17696736 0.441 0.358 
 
rs2292239 0.350 0.33 
 
rs12708716 0.354 0.319 
 
rs1701704 0.342 0.319 
 
rs2903692 0.659 0.686 
 
rs1004446 0.629 0.611 
 
rs11171739 0.430 0.407 
 
rs2542151 0.183 0.115 
 
rs2476601 0.093 0.117 
 
rs1990760 0.574 0.625 
Total Mean 
Frequencies N= 20 0.439 0.429 
    
 
 Type 1 
diabetes 
autoantibodies rs7528684 0.525 0.513 
 
rs3024505 0.847 0.819 
 
rs3184504 0.481 0.445 
 
rs763361 0.528 0.504 
Total Mean 
Frequencies N= 4 0.595 0.570 
    Type 1 
diabetes 
nephropathy rs12437854 0.070 0.017 
    
Nephropathy 
(idiopathic 
membranous) rs4664308 0.577 0.535 
    
Nonalcoholic 
fatty liver 
disease rs738409 0.201 0.233 
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Disease SNP ID 
Risk Allele Frequency 
NL population 
Risk Allele Frequency 
CEU population 
Type 2 
diabetes rs7903146 0.323 0.279 
 
rs243021 0.415 0.478 
 
rs4457053 0.317 0.259 
 
rs972283 0.503 0.55 
 
rs896854 0.485 0.436 
 
rs231362 0.501 0.518 
 
rs1552224 0.845 0.867 
 
rs1531343 0.094 0.115 
 
rs11634397 0.695 0.642 
 
rs8042680 0.288 0.261 
 
rs5945326 0.788 0.793 
 
rs7578326 0.636 0.650 
 
rs1387153 0.288 0.272 
 
rs1470579 0.335 0.296 
 
rs10440833 0.257 0.250 
 
rs849134 0.522 0.526 
 
rs10965250 0.823 0.805 
 
rs5015480 0.571 0.580 
 
rs8050136 0.407 0.460 
 
rs864745 0.481 0.487 
 
rs12779790 0.192 0.229 
 
rs7961581 0.260 0.252 
 
rs7578597 0.886 0.876 
 
rs6931514 0.252 0.279 
 
rs4506565 0.348 0.296 
 
rs7754840 0.315 0.336 
 
rs1111875 0.577 0.584 
 
rs4402960 0.336 0.296 
 
rs10811661 0.822 0.801 
 
rs7756992 0.260 0.279 
 
rs5215 0.333 0.398 
 
rs7901695 0.346 0.281 
Total Mean 
Frequencies N =32 0.453 0.451 
 
Multiple SNPs in LD were included within the same mean calculations (Table 2.9). 
 
Table 2.9 Metabolic Diseases – SNPs in LD  
Disease SNP Proxy r2 D’ 
Obesity rs6711012 rs10189761 1 1 
 rs12446632 rs11639988 1 1 
 rs3101336 rs2568958 1 1 
 rs1421085 rs17817449 0.932 0.966 
 rs10871777 rs17782313 0.979 1 
 rs17817449 rs9941349 0.884 0.965 
 rs476828 rs17782313 0.979 1 
 rs17700144 rs476828 0.856 0.977 
 rs17700144 rs17782313 0.834 0.954 
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 rs1421085 rs17817449 0.932 0.966 
 rs10871777 rs476828 1 1 
 rs10871777 rs17782313 0.979 1 
 rs10871777 rs17700144 0.856 0.977 
 rs9941349 rs1421085 0.884 0.965 
     
T1 Diabetes rs1701704 rs2292239 0.851 0.94 
 rs2903692 rs12708716 0.941 0.98 
 rs2476601 rs6679677 1 1 
     
T2 Diabetes rs4506565 rs7903146 0.921 1 
 rs1111875 rs5015480 1 1 
 rs4402960 rs1470579 1 1 
 rs7756992 rs6931514 0.958 0.979 
 rs7901695 rs4506565 0.96 1 
 rs7901695 rs7903146 0.919 0.979 
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2.3.8 Eye Disease 
 
 
 
 
Figure 2.9 Mean risk allele frequencies of eye diseases.  
“A-R macular degen” is age-related macular degeneration, glaucoma is all glaucoma 
SNPs combined, and myopia (pathological). 
 
Table 2.10 SNPs associated with eye disease 
 
Disease SNP ID 
Risk Allele Frequency 
NL population 
Risk Allele Frequency 
CEU population 
Age-related 
macular 
degeneration rs1831282 0.440 0.416 
 
rs522162 0.902 0.938 
 
rs10490924 0.215 0.199 
 
rs3750848 0.217 0.204 
 
rs1329424 0.395 0.392 
 
rs3793917 0.219 0.216 
 
rs1061147 0.392 0.372 
 
rs541862 0.902 0.938 
 
rs10801555 0.392 0.372 
 
rs1061170 0.392 0.282 
 
rs641153 0.904 0.942 
 
rs2230199 0.195 0.175 
 
rs9332739 0.934 0.933 
 
rs10468017 0.720 0.690 
 
rs10033900 0.472 0.451 
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rs3764261 0.342 0.345 
 
rs1329428 0.612 0.576 
 
rs10737680 0.613 0.58 
Total Mean 
Frequencies N =18 0.514 0.501 
 
Glaucoma 
(primary 
open-angle) rs2157719 0.605 0.558 
 
rs10483727 0.415 0.379 
 
rs284489 0.622 0.642 
 
rs4236601 0.278 0.281 
Total Mean 
Frequencies N= 4 0.480 0.465 
    Glaucoma rs4656461 0.092 0.146 
 
rs4977756 0.652 0.584 
    Glaucoma 
(exfoliation) rs3825942 0.844 0.828 
    Keratoconus rs4954218 0.653 0.717 
    Fuchs's 
corneal 
dystrophy rs613872 0.159 0.19 
 
Myopia 
(pathological) rs10747502 0.911 0.932 
 
rs7428796 0.621 0.798 
 
rs4839680 0.026 0.062 
 
rs1656966 0.171 0.153 
 
rs16872571 0.713 0.681 
 
rs6841898 0.028 0.014 
 
rs6857559 0.614 0.897 
 
rs13172324 0.066 0.115 
 
rs10053502 0.959 0.956 
 
rs999556 0.293 0.321 
 
rs12525668 0.072 0.093 
 
rs1302019 0.027 0.027 
 
rs10274279 0.114 0.106 
 
rs4737395 0.106 0.124 
 
rs12216812 0.084 0.111 
 
rs872863 0.088 0.085 
 
rs7077335 0.016 0.009 
 
rs1472750 0.091 0.130 
 
rs17788937 0.790 1.000 
 
rs7323755 0.035 0.053 
 
rs11838472 0.027 0.040 
 
rs11618212 0.220 0.248 
 
rs17822114 0.035 0.058 
 
rs8050940 0.026 0.018 
 
rs923375 0.138 0.177 
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rs17826255 0.065 0.044 
 
rs3786800 0.778 0.902 
 
rs4142248 0.048 0.035 
Total Mean 
Frequencies N= 28 0.256 0.293 
 
 
 Multiple SNPs from the age-related macular degeneration category were included 
in the same calculation, rs1831282/ rs10801555 (r2 = 0.821, D’ = 1.0), rs1831282/ 
rs1061147 (r2 = 0.821, D’ = 1.0), rs522162/ rs541862 (r2 = 1.0, D’ = 1.0), rs10490924/ 
rs3750848 (r2 = 0.974, D’ = 1.0), rs1061147/ rs10801555 (r2 = 1.0, D’ = 1.0), rs1329428/ 
rs10737680 (r2 = 1.0, D’ = 1.0).  
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2.3.9 Lung Disease 
 
 
Figure 2.10 Mean risk allele frequencies of lung diseases.  
 
Table 2.11 SNPs associated with lung disease 
 
Disease SNP ID 
Risk Allele Frequency 
NL population 
Risk Allele Frequency 
CEU population 
Asthma 
(childhood, 
severe) rs6967330 0.172 0.183 
 
rs2305480 0.556 0.536 
 
rs928413 0.259 0.286 
rs3894194 0.471 0.487 
Total Mean 
Frequencies N= 4 0.365 0.373 
    Asthma 
(childhood 
onset) rs7927044 0.009 0.009 
Asthma rs13408661 0.860 0.907 
 
rs2786098 0.741 0.768 
 
rs7216389 0.487 0.491 
Total Mean 
Frequencies N= 3 0.696 0.722 
 
Idiopathic 
pulmonary 
fibrosis rs5743894 0.157 0.155 
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rs5743890 0.858 0.845 
    Interstitial lung 
disease rs6793295 0.267 0.277 
 
rs2609255 0.247 0.212 
 
rs2736100 0.478 0.473 
 
rs2076295 0.435 0.451 
 
rs7934606 0.413 0.463 
 
rs1278769 0.763 0.77 
 
rs2034650 0.477 0.478 
 
rs12610495 0.308 0.314 
Total Mean 
Frequencies N= 8 0.423 0.430 
    
Chronic 
obstructive 
pulmonary 
disease rs7937 0.551 0.553 
 rs7671167 0.526 0.518 
 
Lung 
adenocarcinoma rs31489 0.559 0.607 
 
rs1051730 0.295 0.385 
 
rs2736100 0.478 0.473 
    Lung cancer rs8034191 0.289 0.418 
 
rs4975616 0.558 0.58 
 
rs1051730 0.295 0.385 
 
rs401681 0.537 0.566 
 
rs8042374 0.251 0.201 
 
rs1051730 0.295 0.385 
Total Mean 
Frequencies N= 6 0.371 0.423 
 
 
 Two pairs of SNPs from lung cancer were in LD, rs4975616/rs401681 ( r2 = 
0.882, D’ = 0.964) and rs1051730/rs8034191 (r2 = 0.899, D’ = 1.0). 
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2.3.10 Lymphomas, myelomas and leukemias 
 
 
 
Figure 2.11 Mean risk allele frequencies of lymphomas, myelomas and leukemias.  
“ALL” is acute lymphoblastic leukemia, “CLL” is chronic lymphocytic leukemia, 
Hodgkin’s lymphoma, and “ MM” is multiple myelomas.  
 
Table 2.12 SNPs associated with lymphomas, myelomas and leukemias 
 
Disease SNP ID 
Risk Allele Frequency 
NL population 
Risk Allele Frequency 
CEU population 
Acute 
lymphoblastic 
leukemia 
(childhood) rs17505102 0.847 0.910 
 
rs4132601 0.263403 0.304 
 
rs7089424 0.339161 0.302 
 
rs10821936 0.337995 0.310 
 
rs11978267 0.265252 0.304 
Total Mean 
Frequencies N= 5 0.411 0.426 
    Acute 
lymphoblastic 
leukemia (B-
cell 
precursor) rs10828317 0.652 0.612 
 
rs3824662 0.163 0.143 
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Myeloprolifer
ative 
neoplasms rs10974944 0.269 0.305 
 
Disease SNP ID 
Risk Allele Frequency 
NL population 
Risk Allele Frequency 
CEU population 
Chronic 
lymphocytic 
leukemia rs10936599 0.752 0.732 
 
rs2236256 0.432 0.446 
 
rs1439287 0.480 0.473 
 
rs13397985 0.180 0.207 
 
rs872071 0.515 0.513 
 
rs735665 0.178 0.174 
 
rs7176508 0.415 0.371 
 
rs1044873 0.632 0.612 
 
rs4406737 0.554 0.571 
 
rs4987855 0.897 0.883 
 
rs7944004 0.492 0.491 
 
rs898518 0.586 0.612 
 
rs3769825 0.530 0.513 
 
rs13401811 0.856 0.775 
 
rs17483466 0.205 0.190 
 
rs674313 0.245 0.138 
 
rs9273012 0.254 0.161 
 
rs11636802 0.094 0.150 
 
rs7169431 0.079 0.103 
 
rs305061 0.667 0.683 
 
rs391023  0.626 0.681 
 
rs4987852 0.076 0.080 
 
rs210142 0.733 0.721 
 
rs391525 0.329 0.308 
 
rs11083846 0.300 0.257 
Total Mean 
Frequencies N= 25 0.441 0.434 
 
Hodgkin's 
lymphoma rs3806624 0.441 0.442 
 
rs7745098 0.536 0.544 
 
rs501764 0.173 0.194 
 
rs2019960 0.240 0.243 
Total Mean 
Frequencies N= 4 0.348 0.358 
    Nodular sclerosis 
Hodgkin 
lymphoma rs2858870 0.875 0.841 
    Follicular 
lymphoma rs735665 0.178 0.173 
 
Meningioma rs11012732 0.672 0.673 
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Ewing sarcoma rs9430161 0.780 0.792 
 
rs224278 0.591 0.588 
 
rs4924410 0.258 0.314 
    Multiple 
myeloma rs10936599 0.752 0.730 
 
rs2285803 0.267 0.274 
 
rs4273077 0.094 0.113 
 
rs877529 0.452 0.416 
 
rs4487645 0.670 0.673 
Total Mean 
Frequencies N= 5 0.447 0.441 
    Multiple 
myeloma 
(hyperdiploidy) rs6599175 0.166 0.243 
 
rs139371 0.527 0.544 
 
rs2272007 0.169 0.243 
 
rs4487645 0.670 0.673 
Total Mean 
Frequencies N= 4 0.383 0.426 
    
Amyotrophic 
lateral sclerosis rs12608932 0.339 0.345 
 rs2814707 0.250 0.239 
    
Myasthenia 
gravis rs2476601 0.093 0.117 
 rs4958881 0.119 0.075 
 
 Two SNPs from acute lymphoblastic leukemia (childhood) were in LD, 
rs4132601/rs11978267 (r2 = 1.0, D’ = 1.0). Also, two SNPs from multiple myeloma 
(hyperdiploidy) were in perfect LD (r2 = 1.0, D’ = 1.0).  
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2.3.11 Thyroid Disease 
 
 
Figure 2.12 Mean risk allele frequencies of thyroid disease.  
 
 
Table 2.13 SNPs associated with thyroid disease 
 
Disease SNP ID 
Risk Allele Frequency 
NL population 
Risk Allele Frequency 
CEU population 
Hypo-
thyroidism rs925489 0.652 0.567 
 
rs4915077 0.087 0.072 
 
rs3184504 0.481 0.445 
 
rs6679677 0.092 0.115 
 
rs7850258 0.652 0.633 
Total Mean 
Frequencies N= 5 0.393 0.366 
    Goiter risk rs12138950 0.836 0.814 
 
rs4338740 0.745 0.746 
 
rs17767419 0.323 0.367 
 
rs10917468 0.227 0.270 
 
rs4338740 0.255 0.254 
 
rs3813579 0.547 0.603 
 
rs12045440 0.683 0.699 
Total Mean 
Frequencies N= 7 0.517 0.536 
 
Thyroid cancer rs6759952 0.412 0.447 
 
rs965513 0.349 0.367 
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rs966423 0.429 0.456 
 
rs2439302 0.484 0.465 
 
rs944289 0.587 0.602 
Total Mean 
Frequencies N= 5 0.452 0.467 
 
 No SNPs in LD were included in the same mean frequency calculations. 
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2.3.12 Skin Disease 
 
 
 
Figure 2.13 Mean risk allele frequencies of skin conditions and cancers.  
“A. dermatitis” is atopic dermatitis, “BCC” is basal cell carcinoma, melanoma, psoriasis 
and vitiligo 
 
Table 2.14 SNPs associated with skin disease 
Disease SNP ID 
Risk Allele Frequency 
NL population 
Risk Allele Frequency 
CEU population 
Atopic 
dermatitis rs1295686 0.211 0.217 
 
rs7130588 0.359 0.381 
 
rs6661961 0.423 0.412 
 
rs479844 0.567 0.535 
 
rs2164983 0.161 0.147 
 
rs7927894 0.391 0.394 
Total Mean 
Frequencies N= 6 0.352 0.348 
    
Alopecia 
areata rs1024161 0.412 0.403 
 
rs9479482 0.564 0.504 
 
rs3118470 0.331 0.310 
 
Basal cell 
carcinoma rs214782 0.214 0.144 
 
rs7006527 0.163 0.128 
 
rs7538876 0.378 0.427 
 
rs801114 0.357 0.342 
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rs401681 0.537 0.571 
 
rs2151280 0.516 0.500 
 
rs157935 0.689 0.727 
 
rs1805007 0.088 0.122 
 
rs12210050 0.190 0.152 
Total Mean 
Frequencies N= 9 0.348 0.346 
    Non-
melanoma 
skin cancer rs12203592 0.212 0.156 
 
rs1805007 0.088 0.122 
    Melanoma rs16953002 0.149 0.143 
 
rs13016963 0.409 0.420 
 
rs1801516 0.835 0.811 
 
rs45430 0.647 0.670 
 
rs7023329 0.522 0.509 
 
rs1393350 0.276 0.219 
 
rs258322 0.111 0.138 
 
rs7412746 0.587 0.527 
 
rs17119461 0.011 0.018 
 
rs1393350 0.276 0.219 
 
rs258322 0.111 0.138 
 
rs4785763 0.308 0.380 
 
rs2284063 0.660 0.679 
 
rs910873 0.103 0.080 
Total Mean 
Frequencies N= 14 0.357 0.354 
 
Psoriasis rs2546890 0.521 0.562 
 
rs702873 0.564 0.571 
 
rs17716942 0.838 0.805 
 
rs27524 0.385 0.332 
 
rs240993 0.233 0.250 
 
rs8016947 0.558 0.535 
 
rs12720356 0.892 0.876 
 
rs458017 0.065 0.045 
 
rs465969 0.922 0.942 
 
rs280519 0.485 0.487 
 
rs4112788 0.679 0.597 
 
rs3213094 0.198 0.190 
 
rs2082412 0.802 0.805 
 
rs17728338 0.074 0.080 
 
rs20541 0.795 0.783 
 
rs610604 0.328 0.425 
 
rs2066808 0.934 0.929 
Total Mean 
Frequencies N= 17 0.545 0.542 
 
Vitiligo rs2111485 0.569 0.615 
 
rs10768122 0.410 0.385 
 
rs4409785 0.177 0.142 
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rs2456973 0.343 0.297 
 
rs4766578 0.468 0.422 
 
rs4822024 0.786 0.758 
 
rs4908760 0.372 0.376 
 
rs706779 0.545 0.541 
 
rs1393350 0.724 0.774 
 
rs11203203 0.360 0.323 
 
rs229527 0.391 0.403 
 
rs1464510 0.470 0.456 
Total Mean 
Frequencies N= 12 0.468 0.458 
 
 Two SNPs from atopic dermatitis were in LD, rs7130588/rs7927894 (r2 = 0.948, 
D’ = 1.0). 
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2.3.13 Aneurysms, embolisms and stroke 
 
 
 
Figure 2.14 Mean risk allele frequencies of aneurysms, embolisms and stroke.  
“IC aneurysms” is intracranial aneurysms, all stroke-associate SNPs, and “V T” is venous 
thrombosis. 
 
Table 2.15 SNPs associated with aneurysms, embolisms and stroke 
 
Disease SNP ID 
Risk Allele Frequency 
NL population 
Risk Allele Frequency 
CEU population 
Intracranial 
aneurysm rs9298506 0.783 0.795 
 rs1333040 0.645 0.558 
 rs12413409 0.916 0.925 
 rs9315204 0.219 0.212 
 rs11661542 0.474 0.487 
 rs10958409 0.173 0.159 
Total Mean 
Frequencies N= 6 0.535 0.523 
    
Abdominal 
aortic 
aneurysm rs6511720 0.887 0.894 
 
rs1466535 0.669 0.686 
 
rs7025486 0.242 0.248 
   
Thoracic 
aortic 
aneurysms  rs1036476 0.119 0.075 
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Venous 
thrombosis rs3813948 0.057 0.107 
    Venous 
thrombo-
embolism rs6427196 0.064 0.062 
 
rs687621 0.350 0.356 
 
rs4253399 0.418 0.394 
 
rs6536024 0.556 0.562 
 
rs6025 0.025 0.022 
 
rs495828 0.232 0.186 
 
rs16861990 0.064 0.080 
 
rs2519093 0.205 0.000 
 
rs1018827 0.064 0.076 
 
rs7659024 0.258 0.221 
 
rs505922 0.350 0.363 
 
rs3756008 0.441 0.398 
Total Mean 
Frequencies N= 12 0.252 0.227 
    Stroke 
(ischemic) rs2107595 0.138 0.200 
 
rs6843082 0.175 0.212 
 
rs2200733 0.100 0.115 
Stroke rs11984041 0.088 0.112 
 
rs12425791 0.185 0.177 
Total Mean 
Frequencies N= 5 0.137 0.163 
 
 
 Two SNPs in LD were included in the calculation for venous thromboembolism, 
rs4253399/rs3756008 (r2 = 0.947, D’ = 0.982). 
 
 
  
 107 
2.3.14 Heart and Circulatory Conditions 
 
 
Figure 2.15 Mean risk allele frequencies of heart and circulatory conditions. 
“AF” is atrial fibrillation, “CHD” is coronary heart disease, hypertension, “MI” is 
myocardial infarction, “sudden CA” is sudden cardiac arrest and von Willebrand factor. 
 
Table 2.16 SNPs associated with heart and circulatory conditions 
Disease SNP ID 
Risk Allele Frequency 
NL population 
Risk Allele Frequency 
CEU population 
Brugada 
syndrome rs11708996 0.147 0.200 
 
rs10428132 0.456 0.420 
 
rs9388451 0.489 0.465 
    Congenital 
heart disease rs870142 0.229 0.265 
    Tetralogy of 
Fallot rs7982677 0.262 0.259 
 
rs11065987 0.436 0.336 
    von 
Willebrand 
factor rs687289 0.345 0.358 
 
rs8176704 0.075 0.088 
 
rs1063856 0.655 0.655 
 
rs867186 0.127 0.097 
 
rs9390459 0.444 0.442 
Total Mean 
Frequencies N= 5 0.329 0.328 
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Factor VII rs561241 0.894 0.883 
    
    Aortic-valve 
calcification rs10455872 0.084 0.083 
    Pulmonary 
arterial 
hypertension  rs2217560 0.084 0.111 
    Coronary 
artery 
calcification rs1537370 0.460 0.456 
 
rs1333049 0.470 0.456 
 
rs9349379 0.633 0.628 
    Hypertri-
glyceridemia rs964184 0.143 0.121 
 
rs1260326 0.422 0.420 
    Kawasaki 
disease rs1801274 0.470 0.491 
 
Coronary 
heart disease rs1333049 0.470 0.451 
 
rs7865618 0.606 0.549 
 
rs1746048 0.893 0.853 
 
rs17114036 0.893 0.895 
 
rs12190287 0.636 0.603 
 
rs11556924 0.617 0.612 
 
rs579459 0.232 0.205 
 
rs12413409 0.916 0.924 
 
rs964184 0.143 0.122 
 
rs4773144 0.409 0.424 
 
rs2895811 0.406 0.419 
 
rs3825807 0.564 0.550 
 
rs216172 0.365 0.328 
 
rs12936587 0.479 0.467 
 
rs599839 0.802 0.719 
 
rs6725887 0.125 0.156 
 
rs12526453 0.653 0.634 
 
rs3798220 0.029 0.000 
 
rs4977574 0.463 0.455 
 
rs1122608 0.745 0.746 
 
rs9982601 0.146 0.206 
 
rs1231206 0.363 0.325 
 
rs1994016 0.587 0.572 
 
rs514659 0.351 0.364 
 
rs3739998 0.572 0.563 
 
rs9818870 0.174 0.170 
Total Mean 
Frequencies N= 26 0.486 0.474 
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    Myocardial 
infarction 
(early onset) rs646776 0.194 0.257 
 
rs17465637 0.719 0.734 
 
rs1746048 0.893 0.853 
 
rs12526453 0.653 0.634 
 
rs4977574 0.463 0.455 
 
rs1122608 0.745 0.746 
 
rs9982601 0.146 0.206 
Total Mean 
Frequencies N= 7 0.545 0.555 
    Myocardial 
infarction rs10757278 0.533 0.500 
    Dilated 
cardio-
myopathy rs2234962 0.760 0.792 
 
rs10927875 0.708 0.683 
    Sudden 
cardiac arrest rs4665058 0.016 0.025 
 
rs16866933 0.077 0.076 
 
rs12429889 0.119 0.134 
 
rs7307780 0.183 0.165 
 
rs10765792 0.090 0.121 
 
rs12189362 0.134 0.124 
 
rs2982694 0.136 0.121 
 
rs16942421 0.080 0.091 
Total Mean 
Frequencies N= 8 0.104 0.107 
    Atrial 
fibrillation rs2200733 0.100 0.116 
 
rs10033464 0.075 0.094 
 
rs3903239 0.449 0.448 
 
rs3807989 0.589 0.580 
 
rs10821415 0.450 0.397 
 
rs10824026 0.862 0.835 
 
rs1152591 0.485 0.487 
 
rs7164883 0.159 0.170 
 
rs6666258 0.328 0.298 
 
rs6817105 0.100 0.119 
 
rs2106261 0.186 0.179 
 
rs6843082 0.175 0.210 
 
rs13376333 0.328 0.339 
 
rs7193343 0.174 0.161 
rs1805126 0.626 0.679 
 rs6906287 0.455 0.500 
 rs1321313 0.770 0.695 
 rs2207790 0.519 0.500 
 rs6795970 0.448 0.420 
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Total Mean 
Frequencies N =19 0.318 0.317 
    Hypertension rs6015450 0.128 0.071 
 
rs633185 0.261 0.317 
 
rs1799945 0.136 0.182 
 
rs1173771 0.595 0.513 
 
rs932764 0.400 0.425 
 
rs2681472 0.831 0.884 
Total Mean 
Frequencies N= 6 0.392 0.399 
 
 
For the mean risk allele frequency calculation for coronary heart disease two 
SNPs were in LD, rs4977574/ rs1333049 (r2 = 0.9, D’ = 0.9). 
 
 
 
 
 
 
 
 
 
 
 
 
  
 111 
2.3.15 Inflammatory Conditions 
 
 
 
Figure 2.16 Mean risk allele frequencies of inflammatory conditions.  
“ACAA” is antineutrophil cytoplasmic antibody-associated vasculitis, “IBD” is irritable 
bowel syndrome, “IBD (E-O)” is irritable bowel syndrome (early-onset) and “MS” is 
multiple sclerosis. 
 
Table 2.17 SNPs associated with inflammatory conditions 
 
Disease SNP ID 
Risk Allele Frequency 
NL population 
Risk Allele Frequency 
CEU population 
Antineutrophil 
cytoplasmic 
antibody-
associated 
vasculitis rs6638512 0.501 0.536 
 
rs1972809 0.601 0.62 
 
rs2755459 0.768 0.713 
 
rs7151526 0.937 0.938 
 
rs5954596 0.816 0.839 
Total Mean 
Frequencies N= 5 0.724 0.729 
    
 
Inflammatory 
bowel disease rs35675666 0.803 0.833 
 
rs12568930 0.845 0.814 
 
rs11209026 0.940 0.959 
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rs4845604 0.831 0.867 
 
rs670523 0.358 0.363 
 
rs4656958 0.702 0.646 
 
rs1801274 0.470 0.491 
 
rs2488389 0.213 0.207 
 
rs7554511 0.708 0.673 
 
rs3024505 0.153 0.181 
 
rs6545800 0.437 0.416 
 
rs925255 0.566 0.527 
 
rs10495903 0.141 0.146 
 
rs7608910 0.414 0.379 
 
rs917997 0.237 0.204 
 
rs1517352 0.591 0.624 
 
rs2382817 0.389 0.345 
 
rs3749171 0.163 0.210 
 
rs4256159 0.156 0.164 
 
rs3197999 0.258 0.261 
 
rs7657746 0.770 0.790 
 
rs11742570 0.628 0.646 
 
rs1363907 0.429 0.442 
 
rs4836519 0.770 0.730 
 
rs2188962 0.433 0.402 
 
rs6863411 0.629 0.633 
 
rs11741861 0.069 0.044 
 
rs6871626 0.330 0.367 
 
rs17119 0.825 0.770 
 
rs9358372 0.388 0.350 
 
rs1847472 0.625 0.692 
 
rs6568421 0.255 0.310 
 
rs3851228 0.058 0.040 
 
rs6920220 0.248 0.165 
 
rs1819333 0.494 0.491 
 
rs1456896 0.678 0.646 
 
rs9297145 0.241 0.305 
 
rs1734907 0.117 0.162 
 
rs921720 0.627 0.619 
 
rs1991866 0.430 0.447 
 
rs10758669 0.385 0.366 
 
rs4743820 0.706 0.699 
 
rs4246905 0.738 0.676 
 
rs10781499 0.455 0.487 
 
rs12722515 0.844 0.850 
 
rs1042058 0.604 0.628 
 
rs11010067 0.325 0.354 
 
rs2790216 0.800 0.779 
 
rs10761659 0.537 0.553 
 
rs2227564 0.759 0.761 
 
rs1250546 0.561 0.558 
 
rs6586030 0.826 0.823 
 
rs4409764 0.497 0.455 
 
rs907611 0.294 0.319 
 
rs10896794 0.798 0.735 
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rs11230563 0.644 0.637 
 
rs4246215 0.323 0.372 
 
rs559928 0.816 0.796 
 
rs2231884 0.147 0.173 
 
rs2155219 0.499 0.487 
 
rs630923 0.838 0.863 
 
rs11564258 0.023 0.027 
 
rs11168249 0.526 0.504 
 
rs7134599 0.420 0.394 
 
rs17085007 0.188 0.150 
 
rs941823 0.746 0.779 
 
rs9557195 0.791 0.774 
 
rs194749 0.227 0.235 
 
rs8005161 0.085 0.140 
 
rs17293632 0.216 0.230 
 
rs7495132 0.897 0.876 
 
rs529866 0.781 0.805 
 
rs7404095 0.570 0.637 
 
rs26528 0.464 0.451 
 
rs10521318 0.910 0.907 
 
rs3091316 0.722 0.686 
 
rs12946510 0.440 0.500 
 
rs12942547 0.633 0.545 
 
rs1292053 0.439 0.451 
 
rs1893217 0.183 0.115 
 
rs7240004 0.641 0.626 
 
rs727088 0.528 0.500 
 
rs11879191 0.801 0.801 
 
rs17694108 0.267 0.305 
 
rs11672983 0.381 0.407 
 
rs6142618 0.515 0.535 
 
rs4911259 0.413 0.345 
 
rs1569723 0.251 0.239 
 
rs259964 0.441 0.464 
 
rs6062504 0.725 0.655 
 
rs2823286 0.684 0.681 
 
rs2836878 0.712 0.712 
 
rs7282490 0.399 0.429 
 
rs2266959 0.204 0.168 
 
rs2412970 0.456 0.385 
 
rs2413583 0.851 0.854 
 
rs2315008 0.723 0.659 
 
rs5743289 0.196 0.226 
 
rs2076756 0.263 0.323 
Total Mean 
Frequencies N= 99 0.500 0.498 
    
Inflammatory 
bowel disease 
(early onset) rs10500264 0.161 0.179 
 rs2412973 0.439 0.385 
 rs8049439 0.583 0.615 
 rs1250550 0.640 0.633 
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Total Mean 
Frequencies N= 4 0.456 0.453 
 
Disease SNP ID 
Risk Allele Frequency 
NL population 
Risk Allele Frequency 
CEU population 
Multiple 
sclerosis rs9292777 0.630 0.649 
 
rs2300747 0.896 0.867 
 
rs12368653 0.500 0.447 
 
rs11154801 0.371 0.397 
 
rs7522462 0.708 0.673 
 
rs2293370 0.788 0.850 
 
rs650258 0.628 0.638 
 
rs1335532 0.892 0.863 
 
rs9282641 0.936 0.902 
 
rs7200786 0.580 0.540 
 
rs2248359 0.639 0.588 
 
rs2303759 0.247 0.296 
 
rs11129295 0.356 0.363 
 
rs11810217 0.256 0.257 
 
rs2119704 0.913 0.932 
 
rs7923837 0.593 0.633 
 
rs2546890 0.521 0.562 
 
rs17066096 0.252 0.181 
 
rs7090512 0.312 0.314 
rs7238078 0.780 0.796 
 
rs2283792 0.535 0.527 
 
rs4648356 0.727 0.668 
 
rs4410871 0.719 0.712 
 
rs12466022 0.746 0.748 
 
rs669607 0.491 0.487 
 
rs2425752 0.267 0.252 
 
rs771767 0.283 0.350 
 
rs7595037 0.532 0.549 
 
rs4613763 0.128 0.168 
 
rs802734 0.690 0.708 
 
rs2019960 0.240 0.243 
 
rs11581062 0.286 0.292 
 
rs10201872 0.156 0.196 
 
rs9891119 0.329 0.389 
 
rs1738074 0.584 0.535 
 
rs1800693 0.387 0.482 
 
rs1077667 0.774 0.786 
 
rs4902647 0.531 0.562 
 
rs1250550 0.360 0.367 
 
rs354033 0.776 0.765 
 
rs3118470 0.331 0.310 
 
rs703842 0.686 0.664 
 
rs17445836 0.788 0.733 
 
rs17824933 0.231 0.195 
 
rs10492972 0.314 0.336 
Total Mean 
Frequencies N= 45 0.526 0.528 
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Sarcoidosis rs479777 0.693 0.633 
    
Primary 
sclerosing 
cholangitis  rs3197999 0.258 0.261 
    Chronic 
hepatitis C 
infection rs8099917 0.205 0.150 
    Pancreatitis rs10273639 0.570 0.589 
 
rs12688220 0.268 0.333 
   
Periodontitis rs1537415 0.576 0.571 
 
 Two SNPs for inflammatory bowel disease are in LD, rs6062504/rs2315008 (r2 = 
0.981, D’ = 1.0). The SNPs in LD for multiple sclerosis calculations were 
rs2300747/rs1335532 (r2 = 0.964, D’ = 1.0). 
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2.3.16 Brain Tumours and Others 
 
 
 
Figure 2.17 Mean risk allele frequencies of brain tumours and other conditions.  
“Dupuytren’s” is Dupuytren’s  contracture, “Glioma” is all SNPs associated with forms 
of gliomas, Schizophrenia and “Wilms’ T” is Wilms’ tumour. 
 
Table 2.18 SNPs associated with brain tumours and other conditions 
Disease SNP ID 
Risk Allele Frequency 
NL population 
Risk Allele Frequency 
CEU population 
Dupuytren's 
disease  rs7524102 0.155 0.186 
 rs16879765 0.115 0.045 
 rs611744 0.885 0.554 
 rs2912522 0.758 0.739 
 rs10809650 0.740 0.705 
 rs11672517 0.228 0.221 
 rs8124695 0.080 0.097 
 rs6519955 0.390 0.363 
Total Mean 
Frequencies N= 8 0.419 0.364 
    
Glioma rs2736100 0.522 0.527 
 rs6010620 0.797 0.757 
 rs4295627 0.156 0.128 
 rs2157719 0.395 0.442 
 rs498872 0.332 0.310 
 rs2853676 0.295 0.286 
 rs891835 0.229 0.192 
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 rs4977756 0.349 0.416 
Total Mean 
Frequencies N= 8 0.384 0.382 
    
Glioma 
(high-grade) rs1412829 0.383 0.427 
 rs4809324 0.107 0.088 
 rs6010620 0.797 0.757 
    
Neuro-
blastoma rs4336470 0.635 0.625 
 
rs7587476 0.251 0.265 
 
rs9295536 0.472 0.398 
 
rs110419 0.515 0.504 
 
rs4712653 0.492 0.425 
 
rs3768716 0.228 0.243 
 
rs6939340 0.500 0.460 
Total Mean 
Frequencies N= 7 0.442 0.417 
    Neuro-
blastoma  
(high-risk) rs6435862 0.240 0.304 
 
Schizo-
phrenia rs7085104 0.655 0.688 
 
rs6461049 0.530 0.580 
 
rs1198588 0.797 0.808 
 
rs4129585 0.441 0.393 
 
rs10789369 0.382 0.406 
 
rs7940866 0.506 0.554 
 
rs17504622 0.029 0.033 
 
rs2905424 0.349 0.362 
 
rs2373000 0.418 0.428 
 
rs1261117 0.966 0.955 
 
rs7527939 0.837 0.795 
 
rs11191580 0.912 0.924 
 
rs1625579 0.821 0.833 
 
rs6932590 0.742 0.799 
 
rs12807809 0.835 0.826 
 
rs9960767 0.052 0.067 
 
rs1006737 0.338 0.347 
 
rs17693963 0.868 0.920 
Total Mean 
Frequencies N= 18 0.582 0.595 
    
Bipolar 
disorder rs1064395 0.168 0.152 
 
rs420259 0.723 0.804 
 
rs10994336 0.069 0.067 
    Major 
depressive rs1545843 0.475 0.478 
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disorder 
    
Autism rs4307059 0.615 0.628 
 
Wilms 
tumour rs3755132 0.130 0.150 
 rs1027643 0.054 0.075 
 rs790356 0.516 0.527 
 rs2283873 0.018 0.031 
 rs5955543 0.022 0.006 
 rs807624 0.330 0.326 
Total Mean 
Frequencies N= 6 0.178 0.186 
    Epilepsy 
(generalized) rs13026414 0.578 0.650 
 
rs10496964 0.799 0.801 
    Hippo-campal 
atrophy rs6703865 0.073 0.034 
    
Cystic fibrosis 
severity rs12793173 0.213 0.257 
 
Essential 
tremor rs9652490 0.228 0.199 
    
Narcolepsy rs1154155 0.158 0.146 
 
 For the neuroblastoma calculations two pairs of SNPs were in LD, 
rs7587476/rs3768716 (r2 = 0.896, D’ = 1.0) and rs9295536/ rs4712653 (r2 = 0.835, D’ = 
0.963). 
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2.3.17  Summary of Statistically Significant Results 
 
Several diseases showed statistically significant results including bladder cancer, 
coronary heart disease and celiac disease. All three had p < 0.05, and ulcerative colitis 
had a near significant result at p = 0.06. The mean risk allele frequencies for these 
diseases were all higher in Newfoundland than in the CEU population (see figure 2.18). 
 
 
Figure 2.18 Significant Results - mean risk allele frequencies more prevalent in 
Newfoundland 
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Several diseases also showed significantly lower mean risk allele frequencies (p < 
0.05) in Newfoundland as compared to the outbred population, including myopia, obesity 
and schizophrenia (see figure 2.19).  
 
Figure 2.19 Significant Results - mean risk allele frequencies less prevalent in 
Newfoundland 
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2.4 CHAPTER 4. Discussion 
 
Based on a current hypothesis of the evolution of complex disease, that complex 
diseases have developed due to an accumulation of multiple, low-penetrant 
polymorphisms, this study assesses the mean frequencies of the known risk alleles 
associated with disease in the Newfoundland and Labrador population. Many variants 
associated with complex diseases have already been discovered through GWA studies, 
with over 15,000 currently in the NIH catalogue, making it a concise resource for 
hundreds of SNPs associated with many different diseases. However, even when 
factoring in all risk alleles for a particular complex disease, the combined contribution of 
identified loci to disease variation is often less than 10% (Bjorkegren et al., 2015). By 
combining SNPs for a given disease the statistical power is increased and a broader 
picture of the burden of disease in a given population may be achieved. For example, a 
study of the complex trait of height utilized a “polygenic” model to combine all height-
associated SNPs and explained up to 40% of genetic variance (Yang et al., 2010). This 
approach can be expanded to estimate the genetic contribution of risk alleles for common 
complex diseases.  The unique genetic structure of founder populations could result in 
higher rates of certain diseases due to higher frequencies of risk alleles, making them 
particularly useful populations to study the genetic basis of complex disease. This has 
driven studies of monogenic disorders, rare in out-bred populations, but present at a 
higher rate in genetically isolated populations due to founder effects. These populations 
may also exhibit extended linkage disequilibrium than that found in out-bred populations. 
If proven, this would mean that fewer SNPs are required for studying genetic association. 
In simulations of recent bottleneck populations, natural selection has not had sufficient 
time to decrease the proportion of risk alleles to the equilibrium found in the out-bred 
populations (Lohmueller et al., 2008). Newfoundland has been identified as a founder 
population where a number of diseases are reported at higher rates and therefore, it can be 
assumed that there is a higher frequency of certain risk variants for complex traits. These 
risk variants likely rose in frequency during the population bottleneck Newfoundland 
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experienced during its settlement and may have spread through the population due to the 
low genetic diversity and higher rate of inbreeding subsequent to the bottleneck. By 
calculating the mean frequencies of risk alleles associated with a given disease in the 
Newfoundland population we identified several diseases with a significantly higher mean 
frequency of risk alleles in the NL population compared to the CEU sample. This is a 
novel method to study potential disease burden, as there are few reported studies using 
this method. One article by Lim and colleagues studied low-frequency loss-of-function 
variants. They were able to successfully identify an enrichment of risk variants and 
several health-related consequences in the Finnish population (Lim et al., 2014). Our 
study uses a similar method, involving common variants to assess disease allele burden in 
the Newfoundland and Labrador founder population as compared to the out-bred CEU 
population of similar ancestry. The Canadian prevalence of disease is also discussed as a 
reference to the NL disease prevalence. A comparison is drawn between the statistical 
prevalence and mean disease-associated SNP prevalence. The Canadian population was 
chosen due to its close geographic proximity to Newfoundland, similar environments and 
ethnic distribution in an attempt to compare disease burden in a founder population (NL) 
to an outbred population (Canada). Due to the high number of diseases included in the 
study, only those with significant or unexpected results will be discussed in detail. 
 
2.4.1 Arthritis 
 
Arthritis, particularly psoriatic arthritis and OA are reported at a higher frequency 
in NL (as explained in part 1) as compared to other areas of Canada. When combining 
risk alleles for ankylosing spondylitis, gout, OA and RA, none of the allele associations 
reached significance. However, of particular interest was OA for which there were only 4 
SNPs included in the analysis, but still reached a p-value of 0.068. However, all four 
SNPs were found at a higher frequency in the NL population. And the difference between 
the populations was one of the largest recorded in this study, with the mean risk 
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frequency in NL at 0.25 compared to CEU at 0.21. It is possible that this difference could 
become significant if more SNPs were included in the analysis. 
 
2.4.2 Common Cancers 
 
The cancers included in this study were bladder, breast, colorectal, ovarian, 
prostate and testicular cancers. Of these, only bladder cancer risk alleles were found at a 
significantly different rate. The mean risk frequency for the CEU population is 0.484, 
while the NL population is 0.515, with a p-value of 0.016. The incidence of bladder 
cancer is NL was reported at 17.8 new cases/ 100,000 (age-standardized) in 2010, while 
Canada-wide it was 16.1/ 100,000 in 2010 (Statistics Canada, 2010). Therefore, according 
to Statistics Canada, the province of Newfoundland and Labrador has a higher incidence 
of bladder cancer than the national average. The higher mean frequency of risk variants in 
NL as compared to CEU found in the study support a higher rate of bladder cancer 
incidence in NL. 
Interestingly, colorectal cancer, which is reported at a significantly higher rate in 
NL, did not show a significantly different frequency of risk alleles in this study. These 
results could be due to the NL study population being taken from a control group of a 
colorectal cancer research study. Any participants diagnosed with colorectal cancer were 
excluded from the study as controls. Therefore, the study population from NL is not 
necessarily a true representation of a random sample of the population in terms of 
colorectal cancer development. This could alter the results for the colorectal cancer 
frequencies, and also other related types of cancer may be skewed. For example, Lynch 
syndrome, observed at a high rate in NL as compared to the rest of Canada has an 
increased risk primarily of colorectal cancer, but also an increased risk of endometrial 
cancer. Therefore, the data may not accurately reflect the frequency of colorectal cancer 
and related cancer types.  
 
 124 
2.4.3 Eye Diseases 
 
Several genetic eye conditions are known to be higher in NL, such as 
achromatopsia (Doucette et al., 2013). Interestingly, the mean frequency of risk alleles for 
pathological myopia in NL is significantly lower than in the CEU population (Doucette et 
al., 2013). Canada-wide, the risk of myopia is reported at 30% (Doctors of optometry 
Canada, ). Unfortunately, statistical data on the rates by province of myopia are not 
available. Therefore, the results cannot be compared to a provincial prevalence. 
 
2.4.4 Heart and Circulatory Diseases 
 
Atrial fibrillation, coronary heart disease, hypertension, myocardial infarction, 
sudden cardiac arrest and von Willebrand Factor were included in heart and circulatory 
conditions. The mean frequency for risk alleles for coronary heart disease was 
significantly higher in NL at 0.486 versus CEU at 0.473, with a p-value of 0.02. NL is 
well known for cardiomyopathies and heart disease. Age-standardized mortality rates of 
ischemic heart disease in 2011 in Canada are 2.1/ 100,000, while in NL the rate is 3.3/ 
100,000 (Statistics Canada, 2011a). In addition the rates of self-reported heart disease in 
Canada are 4.9%, in NL the Central region is 7.9%, the Eastern region is 5.8%, Labrador 
is 4.5% and the Western region 7.4% (Statistics Canada, 2011b). The mean risk allele 
frequencies in the study lend support to the high rate of cardiac disease in NL and suggest 
that coronary heart disease in NL may be significantly influenced by genetics. 
 
2.4.5 Renal and Digestive Tract Disorders 
 
Celiac disease affects as many as 1 in every 100-200 people in North America and 
as many as 300,000 Canadians (Statistics Canada, 2012b). The clinical presentation of the 
disease is varied, which can make a diagnosis difficult (Green, Lebwohl, & Greywoode, 
2015). Celiac disease is generally under diagnosed; in the U.S. less than 20% of people 
with celiac disease receive a diagnosis (Rubio-Tapia, Ludvigsson, Brantner, Murray, & 
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Everhart, 2012). The prevalence of celiac disease has not previously been reported in 
individual provinces.  Therefore, the prevalence in NL is not available for analysis or for 
comparison to other out-bred population. Although, our data indicate that the mean risk 
allele frequency is higher in NL at 0.438 than in the CEU population 0.423, at p = 0.04. 
This could suggest that the rate of Celiac disease may be higher in NL as compared to 
other populations. Further research into the provincial rates of celiac disease is necessary. 
Of the other conditions – chronic kidney disease, Crohn’s disease and ulcerative 
colitis – none of the mean risk allele frequencies were significantly different between the 
two populations. Interestingly, the prevalence of ulcerative colitis in NL was also higher 
than in the CEU population with a p-value near significant of 0.057. The national rate of 
self-reported bowel disorders in 2011/2012 is 4.3% (Statistics Canada, 2012b). While the 
rate in Central NL is 9.8%, Eastern 7.8%, Labrador 2.1% and Western NL is 6.8% 
(Statistics Canada, 2012b), indicating that NL has a higher rate of bowel disorders in 
general and celiac disease and ulcerative colitis may represent a significant proportion of 
this. 
 
2.4.6 Metabolic Syndrome and associated conditions 
 
Mean frequencies of metabolic syndrome, type 1 diabetes and type 2 diabetes risk 
alleles were not significantly different. This is surprising considering the well-
documented high prevalence of diabetes in Newfoundland. Although the mean risk 
frequency was higher, it was not significant. Perhaps even more surprising was mean risk 
frequency for obesity, found to be significantly lower in the NL population at p = 0.03. 
NL has the highest rate of obesity in Canada and it is considered a significant health 
burden. These results suggest the high rate of obesity and diabetes in Newfoundland are 
more likely due to the environment than to risk-associated genetic variants. Extreme 
obesity, while not significant at p = 0.08, was also higher in the CEU population. 
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Alternatively, there may be specific genetic factors responsible for obesity and diabetes in 
the NL that have not been identified yet. 
 
2.4.7 Schizophrenia 
 
Of the mood disorders evaluated, only the mean risk frequency for schizophrenia 
was different, at a significantly lower rate in NL of 0.58 than in CEU at 0.60, p = 0.03. 
Statistics Canada reports the prevalence of schizophrenia or psychosis at 0.8% (age >15, 
2012) as compared to the national average at 1.3% (Statistics Canada, 2012a). This 
analysis supports a lower rate of schizophrenia in NL. 
 
2.4.8 Other Conditions 
 
The remaining conditions reported in the results included bone conditions, 
leukemias, lymphomas, myelomas, lung conditions, skin conditions and cancers, 
inflammatory conditions, thyroid disorders, aneurysms, embolisms, stroke, autoimmune 
disorders, and brain or neurological conditions. Of the mean risk allele frequencies from 
complex diseases in these categories, none were found to be significantly different 
between the NL population and the CEU population. 
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2.5 CHAPTER 5. Conclusions 
2.5.1 Study Strengths 
Assessing the impact of individual SNPs with low penetrance may not be 
particularly useful to describe a complex disease in a population as a whole, as the disease 
may be related to multiple, low-penetrance variants. Even when factoring in all risk 
alleles for a particular complex disease, the combined contribution of identified loci to 
disease variation is often less than 10% (Bjorkegren et al., 2015). This could explain the 
small variation observed in the mean risk frequencies between the NL and CEU 
population for most complex diseases studied here. However, by combining SNPs for a 
given disease the statistical power is increased and a broader picture of the burden of 
disease in a given population may be achieved. For example, a study of the complex trait 
of height utilized a “polygenic” model to combine all height-associated SNPs and was 
able to explain up to 40% of genetic variance (Yang et al., 2010). This approach can be 
expanded to estimate the genetic contribution of risk alleles for common complex disease. 
The mean frequencies can be compared between populations and an estimate of the 
overall prevalence can be calculated. The current study is unique, as it seems this method 
has not be used to study population genetics of common complex diseases previously. A 
similar study was recently published by Lim et al., comparing loss-of-function variants in 
the rare variant 0.5-5% range (Lim et al., 2014). However, they found no significant 
difference in the rates of common variants between the Finnish and other out-bred 
European populations, possibly due to their comparisons of individual SNPs as opposed 
to grouped (Lim et al., 2014). Whereas the current study takes into account all SNPs 
reported to be associated with given disease. The data obtained with this study could help 
direct public policy by identifying complex conditions that have a higher overall risk 
allele frequency in the NL population. In genetically isolated communities, such as many 
areas in NL, the large majority of couples are members of the same population. This can 
have implications for disease risk to children. Ancestry based targeted screening is 
already used for specific mutations for some disorders, and is considered an effective way 
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to inform and identify couples at risk for rare disorders (Mathijssen et al 2015). While the 
current usage is for specific, rare or severe disease, it could be expanded to complex 
diseases or to a population-scale risk assessment. 
 
2.5.2 Study limitations  
This study has several limitations. Any limitations from SNPs reported in the 
genome-wide association studies catalogue can impact this study. For example, careful 
selection of phenotypic qualification of a disease is important. Diseases where a lot of 
ambiguity or heterogeneity exists can make classification difficult. Also, a study on 
available catalogues of disease alleles found many are imperfect or incomplete and as 
much as 27% of database entries were potentially unreliable by containing entries that 
have been erroneously included as disease variants (Bell et al., 2011). Sequencing studies 
are limited by the large numbers of variants with modest or low effects, allelic 
heterogeneity and neutral variants, and the information presented in the GWAS catalogue 
is not always reliably reviewed or monitored. Due to the study’s reliance on previously 
reported SNPs associated with disease, any SNPs that have been incorrectly reported 
could potentially skew our data.  Also, the effect sizes of the risk alleles were not 
considered in the analysis, risk alleles were evaluated as if they had the same effect. It 
would have been beneficial to include effect sizes in the analysis. 
Another limitation is our study population. Our genotype data is from a random 
sample of Newfoundlanders. However, because the samples were originally controls from 
a colorectal cancer research study, participants were excluded if they had a personal 
history of colorectal cancer. This could affect the results, particularly for the colorectal 
cancer data, and related types of cancers.  
The data on the CEPH/CEU population from the HapMap International Project 
may be limited. In the “Guidelines for Referring to the HapMap Populations in 
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Publications and Presentations” there is a cautionary note that the CEU genotypes may 
not accurately reflect the patterns of genetic variation in people with northern and western 
European ancestry due to the limited information collected regarding ancestral geography 
of the study participants (International HapMap Consortium, 2003). No phenotypic 
information or medical information was collected with the samples, and at the time, 
collection of ancestry information was not considered important to the research. A better 
study population, with more accurate ancestry information would be useful for future 
analysis. Furthermore, the HapMap population was used as the reference genome for the 
imputation analysis. This may introduce some bias as the same population was used for 
SNP imputation and risk allele population comparison. 
 The Newfoundland population may have lower LD than other recent founder 
populations. A significant inbreeding rate may be more responsible for high frequencies 
of risk variants (Service et al., 2006). A study by Lohmueller et al., of a simulated 
bottleneck population, suggests that the interaction of demographic processes and 
purifying selection can have an important impact on the distribution of deleterious 
variation, even in populations that did not undergo a severe founder effect (Lohmueller et 
al., 2008). It is suggested that association studies from these populations could be more 
useful than out-bred populations (Service et al., 2006) even with no evidence of linkage 
disequilibrium (Pope et al., 2011). Therefore, Newfoundland is considered a useful 
resource for studying risk variants even if the NL population does not exhibit extended 
linkage disequilibrium.  
 
2.5.3 Future Directions 
 
These results have implications for the burden of disease due to common risk 
variants, in Newfoundland in particular. A greater predictive capacity of disease burden 
could be achieved through assessing prevalence of disease in Newfoundland from groups 
of SNPs compared to individual SNPs alone. This could help inform public health policy. 
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Obesity, for example, is prevalent in Newfoundland and Labrador, at a rate of 27.7% in 
2011 compared to the national average at 18.3%. NL has the highest obesity rate of any 
province and by 2019, it is estimated that 71% of the adult population in NL will be either 
overweight or obese. Based on our data, the mean overall frequency of risk variants for 
obesity is actually significantly lower than the outbred CEU population. This suggests 
that obesity in NL may be due to environmental factors rather than genetics. This 
information can help guide public health policy in addressing the obesity epidemic in NL 
by focusing on environmental risk factors that could be changed. On the other hand, it 
could suggest that there may be specific genetic factors responsible for the NL population 
not covered in this research. Further genetic studies using the NL population to help 
identify potential genes related to obesity could help clarify this question. An important 
factor to consider in future studies is the effect size of the risk alleles, which would need 
to be calculated in future comparisons using this method. 
There are many possible future directions for this study. The method is novel, and 
therefore, studying common risk variants in other founder populations to see if similar 
results can be obtained is important. Alternatively, comparing two founder populations 
from the same out-bred population, such as Finland and Newfoundland could provide 
interesting results. Additionally, studying low-frequency variants in the Newfoundland 
population could yield further insights into certain disease prevalences in the population. 
For example, if the high rate of Type 1 Diabetes in Newfoundland were a product of a 
number of rare variants at a frequency of less than 5 %, the current study would not yield 
significant results. Regardless, further application of this method could yield interesting 
results in the future.  
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APPENDICES 
A. Sample Calculations 
 
Example of relative quantity (RQ) calculations for MMP-13 
 
1. Ctm = (Ct1 + Ct2 + Ct3) / 3 
Sample 
Name 
Target 
Name Cт CTm 
Sample1 MMP-13 34.26573 34.171412 
Sample1 MMP-13 34.00884   
Sample1 MMP-13 34.23967   
Sample2 MMP-13 34.55347 34.420247 
Sample2 MMP-13 34.34153   
Sample2 MMP-13 34.36574   
Ctl MMP-13 27.68807 27.772725 
Ctl MMP-13 27.84452   
Ctl MMP-13 27.78559   
Sample1 Gapdh 24.52023 24.56497 
Sample1 Gapdh 24.57550  
Sample1 Gapdh 24.59918  
Sample2 Gapdh 26.10388 26.187399 
Sample2 Gapdh 26.29309  
Sample2 Gapdh 26.16522  
Ctl Gapdh 25.65107 25.595953 
Ctl Gapdh 25.60254  
Ctl Gapdh 25.53425  
 
2. ΔCt = Ctm1 - CtmGAPDH 
Sample 
Name CTmMMP-13  CTmGAPDH ΔCt 
Sample1 34.171412 24.56497 9.606442 
 Sample2 34.420247 26.187399 8.232848 
Ctl 27.772725 25.595953 2.176772 
 
3. ΔΔCt = ΔCt1 - ΔCtCtl 
Sample 
Name ΔCt1 ΔCtCtl ΔΔCt 
Sample1 9.606442 2.176772 7.42967 
Sample2 8.232848 2.176772 6.056076 
Ctl 2.176772 2.176772 0 
 
4. RQ = 2(-ΔΔCt) 
Sample 
Name ΔΔCt RQ 
Sample1 7.42967 0.0058003 
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Sample2 6.056076 0.0150293 
Ctl 0 1 
 
 
Example of body mass index calculation 
 
BMI = weight (kg)/height (m) 2 
 
Sample 
ID 
Height Weight kg/m2 kg/m2 
*10000 
BMI 
P2 177.5 99.7 99.7/(177.52) 0.00316445 
* 10000 
31.65 
P3 177 63.2 63.2/(1772) 0.0020173 * 
10000 
20.17 
C2 187 90 90/(1872) 0.00257371 
*10000 
25.7 
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B. Consent Form for Study Participants 
 
OA#patients:#
 
 Version date:  10 March 2015 -1- Initials: ________ 
 
Consent to Take Part in Research 
 
  
TITLE:           Newfoundland Osteoarthritis Study (NFOAS)    
 
INVESTIGATOR(S): Drs. G. Zhai, A. Furey, G. Martin, P. Rahman, R. Green, and G. Sun. 
 
You have been invited to take part in a research study.  It is up to you to decide whether to be in the 
study or not.  Before you decide, you need to understand what the study is for, what risks you might 
take and what benefits you might receive.  This consent form explains the study. 
 
The researchers will: 
 
• discuss the study with you 
• answer your questions 
• keep confidential any information which could identify you personally 
• be available during the study to deal with problems and answer questions 
 
If you decide not to take part or to leave the study, your normal treatment will not be affected. 
 
1. Introduction/Background: 
You have a form of arthritis called osteoarthritis. Many people in Newfoundland and other 
places have arthritis, but we still don’t know much about what causes it. We know that what 
you inherit from your parents plays a part because if you have a close relative with arthritis, 
you are more likely to get the disease yourself. You inherit genes (made up of DNA) from both 
your parents. As part of this study we will be examining DNA from osteoarthritis patients and 
comparing it with DNA from those who do not have arthritis. 
 
2.    Purpose of study: 
We will recruit about 1000 people who have osteoarthritis and 1000 people who don’t have, 
and be looking to see how the genes you inherit from your parents contribute to the cause of 
arthritis. We will also look to see whether small changes to these genes within the joints 
themselves can make a difference. 
 
3.    Description of the study procedures and tests: 
You are going to have a knee or hip joint replaced because of arthritis in the joint.  You will get 
exactly the same treatment whether you decide to join our research study or not. 
 
Faculty of Medicine
Discipline of Genetics
Health Sciences Centre
St. John’s, NL Canada A1B 3V6
Tel: 709 777-6807 Fax:709 777-7497
www.med.mun.ca
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OA#patients:#
 
 Version date:  10 March 2015 -2- Initials: ________ 
If you join the study we will ask you for some extra tubes of blood (up to 4 extra tubes) when 
you have your routine blood collection. From this blood we will prepare your DNA (the 
material that makes up your genes) that we will store in a freezer. We will test the DNA from 
hundreds of arthritis patients to find changes that could be involved in causing arthritis. 
 
We will ask you to complete a questionnaire about your general medical history plus a short 
form just about your arthritis. We will help to complete the questionnaires, if you would like. 
 
During your joint surgery we will be keeping small samples of the cartilage, subchondral bone, 
synovial membrane, and of the fluid inside the joint, which are normally thrown away. This 
material may also be tested for its genetic content.  
 
We also ask your consent to access your medical records, both now and as long as this study 
continues (at least 5 years). This lets us compare the symptoms you have or may develop, and 
when you get them, to any genetic changes we may find. 
 
4.    Length of time: 
Completing the questionnaires should take about 30 minutes. 
There is nothing else for you to do. 
 
5.    Possible risks and discomforts: 
Bruising/discomfort after blood sample. 
 
6.    Benefits: 
It is unlikely that this study will benefit you personally. We hope that our findings may help in 
preventing arthritis in the future or in finding better treatments. 
 
7.    Liability statement: 
Signing this form gives us your consent to be in this study.  It tells us that you understand the 
information about the research study.  When you sign this form, you do not give up your legal 
rights.  Researchers or agencies involved in this research study still have their legal and 
professional responsibilities. 
 
8.    What about my privacy and confidentiality?  
Protecting your privacy is an important part of this study. Every effort to protect your privacy 
will be made. However it cannot be guaranteed. For example we may be required by law to 
allow access to research records. 
 
        When you sign this consent form you give us permission to  
• Collect information from you 
• Collect information from your health record  
• Share information with the people conducting the study 
• Share information with the people responsible for protecting your safety        
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OA#patients:#
 
 Version date:  10 March 2015 -3- Initials: ________ 
Access to records 
The members of the research team will see health and study records that identify you by name. 
Other people may need to look at the study records that identify you by name. This might 
include the research ethics board. You may ask to see the list of these people. They can look at 
your records only when one of the research team is present. 
 
Use of records 
The research team will collect and use only the information they need for this research study.   
      
This information will include your  
• date of birth 
• sex 
• medical conditions 
• medications 
• the results of tests and procedures you had before and during the study 
• information from study interviews and questionnaires 
 
Your name and contact information will be kept secure by the research team in Newfoundland 
and Labrador.  It will not be shared with others without your permission. Your name will never 
appear in any report or article published as a result of this study. 
 
Information collected for this study will be kept for at least five years after the end of the study. 
 
If you decide to withdraw from the study, the information collected up to that time will 
continue to be used by the research team.  It may not be removed. This information will only 
be used for the purposes of this study. At any time, you may ask that your DNA and any other 
specimens be destroyed. 
 
After your part in this study ends, we may continue to review your health records to check that 
the information we collected is correct.  
 
Information collected and used by the research team will be stored by Dr. Zhai who is the 
person responsible for keeping it secure.  
 
Your access to records 
You may ask the study doctor or researcher to see the information that has been collected about 
you.   
 
 
9.    Questions: 
 
If you have any questions about taking part in this study, you can meet with the investigator, 
Dr. Guangju Zhai, 709-864-6683 who is in charge of the study at this institution.   
 
Or you can talk to someone who is not involved with the study, but can advise you on your 
rights as a participant in a research study.  This person can be reached through: Health 
Research Ethics Authority (HREA) at 709-777-6974 or email: info@hrea.ca     
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OA#patients:#
 
 Version date:  10 March 2015 -4- Initials: ________ 
 
Future use of DNA or other samples: 
 
In order to preserve a valuable resource, your DNA and other samples may be stored at the end 
of this research project.  It is possible that these samples may be used in a future research 
project. Any future research would first have to be approved by a Research Ethics Board 
(REB). 
 
Please tick one of the following two options: 
 I agree that my samples can be used for an approved research project without 
contacting me again, but only if my name* cannot be linked, in any way, to the 
samples. 
 Under no circumstances may my samples be used for future research.  My samples 
must be destroyed at the end of this present project. 
 
*Includes name, MCP number or any other identifying information. 
 
 
 
The DNA and other samples from this study will be stored in St. John’s, NL for an indefinite period 
of time.  
 
At any time, you may ask that your DNA and any other specimens be destroyed. To do this please 
call Dr. Zhai at (709) 864-6683, contact anyone else on the research team, or contact the Office of 
the HREA at 709-777-6974 or email: info@hrea.ca   
 
To protect your samples, we will ask that you confirm your request in writing before we destroy 
them. 
 
 
After signing this consent you will be given a copy. 
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OA#patients:#
 
 Version date:  10 March 2015 -5- Initials: ________ 
Signature Page 
 
Study title:  Genetics of Osteoarthritis in Newfoundland 
                                                                                                                                    
Name of principal investigator:  Dr. G. Zhai   
                                                                                                       
 
To be filled out and signed by the participant: 
Please check as appropriate: 
I have read the consent form.        Yes { }     No { } 
I have had the opportunity to ask questions and to discuss this study.  Yes { }     No { } 
I have received satisfactory answers to all of my questions.    Yes { }     No { } 
I have received enough information about the study.     Yes { }     No { } 
I have spoken to  _________ and he/she has answered my questions   Yes { }     No { } 
I understand that I am free to withdraw from the study    Yes { }     No { } 
• at any time 
• without having to give a reason 
• without affecting my future care 
I understand that it is my choice to be in the study and that I may not benefit.  Yes { }     No { } 
I agree that the study doctor or investigator may read the parts of my hospital  Yes { }     No { } 
records which are relevant to the study. 
 
I agree to take part in this study.          Yes { }     No { } 
                                                    
___________________________________           __________________________ 
Signature of participant                        Date 
 
____________________________________           _________________________ 
Signature of witness                                              Date 
 
 
To be signed by the investigator or person obtaining consent 
 
I have explained this study to the best of my ability. I invited questions and gave answers. I believe 
that the participant fully understands what is involved in being in the study, any potential risks of 
the study and that he or she has freely chosen to be in the study. 
 
             
Signature of investigator/person obtaining consent  Date 
 
Telephone number:    _________________________ 
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C. Blood Requisition Form for Study Participants 
 
 
 
 
  
BLOOD REQUISITION 
For DNA research study 
Genetics of Osteoarthritis 
 
 
 
 
Requested by: 
Dr. Guangju Zhai  
777-7286 
Genetics 
Faculty of Medicine 
Memorial University 
 
Study Number:   __________ 
 
 
Patient Name  _____________________________ 
 
 
MCP ____________________________ 
 
                 -OR- 
 
D.O.B ___________________ 
                   Day-Month-Year   
 
Requested by: 
Dr. Guangju Zhai  
777-7286 
Genetics 
Faculty of Medicine 
Memorial University 
INSTRUCTIONS FOR COLLECTION: 
 
1. Draw 20 mL blood in EDTA (lavender) tubes. 
2. Please label all tubes with patient name. 
3. Place in bag with this form.  
 
Date blood drawn     ________________________ 
 
Where collected       ________________________ 
 
 
Send blood to: 
  
Lab Office  
First Floor                                          
Health Sciences Centre 
St. John’s, NL 
Health Sciences Lab Office 
 
On arrival, please call 
Maggie Liu at 777-6774 
Please do not eat or drink anything for 6 hours before blood collection. 
Thank you. 
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D. General Questionnaire for Study Participants 
 
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!ID!Number:!! ! ! ! ! ! !!
Version!08th!August!2011! 1!
!!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
Genetic!Study!of!Osteoarthritis!in!the!Newfoundland!Population!!General!Questionnaire!!!!!!!
!Date!form!completed:!!!!!!!!!(dd/mm/yyyy)!!!!! ! ! /! ! ! /! ! ! ! !
Faculty of Medicine
Discipline of Genetics
Health Sciences Centre
St. John’s, NL Canada A1B 3V6
Tel: 709 777-6807 Fax:709 777-7497
www.med.mun.ca
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!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!ID!Number:!! ! ! ! ! ! !!
Version!08th!August!2011! 2!
!!!!!!!!!!!!!!!!!!!!!!!
!
Instruction!for!completing!the!questionnaire:!
!Please!answer!all!questions!to!the!best!of!your!ability!(leave!blank!if!unknown).!Please!write!in!block!letters!using!the!boxes!where!provided.!Use!a!black/blue!pen.!Cross!out!any!mistakes!&!write!correct!answers!just!below!the!relevant!boxes.!Indicate!your!response!by!filling!in!the!box!next!to!the!most!appropriate!answer!or!by!writing!clearly!in!the!boxes!or!space!provided.!Your!answers!will!be!completely!confidential.!!!!!Self!administered:! !!!Research!assistant!administered:!! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
 165 
 
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!ID!Number:!! ! ! ! ! ! !!
Version!08th!August!2011! 3!
Name!and!address!!Surname!!! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! !!!Given!name!!! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! !!Title!!! ! ! ! ! ! ! ! ! !!Maiden!Name!(if!applicable)!! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! !!Address!!! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! !!! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! !!Province!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Postal!code!! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! !!!Date!of!Birth!(dd/mm/yyyy)!! ! /! ! ! /! ! ! ! !!!Place!of!Birth!City/Town!! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! !!Province/Country!! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! !!!Gender:!!Male! !!Female! !!!MCP!number:!!!!!!!
! ! ! ! ! ! ! ! ! ! ! !
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!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!ID!Number:!! ! ! ! ! ! !!
Version!08th!August!2011! 4!
!
! !1.!Ethnic:!White! !Black! !Other! ,!please!specify!!2.!!Height:!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !cm!3.!Weight:!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !kg!4a.!Smoker:!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!yes!(current)! !!!!!!!!no! !!!!!!!!!ex]smoker! !4b.!If!Yes,!how!many!cigarettes!do/did!you!smoke!a!day?!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !5a.!In!the!past!4!weeks!approximately!how!many!units!of!alcohol!did!you!drink!per!week?!(1!unit!=!1!glass!of!wine/½!pint!of!beer!/1!shot!of!sprit)?!!!!!!!!!!!!!!!!!!!!! !5b.!Do!you!think!your!drinking!habits!in!the!last!4!weeks!reflect!your!typical!drinking!habit?!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Yes! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!no,!less!than!usual! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!no,!more!than!usual! !6a.!How!heavy!were!you!when!you!were!born?!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !grams!or! !lbs! !ozs!6b.!If!weight!unknown,!were!you!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Light! !Average! !Heavy! !6c.!Were!you!born!prematurely!(more!than!1!week!early)!!!!!!!!!!!!!!!!!!!!Yes! !No! !7a.!How!heavy!were!you!at!age!20!yrs?!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !kg!7b.!How!heavy!were!you!at!age!50!yrs?!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !kg!
!
For!women!only:!8.!At!what!age!did!your!period!start?!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !
Section!1:!Demographics!
!
 167 
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!ID!Number:!! ! ! ! ! ! !!
Version!08th!August!2011! 5!
9.!At!what!age!did!your!period!stop?!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!10a.!Have!you!had!a!hysterectomy!(removal!of!the!womb)?!!!!!!!!!!!!!!!!!!!!!Yes! !No! !10b.!If!Yes,!how!old!were!you?!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !10c.!Did!the!hysterectomy!include!removal!of!the!ovaries?!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Yes! !No! !or!Unknown! !11.!Have!you!ever!taken!an!oral!contraceptive!pill?!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Yes! !!No! !12a.!Have!you!ever!taken!hormone!replacement!therapy?!!!!!!!!!!!!!!!!!!!!!!!Yes! !!No! !12b.!If!Yes,!how!long!in!total!did!you!take!it!for?!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Less!than!3!months! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!3!to!12!months! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!1!to!5!years! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Longer!than!5!years! !13.!How!many!live!births!have!you!had?!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!
Section!1:!Demographics!(continued)!
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!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!ID!Number:!! ! ! ! ! ! !!
Version!08th!August!2011! 6!
!!
Section!2!B!Occupation!!14a.!What!was!your!current/last!occupation!(job!title)?!!14b.!In!what!industry!did!you!carry!out!this!occupation!(eg!farming,!shipyard,!car!factory,!shoe!shop,!hospital,!insurance!office)?!!14c.!Number!of!years!in!job:!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !15a.!What!was!the!main!occupation!that!you!held!for!the!longest!period!of!time!(job!title)?!!15b.!In!what!industry!did!you!carry!out!this!occupation!(eg!farming,!shipyard,!car!factory,!shoe!shop,!hospital,!insurance!office)?!!15c.!Number!of!years!in!job:!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !For!your!main!occupation!in!an!average!working!day,!did!you:!16.!Sit!for!more!than!two!hours!in!total?!!!!!!!!!!!!!!!!!!!!!!!!!!!!Yes! !No! !Don’t!know! !17.!Stand!or!walk!for!more!than!two!hours!in!total?!!!!!!!Yes! !No! !Don’t!know! !18.!Kneel!for!more!than!one!hour!in!total?!!!!!!!!!!!!!!!!!!!!!!!!!Yes! !No! !Don’t!know! !19.!Squat!for!more!than!one!hour!in!total?!!!!!!!!!!!!!!!!!!!!!!!!!Yes! !No! !Don’t!know! !20.!Drive!for!more!than!4!hours!in!total?!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Yes! !No! !Don’t!know! !21.!Walk!more!than!2!miles!in!total?!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Yes! !No! !Don’t!know! !!!!
!
!
!
!
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!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!ID!Number:!! ! ! ! ! ! !!
Version!08th!August!2011! 7!
!
Section!2!–!Occupation!(continued)!!22.!In!the!course!of!your!work!how!often!on!average!did!you!lift!or!carry!weights!of!10!kg!or!more?!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Never! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Less!than!once!per!week! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!1!to!10!times!per!week! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!More!than!10!times!per!week! !23.!In!the!course!of!your!work!how!often!on!average!did!you!lift!or!carry!weights!of!25kg!or!more!(Equivalent!to!half!a!bag!of!cement)!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Never! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Less!than!once!per!week! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!1!to!10!times!per!week! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!More!than!10!times!per!week! !!!!!!!!!
 170 
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!ID!Number:!! ! ! ! ! ! !!
Version!08th!August!2011! 8!
!
Section!3!–!Medical!history!(1)!!Please!list!in!the!box!below!all!medication!that!the!patient!is!currently!taking:!!
Have!you!EVER!been!told!by!a!Doctor!or!other!health!professional!that!you!have!
ANY!of!the!following!conditions!(please!tick!all!that!apply!to!you):!
Cardiology!24.!Congenital!Heart!Disease!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!!!!!!!!29.!Angina!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !25.!Coronary!Heart!Disease!!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!!!!!!!!30.!High!Cholesterol!!!!!!!!!!!!!!!!!!! !26.!Heart!Attack!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!!!!!!!!31.!Deep!Vein!Thrombosis!!!!!!! !27.!Hypertension!(high!blood!pressure)!! !!!!!!!!!!!!!!!32.!Varicose!Veins!!!!!!!!!!!!!!!!!!!!!! !28.!High!Blood!Pressure!in!Pregnancy!!!!!! !!!!!!!!!!!!!!!33.!Pulmonary!Embolism!!!!!!!! !!
Immunology/Chest!Medicine!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Gastroenterology/Endocronology!34.!Asthma!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!!!!!!!!38.!Heartburn!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !35.!Hayfever!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!!!!!!!!39.!Irritable!Bowel!Syndrome!! !36.!Eczema!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!!!!!!!!40.!Crohn’s!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !37.!Sinusitis!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!!!!!!!!41.!Diabetes!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!!
Neurology/Psychiatry!!!!!!!!!!!!!!!!!!!!!!!!!42.!Dyslexia!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!!!!!!!46.!Stroke!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !43.!Clinical!Depression!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!!!!!!!47.!Motion!Sickness!!!!!!!!!!!!!!!!!!!!! !44.!Anxiety/Stress!Disorder!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!!!!!!!48.!Migraine!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !45.!Epilepsy!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !
!
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!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!ID!Number:!! ! ! ! ! ! !!
Version!08th!August!2011! 9!
!
Section!3!–!Medical!history!(2)!!Have!you!EVER!been!told!by!a!Doctor!or!other!health!professional!that!you!have!
ANY!of!the!following!conditions!(please!tick!all!that!apply!to!you):!!
Oncology/Cancers!49.!Breast!Cancer!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!51a.!Skin!Cancer! !if!yes,!was!it:!50.!Colon!Cancer!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!51b.!Melanoma!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!51c.!Basal!Cell!Carcinoma!!!!!!!!!!! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!51d.!Squamous!Cell!Carcinoma! !!
Rheumatology!52.!Gout!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!!!!!56.!Osteoporosis!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !53.!Paget’s!Disease!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!!!!!!57.!Carpal!Tunnel!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !54.!Bunions!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!!!!!58.!Tennis!Elbow!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !55.!Frozen!Shoulder!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!!!!!59.!Golfer’s!Elbow!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!
Dermatology/Skin!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Hearing!60.!Acne!(that!caused!scarring)!!!!!!!! !!!!!!!!!!!63.!Hearing!Loss!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !61.!Viral!Warts!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!!!!64.!Tinnitus!(ringing!in!ears)!!!!!!!!!!!!!!!! !62.!Cold!Sores!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!
Opthalmology/Eyes!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Urology!65.!Glaucoma! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!69.!Incontinence!(leak!urine)!!!!!!!!!!!!!!! !66.!Cataract! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!70.!Polycystic!ovary!syndrome!!!!!!!!!!!! !67.!Myopia!(short!sightedness)! !68.!Age]related!Macular!Degeneration!(AMD)! !!!
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Section!3!–!Medical!history!(3)!!
Please!answer!the!following!questions!by!ticking!the!appropriate!box:!!71a.!Have!you!ever!lost!the!use!of!an!arm,!leg,!vision,!or!ability!to!speak?!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Yes! !No! !71b.!If!Yes,!how!long!for!:!!!!!!!!!!!!!!!!!!!!!!less!than!24!hours! !or!more!than!24!hours! !72a.!Do!you!usually!bring!up!phlegm!from!your!chest!in!winter?!!!!!!!!!!!!!!Yes! !No! !72b.!Do!you!usually!bring!up!phlegm!on!most!days!for!at!least!3!months!a!year?!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Yes! !No! !73a.!Have!you!had!heartburn!or!acid!regurgitation!in!the!last!year?!!!!!!!!Yes! !No! !73b.!If!Yes,!how!many!times!have!you!had!heartburn/acid!regurgitation!in!the!last!year?!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Less!than!once!a!month! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!About!once!a!month! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Once!a!week!or!more! !74a.!Have!you!been!bothered!by!recurrent!headaches?!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Yes! !No! !74b.!If!Yes,!do!you!still!have!recurrent!headaches?!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Yes! !No! !74c.!If!Yes,!are!your!most!troubling!headaches!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!One!sided! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Accompanied!by!sensitivity!to!light/noise! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!4!to!72!hours!in!duration!if!untreated! !!
 173 
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!ID!Number:!! ! ! ! ! ! !!
Version!08th!August!2011! 11!
!
Section!3!–!Medical!history!(4)!!
Please!answer!the!following!questions!by!ticking!the!appropriate!box:!!75.!Since!turning!16!have!you!ever!fractured!or!broken!a!bone?!!Yes! !No! !If!Yes,!please!tick!which!of!the!following!bones!you!have!fractured!or!broken!!!!!!!!!!!!!!!!!!!!!!!!!!Wrist! !Arm! !Ribs! !Hip! !Ankle! !Vertebra! !Other! !76.!In!the!past!3!months!have!you!had!pain!in!your!back!on!most!days?!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Yes! !No! !If!Yes,!does!this!pain!typically!radiate!to!either!leg?!!!!!!!!!!!!!!!!!!!!!!!!Yes! !No! !77.!In!the!past!3!months!have!you!had!any!pain!in!any!part!of!your!body!lasting!at!least!24!hours?!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Yes! !No! !!!!!!!!!!!!
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!
Section!4!–!Nodal!status!!We!are!interested!in!knowing!whether!you!have!any!finger!nodes.!These!sometimes!relate!to!arthritis!at!the!hand!and!other!joints.!A!finger!node!is!a!firm,!bobbly!swelling!on!the!back!of!the!finger!joint.!For!example:!!A!finger!without!nodes:!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!A!finger!with!nodes:!
!
! ! !When!you!meet!with!the!research!assistant,!please!look!at!your!hands!and!then!answer!the!following!questions:!78a.!Do!you!think!you!have!any!nodes/swellings!on!your!hands?!!!!!Yes! !No! !If!Yes,!for!each!hand!please!circle!the!finger!joint(s)!where!you!have!these!nodes.!(You!may!circle!several!joints).!!!!!!!!!!!!
!
L! R!
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Section!4!–!Nodal!status!(continued)!!78b.!If!Yes,!at!what!age!did!the!nodes!first!develop?!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !78c.!How!many!nodes!do!you!have!on!the:!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!left!hand!! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!right!hand! !79.!Which!hand!do!you!write!with?!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Left! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Right! !80a.!Have!you!suffered!from!pain!in!the!fingers!for!most!days!for!at!least!one!month?!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Yes! !No! !80b.!If!Yes,!at!what!age!did!you!first!develop!‘significant’!pain!in!your!fingers?! !81.!Do!you!have!pain!in!the!base!of!your!thumb!(as!arrow!on!drawing)?!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Yes! !No! !!!!!!!!!!!!!!!!!!
Base!of!thumb!
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Section!5!–!Family!History!of!Osteoarthritis!!82.!Does/did!your!mother!suffer!from!osteoarthritis!of!the!knee/hip?!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Yes! !No! !Don’t!know! !!!!!!!!!If!Yes,!has/did!your!mother!had/have!a!total!joint!replacement!of!the!knee/hip?!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Yes! !No! !Don’t!know! !83.!Does/did!your!father!suffer!from!osteoarthritis!of!the!knee/hip?!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Yes! !No! !Don’t!know! !!!!!!!!!!!If!Yes,!has/did!your!father!had/have!a!total!joint!replacement!of!the!knee/hip?!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Yes! !No! !Don’t!know! !84.!Does/did!your!brothers/sisters!suffer!from!osteoarthritis!of!the!knee/hip?!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Yes! !No! !Don’t!know! !!!!!!!!!!If!Yes,!has/did!your!brothers/sisters!had/have!a!total!joint!replacement!of!the!knee/hip?!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Yes! !No! !Don’t!know! !!!!!!!!
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Genetic'Study'of'Osteoarthritis'in'the'Newfoundland'Population'
'The!Western!Ontario!and!McMaster!Universities!Osteoarthritis!Index!(WOMAC)!!Name!and!address!!Surname!!! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! !!!Given!name!!! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! !!Title!!! ! ! ! ! ! ! ! ! !!Maiden!Name!(if!applicable)!! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! !!Address!!! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! !!! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! !!Province!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Postal!code!! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! !!!Date!of!Birth!(dd/mm/yyyy)!! ! /! ! ! /! ! ! ! !!!Place!of!Birth!City/Town!! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! !!Province/Country!! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! !!!Gender:!!Male! !!Female! !!MCP!number:! !!!
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!This!section!assesses!pain,!stiffness,!and!functional!deficit!on!a!scale!from!0!to!4.!Example:!! None!0! !1! !2! !3! Severe!4!Example!of!no!pain! ! ! ! ! !Example!of!severe!pain! ! ! ' ' !!1.!Referring!to!your!knees!only!how!much!pain!do!you!experience!when!! None!0! !1! !2! !3! Severe!4!a.!Walking!on!a!flat!surface! ! ! ! ! !b.!Going!up!and!down!stairs! ! ! ! ! !c.!At!night!while!in!bed! ! ! ! ! !d.!Sitting!or!lying! ! ! ! ! !e.!Standing!upright! ! ! ! ! !!2.!Referring!to!your!knees!only!how!much!stiffness'do!you!experience!! None!0! !1! !2! !3! Severe!4!a.!After!first!awakening! ! ! ! ! !b.!Later!in!the!day! ! ! ! ! !!!!!!!!!!
Section'1'–'WOMAC'for'knee!
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Section'1'–'WOMAC'for'knee'(continued)!!3.!Referring!to!your!knees!only!how!much!functional'deficit!do!you!experience!when!! None!0! !1! !2! !3! Severe!4!a.!Descending!stairs! ! ! ! ! !b.!Ascending!stairs! ! ! ! ! !c.!Rising!from!bed! ! ! ! ! !d.!Rising!from!sitting! ! ! ! ! !e.!Putting!on!socks! ! ! ! ! !f.!Taking!off!socks! ! ! ! ! !g.!Bending!to!the!floor! ! ! ! ! !h.!Lying!in!bed! ! ! ! ! !i.!Walking!on!flat!surface! ! ! ! ! !j.!Getting!in/out!of!the!bath! ! ! ! ! !k.!Standing! ! ! ! ! !l.!Sitting! ! ! ! ! !m.!Getting!in/out!of!the!car! ! ! ! ! !n.!Getting!on/off!the!toilet! ! ! ! ! !o.!Heavy!domestic!chores! ! ! ! ! !p.!Light!domestic!chores! ! ! ! ! !q.!Shopping! ! ! ! ! !!!!!
 180 
 
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!ID!Number:!! ! ! ! ! ! !!
Version!08th!August!2011! 4!
Section'2'–'WOMAC'for'hip!!4.!Referring!to!your!hips!only!how!much!pain!do!you!experience!when!!! None!0! !1! !2! !3! Severe!4!a.!Walking!on!a!flat!surface! ! ! ! ! !b.!Going!up!and!down!stairs! ! ! ! ! !c.!At!night!while!in!bed! ! ! ! ! !d.!Sitting!or!lying! ! ! ! ! !e.!Standing!upright! ! ! ! ! !!5.!Referring!to!your!hips!only!how!much!stiffness!do!you!experience!! None!0! !1! !2! !3! Severe!4!a.!After!first!awakening! ! ! ! ! !b.!Later!in!the!day! ! ! ! ! !!!!!!!!!!!!!!!!!!!!
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Section'2'–'WOMAC'for'hip'(continued)!!6.!Referring!to!your!hips!only!how!much!functional'deficit!do!you!experience!when!! None!0! !1! !2! !3! Severe!4!a.!Descending!stairs! ! ! ! ! !b.!Ascending!stairs! ! ! ! ! !c.!Rising!from!bed! ! ! ! ! !d.!Rising!from!sitting! ! ! ! ! !e.!Putting!on!socks! ! ! ! ! !f.!Taking!off!socks! ! ! ! ! !g.!Bending!to!the!floor! ! ! ! ! !h.!Lying!in!bed! ! ! ! ! !i.!Walking!on!flat!surface! ! ! ! ! !j.!Getting!in/out!of!the!bath! ! ! ! ! !k.!Standing! ! ! ! ! !l.!Sitting! ! ! ! ! !m.!Getting!in/out!of!the!car! ! ! ! ! !n.!Getting!on/off!the!toilet! ! ! ! ! !o.!Heavy!domestic!chores! ! ! ! ! !p.!Light!domestic!chores! ! ! ! ! !q.!Shopping! ! ! ! ! !!!
